deferoxamine has been researched along with Iron Overload in 448 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Iron Overload: An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine." | 10.23 | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024) |
| " The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited." | 9.51 | Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022) |
| "Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown." | 9.27 | Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage. ( Alborch, E; Castelló-Ruiz, M; Castillo, J; Dávalos, A; DeGregorio-Rocasolano, N; García-Yébenes, I; Gasull, T; Guirao, V; Lizasoain, I; Martí-Sistac, O; Millán, M; Ponce, J; Ramos-Cabrer, P; Salom, JB, 2018) |
| "To examine the efficacy of deferasirox (DFX) by comparison with deferoxamine (DFO) in managing iron overload in patients with sickle cell anaemia (SCA)." | 9.22 | Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis. ( Qadah, T, 2022) |
| "Oral deferiprone (L1) appears to be promising in the treatment of beta-thalassemia major (TM) patients." | 9.12 | Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. ( Capra, M; Cracolici, E; De Marchi, D; Lombardi, M; Maggio, A; Malizia, R; Midiri, M; Pepe, A; Positano, V; Prossomariti, L, 2006) |
| "Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload." | 9.12 | A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. ( Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F, 2007) |
| " deferoxamine in 586 patients with beta-thalessemia and transfusional hemosiderosis." | 9.12 | Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. ( Al-Fayoumi, S; Castillo, S; Chakraborti, T; Choudary, J; Frankewich, R; Kacuba, A; Pazdur, R; Rieves, D; Robie-Suh, K; Shashaty, G; Weiss, K, 2006) |
| "Iron chelation therapy (ICT) with deferoxamine (DFO), the current standard for the treatment of iron overload in patients with transfusion-dependent disorders such as beta-thalassemia, requires regular subcutaneous or intravenous infusions." | 9.12 | Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. ( Abetz, L; Abish, S; Agaoglu, L; Baladi, JF; Bejaoui, M; Cappellini, MD; Cario, H; Coates, T; Ferster, A; Girot, R; Jeng, M; Lai, ME; Loggetto, S; Mangiagli, A; Opitz, H; Porter, J; Ressayre-Djaffer, C; Rofail, D; Strauss, G; Vichinsky, E; Watman, N; Zoumbos, N, 2007) |
| "We compared 48-hour urinary iron excretion after a twice-daily subcutaneous bolus injection of deferoxamine and after 12 hours of subcutaneous continuous infusion of the drug in 27 patients with iron overload (mean age, 55." | 9.09 | Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. ( Aprili, G; Borgna-Pignatti, C; de Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 2000) |
| "Deferasirox (DFX) has recently been used to treat thalassemia with iron overload; however, its long-term effectiveness and safety await multi-year studies." | 9.01 | Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis. ( Chen, G; Dou, H; Qin, Y; Zhao, Y, 2019) |
| "To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and iron overload." | 8.95 | Deferasirox for managing iron overload in people with thalassaemia. ( Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK, 2017) |
| "To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and secondary iron overload." | 8.88 | Deferasirox for managing iron overload in people with thalassaemia. ( Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G, 2012) |
| "To assess the effectiveness and safety of oral deferasirox in people with SCD and secondary iron overload." | 8.86 | Deferasirox for managing transfusional iron overload in people with sickle cell disease. ( Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Niemeyer, C; Rücker, G, 2010) |
| "For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation." | 8.83 | Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006) |
| "Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions." | 8.83 | Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006) |
| " Iron removal in transfusional iron overload is achieved using chelation therapy with the chelating drugs deferoxamine (DF) and deferiprone (L1)." | 8.80 | Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). ( Hadjigavriel, M; Kolnagou, A; Kontoghiorghes, GJ; Pattichi, K, 2000) |
| "Although deferoxamine (DFO) has been approved for the treatment the iron overloaded diseases, its clinical application is impeded by very short circulation time and its relating toxicity." | 8.12 | Fluorene methoxycarbonyl-PEG-deferoxamine conjugates "hitchhike" with albumin in situ for iron overload therapy. ( Guan, R; Jiang, Y; Li, Y; Liu, H; Xu, L; Yu, B, 2022) |
| " Iron chelation and iron overload was achieved by deferoxamine mesylate or iron dextran injection." | 8.02 | Iron chelation suppresses secondary bleeding after intracerebral hemorrhage in angiotensin II-infused mice. ( Chen, WX; Feng, H; Ge, HF; Guo, C; Li, CC; Tang, XQ; Wang, B; Wang, J; Xia, M; Yin, Y, 2021) |
| "To report a case of acute bilateral central serous retinopathy associated with deferoxamine therapy in the context of paroxysmal nocturnal hemoglobinuria." | 7.83 | Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine. ( Giasin, O; Kaneshyogan, H; Makrygiannis, G; Sian, IS; Vahdani, K, 2016) |
| "The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its oral tablet form." | 7.79 | A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. ( Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL, 2013) |
| "The study evaluated the cost effectiveness of deferasirox (Exjade * ) compared to non-proprietary desferrioxamine (DFO) for the control of transfusional iron overload in lower risk myelodysplastic syndromes (MDS) patients." | 7.76 | Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. ( Bozkaya, D; Li, Q; Migliaccio-Walle, K; Miranda, E; Oliver, N; Tolley, K, 2010) |
| " The known predisposing factors of infection include prior splenectomy, iron overload and use of iron chelator such as deferoxamine (DFO)." | 7.75 | Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. ( Chan, GC; Chan, S; Ha, SY; Ho, PL, 2009) |
| "Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload." | 7.74 | Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. ( Baladi, JF; Coates, TD; Delea, TE; Hagiwara, M; Phatak, PD; Thomas, SK, 2008) |
| "For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group comprising 19 patients on a deferiprone (L1) and DFO combination therapy (L1 75-100 mg/kg/day and DFO 30-60 mg/kg, 1-5 days/week), have been studied and compared before and after the introduction of the combination therapy." | 7.74 | Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2008) |
| "To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload." | 7.72 | Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "To verify efficacy and tolerability of deferoxamine by subcutaneous bolus injection as compared to the conventional pump-driven slow infusion, eleven patients affected by oncohematologic diseases were given 2 g of deferoxamine diluted in 10 mL of distilled water over twelve hours by continuous infusion, or by bolus injection in two divided doses." | 7.70 | Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. ( Aprili, G; Borgna-Pignatti, C; De Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 1998) |
| " The resultant iron overload must be treated with chelation therapy using deferoxamine." | 7.69 | Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy. ( Berdon, WE; Hurlet-Jensen, A; Piomelli, S; Ruzal-Shapiro, C; Sheth, S, 1997) |
| "DFP/DFX combination proved superior in improving cardiac T2*, treatment compliance, and patients satisfaction with no greater adverse events." | 6.80 | Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. ( Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y, 2015) |
| "Iron overload is the primary cause of mortality and morbidity in thalassemia major despite advances in chelation therapy." | 6.78 | Combined chelation therapy with deferasirox and deferoxamine in thalassemia. ( Evans, P; Harmatz, P; Kurio, G; Lal, A; Neumayr, L; Ng, V; Porter, J; Sweeters, N; Vichinsky, E, 2013) |
| "Iron overload is the main cause of morbidity and mortality especially from heart failure in patients with beta thalassemia major (TM)." | 6.72 | Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. ( Daar, S; Pathare, AV, 2006) |
| " There was no significant difference in the proportion of patients with adverse events in the two therapy groups although the nature of the adverse events differed according to the chelation regimen." | 6.72 | A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. ( Fischer, R; Galanello, R; Kattamis, A; Ladis, V; Leoni, G; Lund, U; Piga, A; Tricta, F; Voi, V, 2006) |
| " Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage." | 6.53 | Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016) |
| "Deferiprone was more efficacious than DFO in improving cardiac ejection fraction [MD 2." | 6.50 | A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. ( Kuo, KH; Mrkobrada, M, 2014) |
| "Deferasirox is a new orally effective iron chelator which has been shown to be non-inferior to deferoxamine in clinical trials." | 6.44 | Current status of iron overload and chelation with deferasirox. ( Choudhry, VP; Naithani, R, 2007) |
| "This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine." | 6.23 | Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study. ( Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Fradette, C; Hamdy, M; Inusa, B; Kanter, J; Kwiatkowski, JL; Lee, D; Temin, NT; Tricta, F; Veríssimo, MPA; Williams, S, 2024) |
| "Iron overload is a major complication of transfusion-dependent thalassemia (TDT) and requires iron chelation (IC) therapy." | 5.62 | Using of deferasirox and deferoxamine in refractory iron overload thalassemia. ( Buaboonnam, J; Narkbunnam, N; Phuakpet, K; Pongtanakul, B; Sanpakit, K; Takpradit, C; Vathana, N; Viprakasit, V, 2021) |
| "Reversal of arrhythmia to sinus rhythm was noted in all patients." | 5.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
| " The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited." | 5.51 | Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022) |
| "Iron overload is commonly observed during the course of aplastic anemia (AA), which is believed to aggravate hematopoiesis, cause multiple organ dysfunction, lead to disease progression, and impair quality of life." | 5.48 | Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload. ( Hu, H; Liu, W; Wen, X; Wu, D; Ye, B; Zhou, Y, 2018) |
| "Iron overload is a common complication of patients with β-thalassemia major (TM)." | 5.40 | Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden. ( Akianidis, V; Christoulas, D; Karavas, A; Komninaka, V; Terpos, E; Voskaridou, E, 2014) |
| "Cardiovascular diseases are a common cause of morbidity and mortality in subjects on regular hemodialysis." | 5.40 | Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload. ( Alnahal, AA; Fathy, A; Fathy, T; Tahan, M, 2014) |
| "Caffeine is a safe, rapidly absorbable molecule that can be linked to other compounds to improve their cell permeability." | 5.40 | Desferrioxamine-caffeine (DFCAF) as a cell permeant moderator of the oxidative stress caused by iron overload. ( Alta, EC; Espósito, BP; Goswami, D; Machini, MT; Nomura, CS; Silvestre, DM, 2014) |
| "Thalassemia major is an inherited form of chronic hemolytic anemia that results in iron overload due to regular blood transfusions." | 5.40 | Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine. ( Poachanukoon, O; Satayasai, W; Silapamongkonkul, P; Surapolchai, P, 2014) |
| "Deferasirox is a newer chelation therapy that is taken orally once daily." | 5.38 | Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective. ( Chandiwana, D; Karnon, J; Tolley, K; Vieira, J, 2012) |
| "Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy." | 5.37 | Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011) |
| "Five thalassemia major (TM) patients who were undergoing chelation monotherapy with DFO were enrolled." | 5.35 | Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia. ( Aessopos, A; Assimakopoulos, G; Polonofi, K; Rigaki, K; Tsironi, M, 2008) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 5.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "Iron overload was evaluated for 26 beta-thalassemia homozygous patients, and 14 of them were submitted to intensive chelation therapy with high doses of intravenous deferoxamine (DF)." | 5.31 | Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. ( Boturao-Neto, E; Marcopito, LF; Zago, MA, 2002) |
| "Three iron chelators are used to treat transfusion-dependent beta-thalassemia: desferrioxamine (DFO), deferasirox (DFX), and deferiprone (DFP)." | 5.30 | Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study. ( Chen, X; Hsieh, YW; Lin, CH; Peng, CT; Song, TS; Weng, TF; Wu, CC; Wu, KH, 2019) |
| "Despite transferrin being the main circulating carrier of iron in body fluids, and iron overload conditions being known to worsen stroke outcome through reactive oxygen species (ROS)-induced damage, the contribution of blood transferrin saturation (TSAT) to stroke brain damage is unknown." | 5.27 | Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage. ( Alborch, E; Castelló-Ruiz, M; Castillo, J; Dávalos, A; DeGregorio-Rocasolano, N; García-Yébenes, I; Gasull, T; Guirao, V; Lizasoain, I; Martí-Sistac, O; Millán, M; Ponce, J; Ramos-Cabrer, P; Salom, JB, 2018) |
| "To examine the efficacy of deferasirox (DFX) by comparison with deferoxamine (DFO) in managing iron overload in patients with sickle cell anaemia (SCA)." | 5.22 | Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis. ( Qadah, T, 2022) |
| "The randomized comparison of deferasirox to deferoxamine for myocardial iron removal in patients with transfusion-dependent anemias (CORDELIA) gave the opportunity to assess relative prevalence and body distribution of iron overload in screened patients." | 5.20 | Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. ( Aydinok, Y; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Pennell, DJ; Piga, A; Porter, JB; Quebe-Fehling, E; Viprakasit, V; Yesilipek, A, 2015) |
| " We report baseline LIC results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients." | 5.20 | Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. ( Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC, 2015) |
| "We report a prospective, randomized, Phase II study of deferasirox and deferoxamine (DFO) in sickle cell disease patients with transfusional iron overload, with all patients continuing on deferasirox after 24 weeks, for up to 2 years." | 5.17 | Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. ( Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y, 2013) |
| "The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients > or =2 yr with beta-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone." | 5.14 | Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. ( Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A, 2009) |
| " In 18 requiring thyroxine supplementation for hypothyroidism, 10 were able to discontinue, and four reduced their thyroxine dose." | 5.14 | Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. ( Berdoukas, V; Chouliaras, G; Farmaki, K; Pappa, C; Tzoumari, I, 2010) |
| "Deferoxamine (DFO) is an iron chelator used to treat iron overload in patients receiving chronic blood transfusions, and is usually administered as overnight subcutaneous infusions." | 5.14 | Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results. ( Bachir, D; Bisot-Locard, S; Gardembas-Pain, M; Hacini, M; Merlat-Guitard, A; Pégourié-Bandelier, B; Thuret, I, 2009) |
| " Transfusional iron overload in patients with thalassaemia could be reduced to normal body iron range levels using effective deferiprone/deferoxamine combinations." | 5.14 | Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. ( Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ, 2010) |
| " The following prospective, randomized trial was carried out to determine the effectiveness, in children and young adults, of combined deferiprone (DFP) and deferoxamine (DFO) in reducing transfusional iron overload compared to either drug alone and to assess the safety and tolerability of DFP." | 5.13 | Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. ( El-Beshlawy, A; Eltagui, M; Hamdy, M; Hoffbrand, AV; Manz, C; Mostafa, A; Naja, M; Shaker, O; Sharaf, I; Sobh, H; Taher, A; Tarabishi, C; Youssry, I, 2008) |
| "Deferoxamine retinopathy is the informally designated term used to describe a characteristic pattern of outer retinal degeneration in iron-overloaded chronic anemia patients who are treated with deferoxamine." | 5.12 | Iron overload and iron chelating agent exposure in anemia-associated outer retinal degeneration: a case report and review of the literature. ( Belmouhand, M; Eckmann-Hansen, C; Ilginis, T; Larsen, M; Leinøe, EB; Mortensen, BK, 2021) |
| "Oral deferiprone (L1) appears to be promising in the treatment of beta-thalassemia major (TM) patients." | 5.12 | Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. ( Capra, M; Cracolici, E; De Marchi, D; Lombardi, M; Maggio, A; Malizia, R; Midiri, M; Pepe, A; Positano, V; Prossomariti, L, 2006) |
| " We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with beta-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications." | 5.12 | Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. ( Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH, 2006) |
| "Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload." | 5.12 | A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. ( Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F, 2007) |
| " deferoxamine in 586 patients with beta-thalessemia and transfusional hemosiderosis." | 5.12 | Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. ( Al-Fayoumi, S; Castillo, S; Chakraborti, T; Choudary, J; Frankewich, R; Kacuba, A; Pazdur, R; Rieves, D; Robie-Suh, K; Shashaty, G; Weiss, K, 2006) |
| "Iron chelation therapy (ICT) with deferoxamine (DFO), the current standard for the treatment of iron overload in patients with transfusion-dependent disorders such as beta-thalassemia, requires regular subcutaneous or intravenous infusions." | 5.12 | Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. ( Abetz, L; Abish, S; Agaoglu, L; Baladi, JF; Bejaoui, M; Cappellini, MD; Cario, H; Coates, T; Ferster, A; Girot, R; Jeng, M; Lai, ME; Loggetto, S; Mangiagli, A; Opitz, H; Porter, J; Ressayre-Djaffer, C; Rofail, D; Strauss, G; Vichinsky, E; Watman, N; Zoumbos, N, 2007) |
| "We compared 48-hour urinary iron excretion after a twice-daily subcutaneous bolus injection of deferoxamine and after 12 hours of subcutaneous continuous infusion of the drug in 27 patients with iron overload (mean age, 55." | 5.09 | Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. ( Aprili, G; Borgna-Pignatti, C; de Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 2000) |
| "Deferiprone is an orally active iron-chelating agent that is being evaluated as a treatment for iron overload in thalassemia major." | 5.08 | Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. ( Brittenham, GM; Burt, AD; Cameron, RG; Fleming, KA; McClelland, RA; McLaren, CE; Olivieri, NF; Templeton, DM, 1998) |
| "Deferasirox (DFX) has recently been used to treat thalassemia with iron overload; however, its long-term effectiveness and safety await multi-year studies." | 5.01 | Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis. ( Chen, G; Dou, H; Qin, Y; Zhao, Y, 2019) |
| "To compare the efficacy and safety of desferrioxamine (DFO), deferiprone (DFP), deferasirox (DFX) and silymarin in patients with either thalassemia or sickle cell disorder through network meta-analysis." | 4.98 | Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. ( Sivaramakrishnan, G; Sridharan, K, 2018) |
| "To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and iron overload." | 4.95 | Deferasirox for managing iron overload in people with thalassaemia. ( Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK, 2017) |
| "Iron chelating agents - deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX) - are used to treat chronic iron overload in patients with β-thalassemia in an attempt to reduce morbidity and mortality related to siderosis." | 4.93 | Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. ( El Rassi, F; Saliba, AN; Taher, AT, 2016) |
| "Desferrioxamine is the recommended first-line therapy for iron overload in people with thalassaemia major and deferiprone or deferasirox are indicated for treating iron overload when desferrioxamine is contraindicated or inadequate." | 4.89 | Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. ( Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013) |
| "In the absence of data from randomised controlled trials, there is no evidence to suggest the need for a change in current treatment recommendations; namely that deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate." | 4.89 | Oral deferiprone for iron chelation in people with thalassaemia. ( Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013) |
| "To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and secondary iron overload." | 4.88 | Deferasirox for managing iron overload in people with thalassaemia. ( Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G, 2012) |
| "To assess the effectiveness and safety of oral deferasirox in people with SCD and secondary iron overload." | 4.86 | Deferasirox for managing transfusional iron overload in people with sickle cell disease. ( Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Niemeyer, C; Rücker, G, 2010) |
| "Deferoxamine (DFO) was the standard of care for transfusional iron overload for >40 years, requiring subcutaneous infusion for 8-12 h/day, 5-7 days/week." | 4.85 | Oral iron chelators. ( Cappellini, MD; Pattoneri, P, 2009) |
| " Despite the availability of deferoxamine (DFO) in Korea since 1998, data from patients with myelodysplastic syndromes, aplastic anemia, and other BMFS show significant iron overload and damage to the heart and liver." | 4.84 | Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. ( Lee, JW, 2008) |
| "Deferasirox, a tridentate oral chelator approved for the treatment of chronic iron overload due to blood transfusions, offers a promising alternative for patients unwilling or unable to comply with deferoxamine therapy." | 4.84 | Deferasirox. ( Stumpf, JL, 2007) |
| "We found no reason to change current treatment recommendations, namely deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate." | 4.84 | Oral deferiprone for iron chelation in people with thalassaemia. ( Brunskill, SJ; Doree, C; Howard, J; Hyde, CJ; Roberts, DJ; Williams, S, 2007) |
| "The iron chelators deferoxamine (DFO) and deferiprone (L1) have demonstrated their ability to normalize cardiac function in patients with iron overload-induced cardiac disease." | 4.84 | Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. ( Peng, CT; Tsai, CH; Wu, KH, 2008) |
| "For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation." | 4.83 | Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. ( Neufeld, EJ, 2006) |
| "Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions." | 4.83 | Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006) |
| "Therapy with either deferiprone (DFP) or deferoxamine (DFO) is inadequate in achieving negative iron balance in many patients with thalassemia." | 4.82 | Combined therapy with deferoxamine and deferiprone. ( Kattamis, A, 2005) |
| "In patients with thalassemia, the assessment of liver iron concentration (LIC) can be used to initiate chelation treatment with desferrioxamine (DFO), deferiprone (DFP), or novel chelators (deferasirox); to adjust chelation dose according to the actual blood transfusion rate; and to monitor chelation efficacy." | 4.82 | Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. ( Fischer, R; Harmatz, P; Nielsen, P; Piga, A, 2005) |
| " In July 1996, deferoxamine was administered for iron overload." | 4.80 | [Development of arterial thrombus of Mucorales hyphae during deferoxamine therapy in a patient with aplastic anemia in transformation to myelodysplastic syndrome]. ( Kajiguchi, T; Miyata, Y; Saito, M; Takeyama, H, 2000) |
| " Iron removal in transfusional iron overload is achieved using chelation therapy with the chelating drugs deferoxamine (DF) and deferiprone (L1)." | 4.80 | Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). ( Hadjigavriel, M; Kolnagou, A; Kontoghiorghes, GJ; Pattichi, K, 2000) |
| " In this report, we describe two pediatric patients diagnosed with nephrolithiasis while undergoing treatment with the chelating agents deferasirox, deferiprone, and deferoxamine for iron overload secondary to repeat blood transfusion." | 4.31 | Nephrolithiasis in two patients on iron chelation therapy: A case report. ( Baker, Z; Dillon, H; Pena, A; Sparks, S; Syed, H; Wang, Y, 2023) |
| " Given the negative effects of commonly used iron chelators like deferoxamine (DFO), we sought to examine the iron chelation potency of vanillin and evaluate its potential effect in the treatment of iron overload-related disorders." | 4.31 | Vanillin serves as a potential substitute for chemical chelator desferal in iron-overloaded mice. ( Aalikhani, M; Khalili, M; Taheri, E, 2023) |
| " This work evaluated key chemical and biological properties of five candidate phytochelators for iron overload diseases: maltol, mimosine, morin, tropolone, and esculetin." | 4.12 | Intracellular Iron Binding and Antioxidant Activity of Phytochelators. ( Espósito, BP; Silva, FT, 2022) |
| " Although deferoxamine (DFO) has been widely utilized as a clinical first-line siderophore to remove the iron overload, the ROS-inducing damage still greatly limits the therapeutic effect of DFO." | 4.02 | Efficient Iron and ROS Nanoscavengers for Brain Protection after Intracerebral Hemorrhage. ( Gu, Z; Li, Y; Tian, M; Wang, Y; Wei, Y; Yang, P; You, C; Zhong, R; Zhu, F; Zi, L, 2021) |
| " Iron chelation and iron overload was achieved by deferoxamine mesylate or iron dextran injection." | 4.02 | Iron chelation suppresses secondary bleeding after intracerebral hemorrhage in angiotensin II-infused mice. ( Chen, WX; Feng, H; Ge, HF; Guo, C; Li, CC; Tang, XQ; Wang, B; Wang, J; Xia, M; Yin, Y, 2021) |
| " The iron chelator deferoxamine dramatically inhibited PA-induced insulin resistance, and iron donors impaired insulin sensitivity by activating JNK." | 3.91 | Iron overload by transferrin receptor protein 1 regulation plays an important role in palmitate-induced insulin resistance in human skeletal muscle cells. ( Choi, SE; Cui, R; Jeon, JY; Kang, Y; Kim, HJ; Kim, TH; Lee, HJ; Lee, KW; Lee, SJ, 2019) |
| "Deferoxamine (DFO) to treat iron overload (IO) has been limited by toxicity issues and short circulation times and it would be desirable to prolong circulation to improve non-transferrin bound iron (NTBI) chelation." | 3.88 | Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo. ( Chanana, S; Lin, TM; Liu, Z; Wang, Y; Xiong, MP, 2018) |
| "In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39." | 3.83 | Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016) |
| " Deferoxamine (DFX), a metal chelator, removes iron overload and protects against brain damage in intracranial hemorrhage." | 3.83 | Deferoxamine inhibits microglial activation, attenuates blood-brain barrier disruption, rescues dendritic damage, and improves spatial memory in a mouse model of microhemorrhages. ( He, XF; Lan, Y; Liang, FY; Liu, DX; Pei, Z; Wang, Q; Xu, GQ; Zeng, JS; Zhang, Q, 2016) |
| "To report a case of acute bilateral central serous retinopathy associated with deferoxamine therapy in the context of paroxysmal nocturnal hemoglobinuria." | 3.83 | Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine. ( Giasin, O; Kaneshyogan, H; Makrygiannis, G; Sian, IS; Vahdani, K, 2016) |
| " Time after splenectomy >10 years, deferoxamine therapy, and iron overload may be clinical risk factors for severe bacterial infection in patients with NTDT." | 3.81 | Severe bacterial infections in patients with non-transfusion-dependent thalassemia: prevalence and clinical risk factors. ( Chansung, K; Jetsrisuparb, A; Sirijerachai, C; Teawtrakul, N; Wanitpongpun, C, 2015) |
| " Only recently data from combination of Deferasirox/Deferoxamine (DFX/DFO) have been reported showing that it can be safe and efficacious to remove iron overload, particularly in patients who do not respond adequately to a single chelating agent." | 3.80 | Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. ( Cappellini, MD; Cassinerio, E; Duca, L; Fraquelli, M; Orofino, N; Poggiali, E; Roghi, A; Zanaboni, L, 2014) |
| "The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its oral tablet form." | 3.79 | A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. ( Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL, 2013) |
| " The generic drugs deferiprone, deferoxamine and their combination offer a safer, less expensive and complete treatment of iron overload in thalassaemia and other iron loading conditions." | 3.79 | A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? ( Kontoghiorghes, GJ, 2013) |
| " The complete treatment of transfusional iron overload in thalassaemia using the deferiprone (L1) and deferoxamine combination is a paradigm to be followed in the treatment of many other metal toxicity conditions." | 3.79 | The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies. ( Kontoghiorghes, GJ, 2013) |
| "Sixty male mice were randomly divided into five groups: control, iron overload, low-dose Danshen (L-Danshen, 3g/kg/day), high-dose Danshen (H-Danshen, 6g/kg/day) and deferoxamine (DFO) groups (n=12 per group)." | 3.79 | Mechanism of protective effects of Danshen against iron overload-induced injury in mice. ( Chu, L; Gao, Y; Guan, P; Ma, J; Ma, Z; Wang, J; Wang, N; Zhang, J; Zhang, X; Zhang, Y, 2013) |
| "The main objective of the study was to analyze the incidence of iron overload (IO) and its management in transfusion-dependent patients with low-risk myelodysplastic syndrome (MDS) before the license of deferasirox." | 3.76 | Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. ( Arrizabalaga, B; Del Cañizo, C; Remacha, AF; Sanz, G; Villegas, A, 2010) |
| "The iron chelation therapy drugs desferrioxamine B (DFO) and deferiprone (DFP) are used to treat iron overload patients, but not much is known about their adverse effects on other essential metals in vivo." | 3.76 | Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES. ( Gailer, J; Sooriyaarachchi, M, 2010) |
| "In iron overload conditions, plasma contains non-transferrin bound iron species, collectively referred to as plasma NTBI." | 3.76 | Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. ( Eccleston, J; Evans, P; Hider, RC; Kayyali, R; Porter, JB, 2010) |
| "The study evaluated the cost effectiveness of deferasirox (Exjade * ) compared to non-proprietary desferrioxamine (DFO) for the control of transfusional iron overload in lower risk myelodysplastic syndromes (MDS) patients." | 3.76 | Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. ( Bozkaya, D; Li, Q; Migliaccio-Walle, K; Miranda, E; Oliver, N; Tolley, K, 2010) |
| "Since deferoxamine (DFO), a standard iron-chelating agent that is widely used in patients with iron overload such as hemochromatosis or thalassemia, is a kind of hydroxamine siderophore of Streptomyces species, it can accelerate the in vitro growth of ferophilic organisms such as Vibrio vulnificus, Yersinia enterocolitica, and Mucorales." | 3.75 | Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. ( Kim, DM; Neupane, GP, 2009) |
| " The introduction of effective chelation therapy protocols using primarily deferiprone (L1) in combination with deferoxamine (DFO) resulted in the reduction of iron overload induced cardiac failures, which is the main cause of death in thalassemia major." | 3.75 | Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications. ( Kolnagou, A; Kontoghiorghes, GJ, 2009) |
| "Our previous study showed that combined therapy with deferiprone (L1) and deferoxamine (DFO) was safe and efficacious in reducing iron overload in poorly-chelated thalassemia major patients for the short-term but the magnetic resonance imaging (MRI) T2* evaluation was not available at that time." | 3.75 | A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*. ( Chan, GC; Cheuk, DK; Chiang, AK; Chu, WC; Ha, SY; Ho, MH; Mok, AS; Raskalkar, DD, 2009) |
| " The known predisposing factors of infection include prior splenectomy, iron overload and use of iron chelator such as deferoxamine (DFO)." | 3.75 | Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. ( Chan, GC; Chan, S; Ha, SY; Ho, PL, 2009) |
| " Desferrioxamine (DFO) (Desferal; Novartis, Switzerland) and Deferiprone (Ferriprox; Apotex, Canada) are ICTs used to treat iron overload." | 3.74 | Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. ( Abetz, L; Baladi, JF; Desrosiers, MP; Ishak, K; Lordan, N; Payne, KA; Proskorovsky, I; Rofail, D; Viala, M, 2008) |
| "We assessed the degree of iron overload in thalassemia intermedia and major patients by measuring hepatic iron concentration in liver biopsy samples and serum ferritin, estimated erythropoietic drive by assaying soluble transferrin receptor and serum erythropoietin levels and correlated these with urinary hepcidin measurements." | 3.74 | Liver iron concentrations and urinary hepcidin in beta-thalassemia. ( Faa, G; Galanello, R; Ganz, T; Giagu, N; Maccioni, L; Nemeth, E; Origa, R, 2007) |
| " It is also the second case report of a Pearson patient suffering from severe iron overload and liver disease that responded to therapy with deferoxamine." | 3.74 | Pearson syndrome in an infant heterozygous for C282Y allele of HFE gene. ( Augoustides-Savvopoulou, P; Farmaki, E; Karatza, E; Kefala-Agoropoulou, K; Lazaridou, A; Roilides, E; Tsantali, H; Tsiouris, J, 2007) |
| "Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload." | 3.74 | Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. ( Baladi, JF; Coates, TD; Delea, TE; Hagiwara, M; Phatak, PD; Thomas, SK, 2008) |
| " However, other factors may also have similar effects such as the level of iron overload, chronic immuno-stimulation due to transfusions, splenectomy and deferoxamine (DFO)." | 3.74 | Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment. ( Athanassiou-Metaxa, M; Economou, M; Kanakoudi-Tsakalidou, F; Perifanis, V; Taparkou, A; Tourkantoni, N; Tzimouli, V; Zafiriou, D, 2008) |
| "For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group comprising 19 patients on a deferiprone (L1) and DFO combination therapy (L1 75-100 mg/kg/day and DFO 30-60 mg/kg, 1-5 days/week), have been studied and compared before and after the introduction of the combination therapy." | 3.74 | Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2008) |
| "New measures of iron accumulation in liver and heart (superconducting quantum inference device and magnetic resonance imaging), and oral iron chelators (deferiprone and deferasirox) are available for managing iron overload in thalassemia major." | 3.74 | Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. ( Angelucci, E; Barosi, G; Camaschella, C; Cappellini, MD; Cazzola, M; Galanello, R; Marchetti, M; Piga, A; Tura, S, 2008) |
| "The primary objective of the study was to evaluate the cost-utility of deferasirox (Exjade) compared to standard therapy using desferrioxamine (Desferal) for the control of iron overload in patients receiving frequent blood transfusions." | 3.74 | Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. ( Akehurst, R; Jewitt, K; Karnon, J; Ossa, D; Oyee, J; Tolley, K, 2008) |
| "We used combined therapy with desferrioxamine and deferiprone to treat 79 patients with severe iron overload (serum ferritin higher than 3000 ng/mL) who had low compliance with subcutaneous desferrioxamine." | 3.73 | Combined therapy with deferiprone and desferrioxamine in thalassemia major. ( Agus, A; Bina, P; Crobu, G; Defraia, E; Dessì, C; Galanello, R; Leoni, G; Muroni, PP; Origa, R, 2005) |
| " We used cardiovascular magnetic resonance (CMR) to assess the prevalence of myocardial iron overload and ventricular dysfunction in a large cohort of TM patients maintained on conventional chelation treatment with deferoxamine." | 3.73 | Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. ( Anderson, LJ; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Smith, GC; Tanner, MA; Walker, JM; Westwood, MA, 2006) |
| "Deferiprone (L1) is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major." | 3.73 | Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. ( Peng, CT; Tsai, CH; Wu, KH; Wu, SF, 2006) |
| "We investigated the time course of electrocardiographic (ECG) changes in the Mongolian gerbil model of iron overload and the effects of the iron chelator deferoxamine (DFO) on these changes." | 3.72 | Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload." | 3.72 | Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "We studied the changing pattern of the distribution of ferritin levels in 430 regularly-transfused patients with thalassemia in an attempt to evaluate compliance of chelation with deferoxamine." | 3.71 | Variations of ferritin levels over a period of 15 years as a compliance chelation index in thalassemic patients. ( Berdousi, H; Dinopoulos, A; Kattamis, A; Kattamis, C; Ladis, V, 2001) |
| " Because current iron overload therapy uses only Fe(3+) chelators, such as desferrioxamine (DFO), we have tested a hypothesis that addition of a Fe(2+) chelator, 2,2'-dipyridyl (DP), may be more efficient and effective in preventing iron-induced oxidative damage in human liver HepG2 cells than DFO alone." | 3.71 | Ferrous ion autoxidation and its chelation in iron-loaded human liver HepG2 cells. ( Ali, AM; Dai, J; Fournier, J; Frenkel, K; Huang, X; Zhang, Q, 2002) |
| "Compliance with parenteral administration of deferoxamine is often poor in thalassemic patients with iron overload." | 3.71 | Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients. ( Becker, A; Girot, R; Hagège, I; Kanfer, A; Kerdaffrec, T, 2001) |
| "Although the beneficial effects of deferoxamine (DFO) on iron-associated morbidity and mortality are well documented, the role of deferiprone (L1) in the management of transfusional iron overload is controversial." | 3.71 | The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. ( Hershko, C; Huerta, M; Konijn, AM; Link, G; Reinus, C; Rosenmann, E, 2002) |
| "To examine the potential clinical usefulness of the hexadentate phenolic aminocarboxylate iron chelator N, N-bis(2-hydroxybenzyl)ethylenediamine-N,N-diacetic acid (HBED) for the chronic treatment of transfusional iron overload, we compared the iron excretion induced by subcutaneous (SC) injection of HBED and deferoxamine (DFO), the reference chelator, in rodents and primates." | 3.70 | HBED: A potential alternative to deferoxamine for iron-chelating therapy. ( Bergeron, RJ; Brittenham, GM; Wiegand, J, 1998) |
| "To verify efficacy and tolerability of deferoxamine by subcutaneous bolus injection as compared to the conventional pump-driven slow infusion, eleven patients affected by oncohematologic diseases were given 2 g of deferoxamine diluted in 10 mL of distilled water over twelve hours by continuous infusion, or by bolus injection in two divided doses." | 3.70 | Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. ( Aprili, G; Borgna-Pignatti, C; De Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 1998) |
| " The resultant iron overload must be treated with chelation therapy using deferoxamine." | 3.69 | Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy. ( Berdon, WE; Hurlet-Jensen, A; Piomelli, S; Ruzal-Shapiro, C; Sheth, S, 1997) |
| "Iron overload is a pathological condition resulting from a congenital impairment of its regulation, increased intestinal iron absorption secondary to bone marrow erythroid hyperplasia, or a chronic transfusional regimen." | 3.01 | Iron chelation therapy. ( Bova, C; Bruzzese, A; Capodanno, I; Filippelli, G; Gentile, M; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E, 2023) |
| " In principle, iron chelators can be combined with an infinite number of dosing regimens; these involve simultaneous or sequential exposure to the chelators on the same day or alternating the drugs on different days." | 3.01 | Combination chelation therapy. ( Aydinok, Y, 2023) |
| " In this context, the use of curcumin, a dietary phytochemical derived from turmeric, as a natural and safe antioxidant with iron-chelating activity may be a useful strategy for the management of iron overload." | 2.82 | Protective Effects of Curcumin against Iron-induced Toxicity. ( Barati, M; Iranshahy, M; Moinipour, N; Sahebkar, A; Shakeri, A, 2022) |
| "DFP/DFX combination proved superior in improving cardiac T2*, treatment compliance, and patients satisfaction with no greater adverse events." | 2.80 | Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. ( Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y, 2015) |
| "Neutropenia and agranulocytosis were also detected, suggesting needing of strict hematological control." | 2.80 | Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. ( Calvaruso, G; Colletta, G; Di Maggio, R; Gerardi, C; Lai, E; Maggio, A; Pitrolo, L; Quota, A; Rigoli, LC; Sacco, M; Vitrano, A, 2015) |
| "Iron overload is the primary cause of mortality and morbidity in thalassemia major despite advances in chelation therapy." | 2.78 | Combined chelation therapy with deferasirox and deferoxamine in thalassemia. ( Evans, P; Harmatz, P; Kurio, G; Lal, A; Neumayr, L; Ng, V; Porter, J; Sweeters, N; Vichinsky, E, 2013) |
| "We evaluated 36 patients affected by thalassemia major treated with combined chelation therapy." | 2.75 | Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Matola, T; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| "Deferoxamine B is an outstanding molecule which has been widely studied in the past decade for its ability to bind iron and many other metal ions." | 2.72 | Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. ( Bellotti, D; Remelli, M, 2021) |
| "Iron overload is the main cause of morbidity and mortality especially from heart failure in patients with beta thalassemia major (TM)." | 2.72 | Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. ( Daar, S; Pathare, AV, 2006) |
| "Delayed puberty was present in 18." | 2.72 | Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. ( De Sanctis, V; Fortini, M; Galati, MC; Gasser, T; Raiola, G; Roos, M, 2006) |
| " We conclude that the short-term use of L1, with or without DFO, was safe and efficacious in our Chinese patient cohort." | 2.72 | A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. ( Chan, GC; Chik, KW; Ha, SY; Lam, CW; Lee, AC; Ling, SC; Luk, CW; Ng, IO, 2006) |
| " There was no significant difference in the proportion of patients with adverse events in the two therapy groups although the nature of the adverse events differed according to the chelation regimen." | 2.72 | A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. ( Fischer, R; Galanello, R; Kattamis, A; Ladis, V; Leoni, G; Lund, U; Piga, A; Tricta, F; Voi, V, 2006) |
| " Primary objectives included assessment of safety and tolerability (measured by adverse events and clinical laboratory monitoring), pharmacokinetics (measured as drug and drug-iron complex), and cumulative net iron excretion (measured by faecal and urine output minus food input)." | 2.71 | Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. ( Alberti, D; Anderson, JR; Giardina, PJ; Grady, RW; Krebs-Brown, AJ; Nathan, DG; Neufeld, EJ; Nisbet-Brown, E; Olivieri, NF; Séchaud, R; Sizer, KC, 2003) |
| " Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage." | 2.53 | Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016) |
| "Thalassemia is a chronic inherited blood disorder that reduces hemoglobin production, causing chronic hemolytic anemia." | 2.53 | Clinical Management of Patients With Thalassemia Syndromes. ( Haines, D; Martin, M, 2016) |
| "Deferiprone was more efficacious than DFO in improving cardiac ejection fraction [MD 2." | 2.50 | A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. ( Kuo, KH; Mrkobrada, M, 2014) |
| "Iron overload is one of the major causes of morbidity and death in patients undergoing chronic transfusion therapy." | 2.48 | Iron chelation therapy in the management of transfusion-related cardiac iron overload. ( Fernandes, JL, 2012) |
| "Iron overload has many different causes, both genetic and environmental." | 2.48 | Iron mobilization using chelation and phlebotomy. ( Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ, 2012) |
| "Iron overload is frequently observed in patients with hematologic diseases before and after allogeneic stem-cell transplantation because they usually receive multiple red blood cell transfusions." | 2.47 | Iron overload and allogeneic hematopoietic stem-cell transplantation. ( Chao, NJ; Kanda, J; Kawabata, H, 2011) |
| "Deferasirox has been identified to cause fatal gastrointestinal hemorrhages, renal tubulopathy, hepatic and renal failure, alopecia and anaphylactic reactions in addition to previously reported fatal or serious toxic side effects such as agranulocytosis, renal and hepatic toxicity, skin rash and gastric intolerance." | 2.46 | Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. ( Kontoghiorghes, GJ, 2010) |
| "Iron overload is a major cause of morbidity and mortality in transfusion-dependent anemias." | 2.46 | An update on disordered iron metabolism and iron overload. ( Ward, R, 2010) |
| "Monitoring of iron overload has advanced with the increasing use of MRI techniques to estimate iron balance (changes in liver iron concentration) and extrahepatic iron distribution (myocardial T2*)." | 2.46 | Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. ( Porter, JB; Shah, FT, 2010) |
| "Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints." | 2.44 | Chelation therapy for iron overload. ( Barton, JC, 2007) |
| "deferoxamine treatment than combined treatment with deferiprone and deferoxamine." | 2.44 | Light and shadows in the iron chelation treatment of haematological diseases. ( Maggio, A, 2007) |
| "This drug is the most efficacious for treating iron overload but is associated with ocular toxicity: dose and duration related symptomatic optic neuropathy on the one hand, reversible if treatment stopped, and acute retinal involvement followed by irreversible paucisymptomatic pigmentary changes on the other hand." | 2.44 | [Retinal pigment epithelium--desferal]. ( Roulez, F, 2007) |
| "Deferasirox is a new orally effective iron chelator which has been shown to be non-inferior to deferoxamine in clinical trials." | 2.44 | Current status of iron overload and chelation with deferasirox. ( Choudhry, VP; Naithani, R, 2007) |
| "Deferiprone is a three-times-daily oral iron chelator, but has limited availability in the United States." | 2.44 | Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. ( Baladi, JF; Coates, TD; Delea, TE; Edelsberg, J; Phatak, PD; Sofrygin, O; Thomas, SK, 2007) |
| "The only way to treat iron overload caused by blood transfusion is iron chelation therapy." | 2.44 | [Iron overload and iron chelation therapy in transfusion-dependent patients]. ( Suzuki, T, 2008) |
| " However, chelators that access intracellular Fe pools can be toxic by either inhibiting Fe-containing enzymes or promoting Fe-mediated free radical damage." | 2.42 | Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. ( Chaston, TB; Richardson, DR, 2003) |
| "Iron overload was a frequent complication." | 2.42 | Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation. ( Anselstetter, V; Chrobak, L; Denecke, J; Einsiedler, B; Gallmeier, K; Griesshammer, A; Heimpel, H; Janka-Schaub, G; Kohne, E; Kron, M; Marquardt, T, 2003) |
| "If untreated, iron overload is responsible for heart, liver and endocrine diseases." | 2.42 | Pharmacotherapy of iron overload in thalassaemic patients. ( Ceci, A; De Mattia, D; De Sanctis, V; Felisi, M, 2003) |
| " Its regular clinical use is to promote the excretion of an iron overload, when phlebotomy is harmful, and the dosage varies between 2-10 g/d." | 2.41 | Iron metabolism, free radicals, and oxidative injury. ( Beaumont, C; Emerit, J; Trivin, F, 2001) |
| "Deferiprone (L1; CP20) is an orally absorbed bidentate hydroxypyridinone iron chelator that can induce urinary iron excretion, promote negative iron balance and reduce hepatic iron levels in some transfusion-dependent patients, particularly in those who are markedly iron overloaded and have not received regular deferoxamine therapy." | 2.40 | A risk-benefit assessment of iron-chelation therapy. ( Porter, JB, 1997) |
| "Deferoxamine (DFO) is an effective FDA-approved iron chelator." | 1.91 | Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats. ( Jones, G; Kim, J; Zeng, L, 2023) |
| " A complex synthesized from GA and soybean lecithin (SL-GAC), significantly improved bioavailability of GA and pharmacological activities." | 1.91 | Amelioration effects of the soybean lecithin-gallic acid complex on iron-overload-induced oxidative stress and liver damage in C57BL/6J mice. ( Cui, W; Dai, W; Fang, F; Gao, Y; Wu, C; Yan, F; Zhang, W, 2023) |
| " In the United States, deferiprone has been approved for three times daily dosing since 2011 and has recently gained approval for twice-daily administration." | 1.91 | An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes. ( Badawy, SM; Shah, A; Shah, R, 2023) |
| "Deferoxamine (DFO) is an iron-chelator that can protect tissues from iron-induced damage." | 1.91 | Natural polyphenol-based nanoparticles for the treatment of iron-overload disease. ( Gu, Z; Li, Y; Wang, T; Zhang, J; Zhong, J; Zhu, F, 2023) |
| "Iron overload is a major complication of transfusion-dependent thalassemia (TDT) and requires iron chelation (IC) therapy." | 1.62 | Using of deferasirox and deferoxamine in refractory iron overload thalassemia. ( Buaboonnam, J; Narkbunnam, N; Phuakpet, K; Pongtanakul, B; Sanpakit, K; Takpradit, C; Vathana, N; Viprakasit, V, 2021) |
| "Iron overload affects the cell cycle of various cell types, but the effect of iron overload on human pluripotent stem cells has not yet been reported." | 1.56 | Iron overload inhibits self-renewal of human pluripotent stem cells via DNA damage and generation of reactive oxygen species. ( Cao, Y; Chen, L; Djibril, B; Feng, C; Gao, X; Guo, X; Han, Z; Hua, B; Huang, Q; Jin, M; Liu, S; Liu, Y; Ma, W; Wang, X; Xu, Z; Yan, G; Yang, F; Ye, D; Yu, M; Yu, Y; Zhang, W; Zhang, Y, 2020) |
| "Management of beta-thalassemia major (TM) requires life-long hemotransfusions leading to iron overload." | 1.56 | Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities. ( Georgiev, PG; Goranov, SE; Goranova-Marinova, VS; Sapunarova, KG, 2020) |
| "Reversal of arrhythmia to sinus rhythm was noted in all patients." | 1.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
| "Furthermore, NAFLD patients with hepatic RES iron deposition had increased hepatic gene expression levels of M1 markers, IL-6, IL-1β, and CD40 and reduced gene expression of an M2 marker, TGM2, relative to patients with hepatocellular iron deposition pattern." | 1.51 | Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. ( Boukhar, S; Gochanour, E; Handa, P; Kowdley, KV; Maliken, BD; Morgan-Stevenson, V; Thomas, S; Yeh, MM, 2019) |
| "Hypothyroidism is one of the common endocrine complications described in patients with β-thalassemia major (β-TM)." | 1.51 | Compliance with Deferoxamine Therapy and Thyroid Dysfunction of Patients with β-Thalassemia Major in Syria. ( Alquobaili, F; Kabalan, Y; Mukhalalaty, Y; Yassouf, MY, 2019) |
| "Deferiprone was the most effective chelator to improve glucose homeostasis in chronically transfused thalassemics." | 1.48 | Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major. ( Bagmar, S; Dabas, A; Gomber, S; Madhu, SV, 2018) |
| "Deferoxamine treatment of the iron-loaded zebrafish larvae showed a significant decrease in total iron concentration." | 1.48 | Zebrafish larvae as a model to demonstrate secondary iron overload. ( Baji, MH; Mustafa, I; Nasrallah, GK; Shraim, AM; Younes, NN, 2018) |
| "Iron overload is commonly observed during the course of aplastic anemia (AA), which is believed to aggravate hematopoiesis, cause multiple organ dysfunction, lead to disease progression, and impair quality of life." | 1.48 | Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload. ( Hu, H; Liu, W; Wen, X; Wu, D; Ye, B; Zhou, Y, 2018) |
| "Iron-mediated generation of highly toxic Reactive Oxygen Species (ROS) plays a major role in the process leading to iron overload-related diseases." | 1.48 | ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo. ( Liu, Z; Nagy, T; Qiao, J; Xiong, MP, 2018) |
| "Iron overload was assessed by the T2* technique." | 1.48 | The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network. ( Allò, M; Campisi, S; Gamberini, MR; Lisi, R; Mangione, M; Meloni, A; Missere, M; Peluso, A; Pepe, A; Pistoia, L; Positano, V; Renne, S; Ricchi, P; Spasiano, A; Spiga, A, 2018) |
| "Deferasirox monotherapy was less effective than deferiprone in improving myocardial siderosis and biventricular function and less effective than desferrioxamine in improving the LVEF." | 1.48 | MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. ( Allò, M; Cuccia, L; D'Ascola, DG; Gamberini, MR; Lisi, R; Mangione, M; Meloni, A; Pepe, A; Pistoia, L; Positano, V; Restaino, G; Ricchi, P; Righi, R; Rosso, R; Spasiano, A, 2018) |
| "Iron overload was induced by 6 IP injections of Iron dextran (12." | 1.46 | Evaluation of iron chelating and antioxidant potential of Epilobium hirsutum for the management of iron overload disease. ( Desai, TR; Sheikh, NA; Tirgar, PR, 2017) |
| "Cardiac iron overload was induced to a greater extent than in a previous study by feeding the mice with an iron-enriched diet for 4 months." | 1.43 | Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. ( Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S, 2016) |
| "Liver fibrosis is the principal cause of morbidity and mortality in patients with iron overload." | 1.43 | Calcium channel blockers ameliorate iron overload-associated hepatic fibrosis by altering iron transport and stellate cell apoptosis. ( Chang, Y; Chu, L; Chu, X; Gao, Y; Guo, H; Liu, Z; Wang, N; Zhang, J; Zhang, X; Zhang, Y; Zhao, X, 2016) |
| " Using zebrafish embryos and mice, we tested toxicity, iron removal efficacy with low dosing and the biodistribution of ultra-long circulating DFO (ULC-DFO) conjugates." | 1.43 | In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator. ( Abbina, S; Hamilton, JL; Hatef, A; Imran Ul-Haq, M; Kalathottukaren, MT; Kizhakkedathu, JN; Lai, BF; Unniappan, S, 2016) |
| "Iron chelators are used to treat iron overload cardiomyopathy patients." | 1.43 | Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats. ( Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S, 2016) |
| "Patients with thalassemia major become transfusion- dependent with subsequent iron overload." | 1.42 | Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. ( Hagag, AA; Hamam, MA; Hazaa, SM; Taha, OA, 2015) |
| "Pulmonary iron overload was induced in heterozygous β-globin knockout mice (muβth-3/+, BKO)." | 1.42 | Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice. ( Chaisri, U; Fucharoen, S; Hemstapat, W; Morales, NP; Srichairatanakool, S; Svasti, S; Wichaiyo, S; Yatmark, P, 2015) |
| "Iron overload is a common complication of patients with β-thalassemia major (TM)." | 1.40 | Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden. ( Akianidis, V; Christoulas, D; Karavas, A; Komninaka, V; Terpos, E; Voskaridou, E, 2014) |
| "Cardiovascular diseases are a common cause of morbidity and mortality in subjects on regular hemodialysis." | 1.40 | Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload. ( Alnahal, AA; Fathy, A; Fathy, T; Tahan, M, 2014) |
| "Caffeine is a safe, rapidly absorbable molecule that can be linked to other compounds to improve their cell permeability." | 1.40 | Desferrioxamine-caffeine (DFCAF) as a cell permeant moderator of the oxidative stress caused by iron overload. ( Alta, EC; Espósito, BP; Goswami, D; Machini, MT; Nomura, CS; Silvestre, DM, 2014) |
| "Thalassemia major is an inherited form of chronic hemolytic anemia that results in iron overload due to regular blood transfusions." | 1.40 | Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine. ( Poachanukoon, O; Satayasai, W; Silapamongkonkul, P; Surapolchai, P, 2014) |
| "Deferiprone (20·6%) was less commonly prescribed in patients with elevated alanine aminotransferase; while a deferoxamine + deferiprone combination (17·9%) was more commonly used in patients with serum ferritin >2500 ng/ml or CMR T2* <20 ms." | 1.39 | Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. ( Cappellini, MD; Caruso, V; Chiavilli, F; Commendatore, F; Forni, GL; Galanello, R; Longo, F; Mulas, S; Musallam, KM; Piga, A; Quarta, G, 2013) |
| "Deferiprone, because of its lower molecular weight, might cross into heart mitochondria more efficiently, improving their activity and, thereby, myocardial cell function." | 1.39 | Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. ( Barone, R; Calvaruso, G; Campisi, S; Capra, M; Caruso, V; Casale, M; Ciancio, A; Cianciulli, P; Cuccia, L; D'Ascola, G; Filosa, A; Gagliardotto, F; Gerardi, C; Maggio, A; Pitrolo, L; Prossomariti, L; Rigano, P; Rizzo, M; Vitrano, A, 2013) |
| "Transfusional iron overload is of major concern in hematological disease." | 1.39 | Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients. ( Chai, X; Jiang, Y; Liu, Y; Lu, W; Meng, A; Meng, J; Mu, J; Rajbhandary, S; Xie, F; Xu, X; Zhao, M, 2013) |
| " Our results reveal that our novel formulation lowered the dosage requirements by 50%-75%, allowed for less frequent and shorter treatment durations, eliminating the need for a pump and the standard multi-night administration of DFO." | 1.39 | Sickle cell anemia: the impact of discovery, politics, and business. ( Conley, E; Doye, AA; Gwathmey, JK; Xie, LH, 2013) |
| "Deferasirox (DFX) is a novel iron chelator that has been shown to have similar efficacy and safety compared with deferoxamine (DFO) in patients with β-thalassemia." | 1.39 | Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients. ( Javanbakht, M; Karimi, M; Keshtkaran, A; Mashayekhi, A; Nuri, B; Salavati, S, 2013) |
| " Fluctuations in liver enzymes and non-progressive increase in serum creatinine were the most common adverse events (DFX; 9." | 1.38 | Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload. ( Aydinok, Y; Oymak, Y; Türker, ZD; Unal, S; Vergin, C; Yesilipek, A; Yildiz, D, 2012) |
| "Deferasirox is a newer chelation therapy that is taken orally once daily." | 1.38 | Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective. ( Chandiwana, D; Karnon, J; Tolley, K; Vieira, J, 2012) |
| "Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron." | 1.37 | Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. ( Bisconte, MG; Capra, M; Caruso, V; Cianciulli, P; Filosa, A; Lippi, A; Lombardi, M; Maggio, A; Malaventura, C; Meloni, A; Midiri, M; Missere, M; Pepe, A; Pitrolo, L; Positano, V; Prossomariti, L; Putti, MC; Quarta, A; Romeo, MA; Rossi, G, 2011) |
| "Intracerebral hemorrhage was induced by intrastriatal injection of collagenase." | 1.37 | Iron toxicity in mice with collagenase-induced intracerebral hemorrhage. ( Wang, J; Wu, H; Wu, T; Xu, X, 2011) |
| "Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their relative effects on the right ventricle (RV), which is being increasingly recognised as an important prognostic factor in cardiomyopathy." | 1.37 | Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. ( Aessopos, A; Alam, MH; Alpendurada, F; Berdoukas, V; Carpenter, JP; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Roughton, M; Smith, GC; Tanner, MA; Westwood, MA, 2011) |
| "Desferrioxamine has been used for the treatment of iron overload secondary to hemolysis and intrauterine transfusions in Rh isoimmunization cases." | 1.37 | Desferrioxamine treatment of iron overload secondary to RH isoimmunization and intrauterine transfusion in a newborn infant. ( Akısü, M; Arıkan, C; Ay, Y; Bilgin, BS; Köroğlu, OA; Kültürsay, N; Sagol, S; Yalaz, M, 2011) |
| "For chronic conditions such as thalassemia major, even when oral chelation therapy is available, support by an integrated team including a clinical psychologist and nurse specialist working with the treatment center is recommended to achieve optimal results." | 1.37 | Challenges of adherence and persistence with iron chelation therapy. ( El-Beshlawy, A; Evangeli, M; Porter, JB, 2011) |
| "Iron overload is known to exacerbate many infectious diseases." | 1.36 | The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies. ( Kolnagou, A; Kontoghiorghes, GJ; Petrikkos, G; Skiada, A, 2010) |
| "The risk of cardiac death during 1990-1999 and 2000-2008 was compared." | 1.36 | Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. ( Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K, 2010) |
| "Myocardial iron overload is the leading cause of death in patients with beta-thalassemia major." | 1.36 | Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. ( Bina, P; Carta, MP; Cianciulli, P; Farci, P; Galanello, R; Grady, RW; Lai, ME; Maggio, A; Pepe, A; Sau, F; Vacquer, S, 2010) |
| "Patients with thalassemia major accumulate body iron over time as a consequence of continuous red blood cell transfusions which cause hepatic, endocrine, and cardiac complications." | 1.36 | Combined iron chelation therapy. ( Agus, A; Campus, S; Danjou, F; Galanello, R; Giardina, PJ; Grady, RW, 2010) |
| " This regimen is safe and may be an option for poorly compliant patients with significant iron overload." | 1.36 | Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. ( Abboud, MR; Disco, D; Holloman, D; Jackson, S; Kalpatthi, R; Kane, I; Laver, JH; Peters, B; Rackoff, E, 2010) |
| "Brain edema formation following intracerebral hemorrhage (ICH) appears to be partly related to erythrocyte lysis and hemoglobin release." | 1.35 | Brain edema after intracerebral hemorrhage in rats: the role of iron overload and aquaporin 4. ( Dong, YQ; Fang, LD; Heng, PY; Lai, LG; Min, HW; Ping, TQ; Qing, WG; Xia, L, 2009) |
| "Deferoxamine has been used effectively in clinical practice for more than 40 years." | 1.35 | Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias. ( Ault, P; Jones, K, 2009) |
| "Five thalassemia major (TM) patients who were undergoing chelation monotherapy with DFO were enrolled." | 1.35 | Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia. ( Aessopos, A; Assimakopoulos, G; Polonofi, K; Rigaki, K; Tsironi, M, 2008) |
| "We have investigated whether long-term administration of angiotensin (Ang) II causes ferritin induction and iron accumulation in the rat aorta, and their possible relation to regulatory effects on gene expression and vascular function in Ang II-infused animals." | 1.33 | Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats. ( Ishizaka, N; Matsuzaki, G; Mori, I; Nagai, R; Ohno, M; Saito, K, 2005) |
| "In a subset of 10 patients with beta-thalassemia major, the hepatic storage iron concentration had been monitored repeatedly for 12-14 years by chemical analysis of tissue obtained by liver biopsy and by magnetic susceptometry." | 1.33 | Methods for noninvasive measurement of tissue iron in Cooley's anemia. ( Altmann, K; Azabagic, A; Brittenham, GM; Brown, TR; Hordof, AJ; Jensen, JH; Olivieri, NF; Prakash, A; Printz, BF; Sheth, S; Swaminathan, S; Tang, H; Tosti, CL, 2005) |
| "Comprehensive care for thalassemia major (TM) patients has achieved great advances in the world, yet psychosocial developmental aspects of care in families with afflicted members has made only limited progress." | 1.33 | Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan. ( Kuo, HT; Peng, CT; Tsai, MY; Wu, KH, 2006) |
| "The parents of 18 thalassemia major patients (under 12 years of age) were interviewed (in two sessions) to determine their feelings, sources of stress, and support during their childrens' disease process." | 1.33 | Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan. ( Kuo, HT; Peng, CT; Tsai, MY, 2006) |
| "Deferiprone is an iron chelator that has the potential to be more effective than deferoxamine in removing intracellular iron from the heart." | 1.32 | Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. ( Fogliacco, E; Gaglioti, C; Piga, A; Tricta, F, 2003) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 1.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "Treatment of patients with beta-thalassemia major has improved dramatically during the past 40 years; however, the current clinical status of these patients remains poorly characterized." | 1.32 | Complications of beta-thalassemia major in North America. ( Cohen, AR; Cunningham, MJ; Macklin, EA; Neufeld, EJ, 2004) |
| "Type 3 hemochromatosis is a rare autosomal recessive disorder due to mutations of the TFR2 gene." | 1.32 | Type 3 hemochromatosis and beta-thalassemia trait. ( Arosio, C; Bovo, G; Mariani, R; Pelucchi, S; Piperno, A; Riva, A; Salvioni, A; Vergani, A, 2004) |
| "Deferoxamine was more efficient in removing excess iron from the liver but aggravated the disease related anaemia." | 1.32 | Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. ( Arosio, C; Grisoli, M; Mariani, R; Pelucchi, S; Piga, A; Piperno, A; Trombini, P, 2004) |
| "We report a case of thalassemia major with biopsy-proven pulmonary iron overload, in which thoracic high-resolution computed tomography revealed a morphological-functional correlation consistent with small airway disease." | 1.31 | Pulmonary iron overload in thalassemia major presenting as small airway disease. ( Khong, PL; Lam, WK; Ooi, GC; Trendell-Smith, NJ; Tsang, KW, 2002) |
| "Iron overload was evaluated for 26 beta-thalassemia homozygous patients, and 14 of them were submitted to intensive chelation therapy with high doses of intravenous deferoxamine (DF)." | 1.31 | Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. ( Boturao-Neto, E; Marcopito, LF; Zago, MA, 2002) |
| "Congenital erythropoietic porphyria is a rare autosomal recessive disorder of haem biosynthesis caused by a deficiency of uroporphyrinogen III synthetase." | 1.31 | Congenital erythropoietic porphyria: dilemmas in present day management. ( Creamer, JD; Dawe, SA; Du Vivier, A; Peters, TJ, 2002) |
| "Iron overload is associated with long-term cardiac iron accumulation and tissue changes such as fibrosis." | 1.31 | Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. ( Liu, Y; Parkes, JG; Sirna, JB; Templeton, DM, 2000) |
| "Our patient's unusual presentation of intussusception was secondary to the mass effect caused by lymphoid hyperplasia, specifically hypertrophied Peyer's patches in the ileum caused by Y enterocolitica infection." | 1.31 | Intussusception due to Yersinia enterocolitica enterocolitis in a patient with beta-thalassemia. ( Hansen, MG; Levy, M; Pearl, G, 2001) |
| "The recovery from iron overload is hampered by the limited number of pathways and therapeutic agents available for the augmentation of iron secretion/excretion." | 1.31 | Acquisition, storage and release of iron by cultured human hepatoma cells. ( Hirsh, M; Iancu, TC; Konijn, AM, 2002) |
| "To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs, and the patient's physical and social well-being." | 1.31 | Impact of thalassemia major on patients and their families. ( Arana, A; Caro, JJ; Eleftheriou, A; Green, TC; Huybrechts, K; Wait, S; Ward, A, 2002) |
| "Mucormycosis was the primary cause of death in three of the five patients." | 1.30 | Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. ( Boogaerts, MA; Demuynck, H; Maertens, J; Vandenberghe, P; Verbeken, EK; Verhoef, GE; Zachée, P, 1999) |
| "The survival of patients with beta-thalassemia major and intermedia has improved considerably." | 1.30 | Beta-thalassemia and pulmonary function. ( Allegra, L; Ambrosetti, U; Cappellini, MD; Fiorelli, G; Piatti, G; Turati, F, 1999) |
| " This treatment can enhance erythropoiesis without adverse effects." | 1.30 | Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects. ( Chen, JB; Hsu, KT; Lam, KK; Lee, CT; Liao, SC, 1999) |
| "Malondialdehyde values were increased in iron-treated animals, whereas neither ethanol nor desferrioxamine altered malondialdehyde levels significantly." | 1.29 | Hepatotoxicity induced by iron overload and alcohol. Studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation. ( Hagen, K; Hultcrantz, R; Ingelman-Sundberg, M; Johansson, I; Stål, P, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (0.89) | 18.7374 |
| 1990's | 31 (6.92) | 18.2507 |
| 2000's | 198 (44.20) | 29.6817 |
| 2010's | 173 (38.62) | 24.3611 |
| 2020's | 42 (9.38) | 2.80 |
| Authors | Studies |
|---|---|
| Kalinowski, DS | 2 |
| Sharpe, PC | 1 |
| Bernhardt, PV | 2 |
| Richardson, DR | 5 |
| Liu, J | 2 |
| Obando, D | 2 |
| Schipanski, LG | 1 |
| Groebler, LK | 1 |
| Witting, PK | 1 |
| Codd, R | 2 |
| Liao, V | 1 |
| Lifa, T | 1 |
| Jiang, X | 1 |
| Zhou, T | 1 |
| Bai, R | 1 |
| Xie, Y | 1 |
| Moinipour, N | 1 |
| Barati, M | 1 |
| Sahebkar, A | 1 |
| Iranshahy, M | 1 |
| Shakeri, A | 1 |
| Silva, FT | 1 |
| Espósito, BP | 2 |
| Kwiatkowski, JL | 6 |
| Hamdy, M | 3 |
| El-Beshlawy, A | 9 |
| Ebeid, FSE | 2 |
| Badr, M | 1 |
| Alshehri, A | 1 |
| Kanter, J | 2 |
| Inusa, B | 2 |
| Adly, AAM | 1 |
| Williams, S | 3 |
| Kilinc, Y | 5 |
| Lee, D | 2 |
| Tricta, F | 4 |
| Elalfy, MS | 4 |
| Zargari, A | 1 |
| Wu, S | 1 |
| Greenway, A | 1 |
| Cheng, K | 1 |
| Kaplan, Z | 1 |
| Jiang, Z | 1 |
| Wang, H | 3 |
| Qi, G | 1 |
| Jiang, C | 1 |
| Chen, K | 1 |
| Yan, Z | 1 |
| Hašková, P | 1 |
| Applová, L | 1 |
| Jansová, H | 1 |
| Homola, P | 1 |
| Franz, KJ | 1 |
| Vávrová, K | 1 |
| Roh, J | 1 |
| Šimůnek, T | 1 |
| Ni, Z | 1 |
| Li, Y | 7 |
| Song, D | 1 |
| Ding, J | 1 |
| Mei, S | 1 |
| Sun, S | 1 |
| Cheng, W | 1 |
| Yu, J | 1 |
| Zhou, L | 1 |
| Kuang, Y | 1 |
| Li, M | 1 |
| Cai, Z | 1 |
| Yu, C | 1 |
| Di Paola, A | 1 |
| Tortora, C | 1 |
| Argenziano, M | 1 |
| Marrapodi, MM | 1 |
| Rossi, F | 1 |
| Xu, L | 1 |
| Guan, R | 1 |
| Yu, B | 1 |
| Liu, H | 1 |
| Jiang, Y | 2 |
| Feng, W | 1 |
| Xiao, Y | 1 |
| Zhao, C | 2 |
| Zhang, Z | 1 |
| Liu, W | 2 |
| Ma, J | 2 |
| Ganz, T | 2 |
| Zhang, J | 5 |
| Liu, S | 2 |
| Jones, G | 3 |
| Zeng, L | 3 |
| Kim, J | 4 |
| Qadah, T | 1 |
| Wu, C | 1 |
| Zhang, W | 2 |
| Yan, F | 1 |
| Dai, W | 1 |
| Fang, F | 1 |
| Gao, Y | 3 |
| Cui, W | 1 |
| Cui, S | 2 |
| Liu, Z | 7 |
| Nagy, T | 3 |
| Agboluaje, EO | 1 |
| Xiong, MP | 5 |
| Bruzzese, A | 1 |
| Martino, EA | 1 |
| Mendicino, F | 1 |
| Lucia, E | 1 |
| Olivito, V | 1 |
| Bova, C | 1 |
| Filippelli, G | 1 |
| Capodanno, I | 1 |
| Neri, A | 1 |
| Morabito, F | 1 |
| Gentile, M | 1 |
| Vigna, E | 1 |
| Shah, R | 1 |
| Shah, A | 1 |
| Badawy, SM | 1 |
| Zhu, F | 2 |
| Zhong, J | 1 |
| Wang, T | 1 |
| Gu, Z | 2 |
| Dillon, H | 1 |
| Baker, Z | 1 |
| Pena, A | 1 |
| Wang, Y | 4 |
| Syed, H | 1 |
| Sparks, S | 1 |
| Aydinok, Y | 7 |
| Veríssimo, MPA | 1 |
| Temin, NT | 1 |
| Fradette, C | 1 |
| Kumfu, S | 5 |
| Sripetchwandee, J | 3 |
| Thonusin, C | 1 |
| Sumneang, N | 1 |
| Maneechote, C | 1 |
| Arunsak, B | 1 |
| Chunchai, T | 1 |
| Oo, TT | 1 |
| Kongkaew, A | 1 |
| Chattipakorn, SC | 5 |
| Chattipakorn, N | 6 |
| Aalikhani, M | 1 |
| Taheri, E | 1 |
| Khalili, M | 1 |
| Tang, M | 1 |
| Chayakulkeeree, M | 1 |
| Tangkoskul, T | 1 |
| Waywa, D | 1 |
| Tiengrim, S | 1 |
| Pati, N | 1 |
| Thamlikitkul, V | 1 |
| Kang, H | 1 |
| Han, M | 1 |
| Xue, J | 1 |
| Baek, Y | 1 |
| Chang, J | 1 |
| Hu, S | 1 |
| Nam, H | 1 |
| Jo, MJ | 1 |
| El Fakhri, G | 1 |
| Hutchens, MP | 1 |
| Choi, HS | 1 |
| Han, Z | 1 |
| Xu, Z | 2 |
| Chen, L | 1 |
| Ye, D | 1 |
| Yu, Y | 2 |
| Zhang, Y | 9 |
| Cao, Y | 1 |
| Djibril, B | 1 |
| Guo, X | 2 |
| Gao, X | 1 |
| Yu, M | 1 |
| Yan, G | 1 |
| Jin, M | 1 |
| Huang, Q | 1 |
| Wang, X | 1 |
| Hua, B | 1 |
| Feng, C | 1 |
| Yang, F | 1 |
| Ma, W | 1 |
| Liu, Y | 5 |
| Pepe, A | 6 |
| Meloni, A | 4 |
| Filosa, A | 4 |
| Pistoia, L | 3 |
| Borsellino, Z | 1 |
| D'Ascola, DG | 2 |
| Lisi, R | 3 |
| Putti, MC | 3 |
| Allò, M | 3 |
| Gamberini, MR | 3 |
| Quarta, A | 2 |
| Fidone, C | 1 |
| Casini, T | 1 |
| Restaino, G | 2 |
| Midiri, M | 3 |
| Mangione, M | 3 |
| Positano, V | 5 |
| Casale, M | 3 |
| Abobaker, A | 1 |
| Georgiev, PG | 1 |
| Sapunarova, KG | 1 |
| Goranova-Marinova, VS | 1 |
| Goranov, SE | 1 |
| Chuang, TY | 1 |
| Li, JP | 1 |
| Weng, TF | 2 |
| Wu, KH | 8 |
| Chao, YH | 1 |
| Zheng, H | 1 |
| You, J | 1 |
| Yao, X | 1 |
| Lu, Q | 1 |
| Guo, W | 1 |
| Shen, Y | 1 |
| Takpradit, C | 1 |
| Viprakasit, V | 4 |
| Narkbunnam, N | 1 |
| Vathana, N | 1 |
| Phuakpet, K | 1 |
| Pongtanakul, B | 1 |
| Sanpakit, K | 1 |
| Buaboonnam, J | 1 |
| Pinto, VM | 1 |
| Forni, GL | 5 |
| Simchick, GA | 1 |
| Qiao, J | 2 |
| Ashcraft, MM | 1 |
| Zhao, Q | 1 |
| Zi, L | 1 |
| Yang, P | 1 |
| Wei, Y | 2 |
| Zhong, R | 1 |
| You, C | 2 |
| Tian, M | 2 |
| Zeng, X | 1 |
| An, H | 1 |
| Yu, F | 1 |
| Wang, K | 1 |
| Zheng, L | 1 |
| Zhou, W | 1 |
| Bao, Y | 1 |
| Yang, J | 1 |
| Shen, N | 1 |
| Huang, D | 1 |
| Zardkhoni, SZ | 1 |
| Moghaddam, AG | 1 |
| Rad, F | 1 |
| Ghatee, MA | 1 |
| Omidifar, N | 1 |
| Ghaedi, M | 1 |
| Etemadfar, P | 1 |
| Bellotti, D | 1 |
| Remelli, M | 1 |
| Charlebois, E | 1 |
| Pantopoulos, K | 1 |
| Belmouhand, M | 1 |
| Eckmann-Hansen, C | 1 |
| Ilginis, T | 1 |
| Leinøe, EB | 1 |
| Mortensen, BK | 1 |
| Larsen, M | 1 |
| Wang, J | 5 |
| Tang, XQ | 1 |
| Xia, M | 1 |
| Li, CC | 1 |
| Guo, C | 1 |
| Ge, HF | 1 |
| Yin, Y | 1 |
| Wang, B | 1 |
| Chen, WX | 1 |
| Feng, H | 1 |
| Kolnagou, A | 16 |
| Kontoghiorghe, CN | 2 |
| Kontoghiorghes, GJ | 28 |
| Sheikh, NA | 1 |
| Desai, TR | 1 |
| Tirgar, PR | 1 |
| Biliotti, E | 1 |
| Palazzo, D | 1 |
| Serani, M | 1 |
| Silvestri, AM | 1 |
| Volpicelli, L | 1 |
| Esvan, R | 1 |
| Franchi, C | 1 |
| Spaziante, M | 1 |
| Sorrentino, F | 2 |
| Taliani, G | 1 |
| Bollig, C | 1 |
| Schell, LK | 1 |
| Rücker, G | 3 |
| Allert, R | 1 |
| Motschall, E | 2 |
| Niemeyer, CM | 2 |
| Bassler, D | 3 |
| Meerpohl, JJ | 3 |
| Ishida, Y | 1 |
| Okamoto, Y | 1 |
| Matsuoka, Y | 1 |
| Tada, A | 1 |
| Janprasit, J | 1 |
| Yamato, M | 1 |
| Morales, NP | 2 |
| Yamada, KI | 1 |
| Wong, SA | 1 |
| Leitch, HA | 4 |
| Elgharabawy, RM | 1 |
| Elgharbawy, DM | 1 |
| Emara, AM | 2 |
| Gattermann, N | 1 |
| Gomber, S | 1 |
| Dabas, A | 1 |
| Bagmar, S | 1 |
| Madhu, SV | 1 |
| DeGregorio-Rocasolano, N | 1 |
| Martí-Sistac, O | 1 |
| Ponce, J | 1 |
| Castelló-Ruiz, M | 1 |
| Millán, M | 1 |
| Guirao, V | 1 |
| García-Yébenes, I | 1 |
| Salom, JB | 1 |
| Ramos-Cabrer, P | 1 |
| Alborch, E | 1 |
| Lizasoain, I | 1 |
| Castillo, J | 1 |
| Dávalos, A | 1 |
| Gasull, T | 1 |
| Mirlohi, MS | 1 |
| Yaghooti, H | 1 |
| Shirali, S | 1 |
| Aminasnafi, A | 1 |
| Olapour, S | 1 |
| Lin, TM | 2 |
| Chanana, S | 1 |
| Nasrallah, GK | 1 |
| Younes, NN | 1 |
| Baji, MH | 1 |
| Shraim, AM | 1 |
| Mustafa, I | 1 |
| Zou, DM | 1 |
| Rong, DD | 1 |
| Zhao, H | 1 |
| Su, L | 1 |
| Sun, WL | 1 |
| Harrington, JM | 1 |
| Mysore, MM | 1 |
| Crumbliss, AL | 1 |
| Sridharan, K | 1 |
| Sivaramakrishnan, G | 1 |
| Fortin, PM | 1 |
| Fisher, SA | 3 |
| Madgwick, KV | 1 |
| Trivella, M | 1 |
| Hopewell, S | 1 |
| Doree, C | 4 |
| Estcourt, LJ | 1 |
| Wu, D | 1 |
| Wen, X | 1 |
| Hu, H | 1 |
| Ye, B | 1 |
| Zhou, Y | 1 |
| Jauregui, R | 1 |
| Park, KS | 1 |
| Bassuk, AG | 1 |
| Mahajan, VB | 1 |
| Tsang, SH | 1 |
| Ricchi, P | 4 |
| Spasiano, A | 4 |
| Spiga, A | 1 |
| Campisi, S | 2 |
| Peluso, A | 1 |
| Missere, M | 2 |
| Renne, S | 1 |
| Wahidiyat, PA | 1 |
| Yosia, M | 1 |
| Sari, TT | 1 |
| Cui, R | 1 |
| Choi, SE | 1 |
| Kim, TH | 1 |
| Lee, HJ | 1 |
| Lee, SJ | 1 |
| Kang, Y | 1 |
| Jeon, JY | 1 |
| Kim, HJ | 1 |
| Lee, KW | 1 |
| Cuccia, L | 2 |
| Rosso, R | 1 |
| Righi, R | 1 |
| Taher, AT | 6 |
| Origa, R | 6 |
| Perrotta, S | 2 |
| Kouraklis, A | 1 |
| Ruffo, GB | 1 |
| Kattamis, A | 6 |
| Goh, AS | 1 |
| Huang, V | 1 |
| Zia, A | 1 |
| Herranz, RM | 1 |
| Porter, JB | 16 |
| Hider, RC | 4 |
| Hoffbrand, AV | 6 |
| Dou, H | 1 |
| Qin, Y | 1 |
| Chen, G | 1 |
| Zhao, Y | 1 |
| Khdair-Ahmad, F | 1 |
| Aladily, T | 1 |
| Khdair-Ahmad, O | 1 |
| Badran, EF | 1 |
| Ghosh, K | 3 |
| Handa, P | 1 |
| Thomas, S | 1 |
| Morgan-Stevenson, V | 1 |
| Maliken, BD | 1 |
| Gochanour, E | 1 |
| Boukhar, S | 1 |
| Yeh, MM | 1 |
| Kowdley, KV | 1 |
| Lin, CH | 1 |
| Chen, X | 1 |
| Wu, CC | 1 |
| Song, TS | 1 |
| Hsieh, YW | 1 |
| Peng, CT | 9 |
| Qi, X | 1 |
| Li, H | 1 |
| Duan, Z | 1 |
| Zhang, F | 1 |
| Ma, L | 1 |
| Eghbali, A | 1 |
| Shokri, P | 1 |
| Afzal, RR | 1 |
| Bagheri, B | 1 |
| Yassouf, MY | 1 |
| Alquobaili, F | 1 |
| Kabalan, Y | 1 |
| Mukhalalaty, Y | 1 |
| Lee, DH | 1 |
| Jang, PS | 1 |
| Chung, NG | 1 |
| Cho, B | 1 |
| Jeong, DC | 1 |
| Kim, HK | 1 |
| Sivgin, S | 1 |
| Eser, B | 1 |
| Ho, WL | 1 |
| Chung, KP | 1 |
| Yang, SS | 1 |
| Lu, MY | 1 |
| Jou, ST | 1 |
| Chang, HH | 1 |
| Yang, YL | 1 |
| Lin, DT | 1 |
| Lin, KH | 1 |
| Piga, A | 13 |
| Longo, F | 2 |
| Musallam, KM | 5 |
| Cappellini, MD | 13 |
| Quarta, G | 1 |
| Chiavilli, F | 1 |
| Commendatore, F | 1 |
| Mulas, S | 1 |
| Caruso, V | 3 |
| Galanello, R | 13 |
| Abdelmoktader, AM | 1 |
| Azer, HY | 1 |
| Vitrano, A | 3 |
| Rigano, P | 2 |
| Calvaruso, G | 3 |
| Barone, R | 2 |
| Capra, M | 3 |
| Gagliardotto, F | 1 |
| Pitrolo, L | 3 |
| Prossomariti, L | 5 |
| Gerardi, C | 2 |
| Cianciulli, P | 3 |
| Rizzo, M | 1 |
| D'Ascola, G | 1 |
| Ciancio, A | 1 |
| Maggio, A | 8 |
| Nairz, M | 1 |
| Schleicher, U | 1 |
| Schroll, A | 1 |
| Sonnweber, T | 1 |
| Theurl, I | 1 |
| Ludwiczek, S | 1 |
| Talasz, H | 1 |
| Brandacher, G | 1 |
| Moser, PL | 1 |
| Muckenthaler, MU | 1 |
| Fang, FC | 1 |
| Bogdan, C | 1 |
| Weiss, G | 1 |
| Olivieri, NF | 6 |
| Brittenham, GM | 9 |
| Lu, W | 1 |
| Zhao, M | 1 |
| Rajbhandary, S | 1 |
| Xie, F | 1 |
| Chai, X | 1 |
| Mu, J | 1 |
| Meng, J | 1 |
| Xu, X | 2 |
| Meng, A | 1 |
| Ammirabile, M | 2 |
| Costantini, S | 2 |
| Di Matola, T | 2 |
| Cinque, P | 2 |
| Voskaridou, E | 2 |
| Komninaka, V | 1 |
| Karavas, A | 1 |
| Terpos, E | 2 |
| Akianidis, V | 1 |
| Christoulas, D | 1 |
| Vichinsky, E | 6 |
| Torres, M | 1 |
| Minniti, CP | 1 |
| Barrette, S | 1 |
| Habr, D | 6 |
| Files, B | 2 |
| Brunskill, SJ | 3 |
| Gooding, S | 2 |
| Chowdhury, O | 2 |
| Roberts, DJ | 4 |
| Danjou, F | 2 |
| Cossa, S | 1 |
| Matta, G | 1 |
| Bina, P | 3 |
| Dessì, C | 4 |
| Defraia, E | 2 |
| Foschini, ML | 1 |
| Leoni, G | 3 |
| Morittu, M | 1 |
| Xie, LH | 1 |
| Doye, AA | 1 |
| Conley, E | 1 |
| Gwathmey, JK | 1 |
| Imran ul-haq, M | 2 |
| Hamilton, JL | 2 |
| Lai, BF | 2 |
| Shenoi, RA | 1 |
| Horte, S | 1 |
| Constantinescu, I | 1 |
| Kizhakkedathu, JN | 2 |
| Pennell, DJ | 11 |
| Lai, Y | 1 |
| Belhoul, KM | 2 |
| Elalfy, M | 4 |
| Yesilipek, A | 4 |
| Lawniczek, T | 1 |
| Weisskopf, M | 1 |
| Chen, B | 1 |
| Yan, YL | 1 |
| Liu, C | 1 |
| Bo, L | 1 |
| Li, GF | 2 |
| Xu, YJ | 2 |
| Assis, RA | 1 |
| Kassab, C | 1 |
| Seguro, FS | 1 |
| Costa, FF | 1 |
| Silveira, PA | 1 |
| Wood, J | 1 |
| Hamerschlak, N | 1 |
| Qiu, D | 1 |
| Chan, GC | 5 |
| Chu, J | 1 |
| Chan, Q | 1 |
| Ha, SY | 5 |
| Moseley, ME | 1 |
| Khong, PL | 3 |
| Coates, TD | 3 |
| Merkel, DG | 1 |
| Nagler, A | 1 |
| Di Maggio, R | 2 |
| Ballas, S | 1 |
| Steinberg, MH | 1 |
| Sacco, M | 2 |
| Telfer, P | 2 |
| Renda, D | 1 |
| Cassinerio, E | 1 |
| Orofino, N | 1 |
| Roghi, A | 1 |
| Duca, L | 2 |
| Poggiali, E | 1 |
| Fraquelli, M | 1 |
| Zanaboni, L | 2 |
| Alnahal, AA | 1 |
| Tahan, M | 1 |
| Fathy, A | 1 |
| Fathy, T | 1 |
| Tanphaichitr, A | 1 |
| Kusuwan, T | 1 |
| Limviriyakul, S | 1 |
| Atipas, S | 1 |
| Pooliam, J | 1 |
| Sangpraypan, T | 1 |
| Tanphaichitr, VS | 1 |
| Medrano-Engay, B | 1 |
| Irun, P | 1 |
| Gervas-Arruga, J | 1 |
| Andrade-Campos, M | 1 |
| Andreu, V | 1 |
| Alfonso, P | 1 |
| Pocovi, M | 1 |
| Giraldo, P | 1 |
| Alta, EC | 1 |
| Goswami, D | 1 |
| Machini, MT | 1 |
| Silvestre, DM | 1 |
| Nomura, CS | 1 |
| Kuo, KH | 1 |
| Mrkobrada, M | 1 |
| Lai, YR | 1 |
| Shen, J | 2 |
| Quebe-Fehling, E | 1 |
| Surapolchai, P | 1 |
| Poachanukoon, O | 1 |
| Satayasai, W | 1 |
| Silapamongkonkul, P | 1 |
| Adly, AM | 1 |
| Wali, Y | 1 |
| Tony, S | 1 |
| Samir, A | 1 |
| Elhenawy, YI | 1 |
| Lai, E | 1 |
| Colletta, G | 1 |
| Quota, A | 1 |
| Rigoli, LC | 1 |
| Cui, L | 1 |
| Chu, X | 2 |
| Chu, L | 3 |
| Badat, M | 1 |
| Kaya, B | 1 |
| Gammella, E | 1 |
| Recalcati, S | 1 |
| Rybinska, I | 1 |
| Buratti, P | 1 |
| Cairo, G | 1 |
| Ünal, Ş | 2 |
| Tezcan, İ | 1 |
| Güçer, Ş | 1 |
| Boyraz, MS | 1 |
| Çağdaş, D | 1 |
| Uçkan Çetinkaya, D | 1 |
| Karakas, Z | 1 |
| Constantinovici, N | 1 |
| Saliba, AN | 2 |
| Wood, JC | 3 |
| Pressel, S | 1 |
| Rogers, ZR | 1 |
| Odame, I | 1 |
| Lee, MT | 2 |
| Owen, WC | 1 |
| Cohen, AR | 6 |
| St Pierre, T | 1 |
| Heeney, MM | 1 |
| Schultz, WH | 1 |
| Davis, BR | 1 |
| Ware, RE | 1 |
| Hagag, AA | 1 |
| Hamam, MA | 1 |
| Taha, OA | 1 |
| Hazaa, SM | 1 |
| Yatmark, P | 1 |
| Chaisri, U | 1 |
| Wichaiyo, S | 1 |
| Hemstapat, W | 1 |
| Srichairatanakool, S | 2 |
| Svasti, S | 1 |
| Fucharoen, S | 5 |
| Teawtrakul, N | 1 |
| Jetsrisuparb, A | 2 |
| Sirijerachai, C | 1 |
| Chansung, K | 1 |
| Wanitpongpun, C | 1 |
| Bellanti, F | 1 |
| Del Vecchio, GC | 1 |
| Cosmi, C | 1 |
| Fotzi, I | 1 |
| Bakshi, SD | 1 |
| Danhof, M | 1 |
| Della Pasqua, O | 1 |
| El Rassi, F | 1 |
| Pelucchi, S | 3 |
| Pelloni, I | 1 |
| Arosio, C | 3 |
| Mariani, R | 3 |
| Piperno, A | 3 |
| Kalanaky, S | 1 |
| Hafizi, M | 1 |
| Safari, S | 1 |
| Mousavizadeh, K | 1 |
| Kabiri, M | 1 |
| Farsinejad, A | 1 |
| Fakharzadeh, S | 1 |
| Nazaran, MH | 1 |
| Tyagi, P | 1 |
| Kumar, A | 1 |
| Gupta, D | 1 |
| Singh, H | 1 |
| Poggi, M | 1 |
| Pugliese, P | 1 |
| Smacchia, MP | 1 |
| Daniele, C | 1 |
| Equitani, F | 1 |
| Terlizzi, F | 1 |
| Guitarrini, MR | 1 |
| Monti, S | 1 |
| Maffei, L | 1 |
| Losardo, A | 1 |
| Pasin, M | 1 |
| Toscano, V | 1 |
| Yadav, SP | 1 |
| Zhao, X | 1 |
| Chang, Y | 2 |
| Zhang, X | 2 |
| Guo, H | 1 |
| Wang, N | 2 |
| He, XF | 1 |
| Lan, Y | 1 |
| Zhang, Q | 2 |
| Liu, DX | 1 |
| Wang, Q | 1 |
| Liang, FY | 1 |
| Zeng, JS | 1 |
| Xu, GQ | 1 |
| Pei, Z | 1 |
| Martin, M | 2 |
| Haines, D | 1 |
| Abbina, S | 1 |
| Kalathottukaren, MT | 1 |
| Hatef, A | 1 |
| Unniappan, S | 1 |
| Wongjaikam, S | 2 |
| Krintratun, W | 1 |
| Khamseekaew, J | 1 |
| Vahdani, K | 1 |
| Makrygiannis, G | 1 |
| Kaneshyogan, H | 1 |
| Sian, IS | 1 |
| Giasin, O | 1 |
| Purro, M | 1 |
| Sun, W | 1 |
| Ling, S | 1 |
| Zhong, G | 1 |
| Zhao, D | 1 |
| Song, J | 1 |
| Song, H | 1 |
| Li, J | 1 |
| You, L | 1 |
| Nie, G | 1 |
| Tauchenová, L | 1 |
| Křížová, B | 1 |
| Kubánek, M | 1 |
| Fraňková, S | 1 |
| Melenovský, V | 1 |
| Tintěra, J | 1 |
| Kautznerová, D | 1 |
| Malušková, J | 1 |
| Jirsa, M | 1 |
| Kautzner, J | 1 |
| Cerchione, C | 1 |
| Cerciello, G | 1 |
| Avilia, S | 1 |
| Della Pepa, R | 1 |
| Pugliese, N | 1 |
| Picardi, M | 1 |
| Catalano, L | 1 |
| Pane, F | 1 |
| Gumus, E | 1 |
| Abbasoglu, O | 1 |
| Tanyel, C | 1 |
| Gumruk, F | 1 |
| Ozen, H | 1 |
| Yuce, A | 1 |
| Yang, H | 1 |
| Ni, W | 1 |
| Gu, Y | 1 |
| Lee, JW | 1 |
| Payne, KA | 2 |
| Rofail, D | 4 |
| Baladi, JF | 6 |
| Viala, M | 1 |
| Abetz, L | 3 |
| Desrosiers, MP | 2 |
| Lordan, N | 2 |
| Ishak, K | 2 |
| Proskorovsky, I | 2 |
| Taher, A | 6 |
| Otto-Duessel, M | 1 |
| Brewer, C | 1 |
| Gonzalez, I | 1 |
| Nick, H | 1 |
| Qing, WG | 1 |
| Dong, YQ | 1 |
| Ping, TQ | 1 |
| Lai, LG | 1 |
| Fang, LD | 1 |
| Min, HW | 1 |
| Xia, L | 1 |
| Heng, PY | 1 |
| Luckie, M | 1 |
| Irwin, B | 1 |
| Nair, S | 1 |
| Greenwood, J | 1 |
| Khattar, R | 1 |
| Al Zir, K | 1 |
| Daar, S | 3 |
| Kriemler-Krahn, U | 1 |
| Hmissi, A | 1 |
| Al Jefri, A | 1 |
| Kim, CM | 1 |
| Shin, SH | 1 |
| Neupane, GP | 1 |
| Kim, DM | 1 |
| Pattoneri, P | 1 |
| Ozawa, K | 1 |
| Barbieri, L | 1 |
| Macrì, A | 1 |
| Lupia Palmieri, G | 1 |
| Aurizi, C | 1 |
| Biolcati, G | 1 |
| Remacha, AF | 1 |
| Arrizabalaga, B | 2 |
| Del Cañizo, C | 1 |
| Sanz, G | 1 |
| Villegas, A | 2 |
| Dahlui, M | 1 |
| Hishamshah, MI | 1 |
| Rahman, AJ | 1 |
| Aljunid, SM | 1 |
| Adamkiewicz, TV | 1 |
| Abboud, MR | 2 |
| Paley, C | 1 |
| Olivieri, N | 1 |
| Kirby-Allen, M | 1 |
| Casella, JF | 1 |
| Alvarez, OA | 1 |
| Barredo, JC | 1 |
| Iyer, RV | 1 |
| Kutlar, A | 1 |
| McKie, KM | 1 |
| McKie, V | 1 |
| Odo, N | 1 |
| Gee, B | 2 |
| Woods, GM | 1 |
| Coates, T | 3 |
| Wang, W | 1 |
| Adams, RJ | 1 |
| Ault, P | 1 |
| Jones, K | 1 |
| Yazman, D | 1 |
| Economides, C | 3 |
| Eracleous, E | 3 |
| Mok, AS | 1 |
| Chu, WC | 1 |
| Raskalkar, DD | 1 |
| Cheuk, DK | 1 |
| Chiang, AK | 1 |
| Ho, MH | 1 |
| Chan, S | 1 |
| Ho, PL | 1 |
| Efstathiou, A | 1 |
| Kleanthous, M | 3 |
| Michaelides, Y | 2 |
| Fernandes, JL | 2 |
| Fabron, A | 1 |
| Verissimo, M | 1 |
| Farmaki, K | 3 |
| Tzoumari, I | 1 |
| Pappa, C | 1 |
| Chouliaras, G | 2 |
| Berdoukas, V | 3 |
| Prus, E | 1 |
| Fibach, E | 1 |
| Thuret, I | 1 |
| Hacini, M | 1 |
| Pégourié-Bandelier, B | 1 |
| Gardembas-Pain, M | 1 |
| Bisot-Locard, S | 1 |
| Merlat-Guitard, A | 1 |
| Bachir, D | 1 |
| Sugishita, K | 1 |
| Asakawa, M | 1 |
| Usui, S | 1 |
| Takahashi, T | 1 |
| Vickars, LM | 1 |
| Rose, C | 2 |
| Brechignac, S | 1 |
| Vassilief, D | 1 |
| Pascal, L | 1 |
| Stamatoullas, A | 1 |
| Guerci, A | 1 |
| Larbaa, D | 1 |
| Dreyfus, F | 1 |
| Beyne-Rauzy, O | 1 |
| Chaury, MP | 1 |
| Roy, L | 1 |
| Cheze, S | 1 |
| Morel, P | 1 |
| Fenaux, P | 2 |
| Najafzadeh, H | 1 |
| Jalali, MR | 1 |
| Morovvati, H | 1 |
| Taravati, F | 1 |
| Huang, XP | 1 |
| Thiessen, JJ | 1 |
| Spino, M | 1 |
| Templeton, DM | 4 |
| Pagano, L | 1 |
| Fausel, CA | 1 |
| Inati, A | 3 |
| Komvilaisak, P | 1 |
| Wiangnon, S | 1 |
| Jetsrisuparb, C | 1 |
| Balocco, M | 1 |
| Carrara, P | 1 |
| Pinto, V | 1 |
| Skiada, A | 1 |
| Petrikkos, G | 1 |
| Ladis, V | 6 |
| Moraitis, P | 1 |
| Zannikos, K | 1 |
| Berdoussi, E | 1 |
| Kattamis, C | 4 |
| Sooriyaarachchi, M | 1 |
| Gailer, J | 1 |
| Waalen, J | 1 |
| Evans, P | 3 |
| Kayyali, R | 1 |
| Eccleston, J | 1 |
| Lai, ME | 2 |
| Grady, RW | 5 |
| Vacquer, S | 1 |
| Carta, MP | 1 |
| Sau, F | 1 |
| Farci, P | 1 |
| Antes, G | 2 |
| Fleeman, N | 2 |
| Niemeyer, C | 1 |
| Hershko, C | 10 |
| Agus, A | 3 |
| Campus, S | 1 |
| Giardina, PJ | 4 |
| Khoriaty, E | 1 |
| Tolley, K | 3 |
| Oliver, N | 1 |
| Miranda, E | 1 |
| Migliaccio-Walle, K | 1 |
| Bozkaya, D | 1 |
| Li, Q | 1 |
| Ward, R | 1 |
| Malaventura, C | 1 |
| Lippi, A | 1 |
| Romeo, MA | 1 |
| Bisconte, MG | 1 |
| Rossi, G | 1 |
| Lombardi, M | 2 |
| Kalpatthi, R | 1 |
| Peters, B | 1 |
| Kane, I | 1 |
| Holloman, D | 1 |
| Rackoff, E | 1 |
| Disco, D | 1 |
| Jackson, S | 1 |
| Laver, JH | 1 |
| Shah, FT | 1 |
| Wu, H | 1 |
| Wu, T | 1 |
| Buchbinder, D | 1 |
| Nugent, D | 1 |
| Vu, D | 1 |
| Soni, A | 1 |
| Stites, J | 1 |
| Hsieh, L | 1 |
| Puthenveetil, G | 1 |
| Kovacevic, Z | 1 |
| Abdalla, MY | 1 |
| Fawzi, M | 1 |
| Al-Maloul, SR | 1 |
| El-Banna, N | 1 |
| Tayyem, RF | 1 |
| Ahmad, IM | 1 |
| Kanda, J | 1 |
| Kawabata, H | 1 |
| Chao, NJ | 1 |
| Mavrogeni, S | 1 |
| Smith, GC | 3 |
| Alpendurada, F | 1 |
| Carpenter, JP | 1 |
| Alam, MH | 1 |
| Karagiorga, M | 1 |
| Aessopos, A | 2 |
| Gotsis, ED | 1 |
| Tanner, MA | 3 |
| Westwood, MA | 5 |
| Roughton, M | 2 |
| Yalaz, M | 1 |
| Bilgin, BS | 1 |
| Köroğlu, OA | 1 |
| Ay, Y | 1 |
| Arıkan, C | 1 |
| Sagol, S | 1 |
| Akısü, M | 1 |
| Kültürsay, N | 1 |
| Evangeli, M | 1 |
| Manz, CY | 1 |
| Taoka, K | 1 |
| Kumano, K | 1 |
| Nakamura, F | 1 |
| Hosoi, M | 1 |
| Goyama, S | 1 |
| Imai, Y | 1 |
| Hangaishi, A | 1 |
| Kurokawa, M | 1 |
| Bakir, ML | 1 |
| Saned, MS | 1 |
| Kadhim, AM | 1 |
| Oymak, Y | 1 |
| Vergin, C | 1 |
| Türker, ZD | 1 |
| Yildiz, D | 1 |
| Suzuki, T | 2 |
| Flaten, TP | 1 |
| Aaseth, J | 1 |
| Andersen, O | 1 |
| Gaur, A | 1 |
| Armand, P | 1 |
| Sainvil, MM | 1 |
| Kim, HT | 1 |
| Rhodes, J | 1 |
| Cutler, C | 1 |
| Ho, VT | 1 |
| Koreth, J | 1 |
| Alyea, EP | 1 |
| Neufeld, EJ | 4 |
| Kwong, RY | 1 |
| Soiffer, RJ | 1 |
| Antin, JH | 1 |
| Shah, J | 1 |
| Kurtin, SE | 1 |
| Arnold, L | 1 |
| Lindroos-Kolqvist, P | 1 |
| Tinsley, S | 1 |
| Natsiopoulos, K | 1 |
| Ioannou, A | 1 |
| Tazmini, K | 1 |
| Bakken, HN | 1 |
| Schjesvold, FH | 1 |
| Karnon, J | 2 |
| Vieira, J | 1 |
| Chandiwana, D | 1 |
| Chattipakorn, S | 1 |
| Zhao, GY | 1 |
| Zhao, LP | 1 |
| He, YF | 1 |
| Gao, C | 1 |
| Li, K | 2 |
| Ma, Z | 1 |
| Guan, P | 1 |
| Lal, A | 1 |
| Porter, J | 3 |
| Sweeters, N | 1 |
| Ng, V | 1 |
| Neumayr, L | 1 |
| Kurio, G | 1 |
| Harmatz, P | 2 |
| Ruivard, M | 1 |
| Keshtkaran, A | 1 |
| Javanbakht, M | 1 |
| Salavati, S | 1 |
| Mashayekhi, A | 1 |
| Karimi, M | 2 |
| Nuri, B | 1 |
| Moayedi, B | 1 |
| Gharagozloo, M | 1 |
| Esmaeil, N | 1 |
| Maracy, MR | 1 |
| Hoorfar, H | 1 |
| Jalaeikar, M | 1 |
| Ooi, GC | 2 |
| Lam, WK | 1 |
| Trendell-Smith, NJ | 1 |
| Tsang, KW | 1 |
| De Sanctis, V | 5 |
| Jensen, PD | 3 |
| Jensen, FT | 3 |
| Christensen, T | 3 |
| Nielsen, JL | 2 |
| Ellegaard, J | 2 |
| Boturao-Neto, E | 1 |
| Marcopito, LF | 1 |
| Zago, MA | 1 |
| Dawe, SA | 1 |
| Peters, TJ | 1 |
| Du Vivier, A | 1 |
| Creamer, JD | 1 |
| Hoffband, AV | 1 |
| Vogel, M | 1 |
| Anderson, LJ | 5 |
| Holden, S | 2 |
| Deanfield, JE | 1 |
| Walker, JM | 5 |
| Davis, BA | 1 |
| Hoffbrand, VA | 1 |
| Wonke, B | 5 |
| Eiskjaer, H | 1 |
| Baandrup, U | 1 |
| Obejero-Paz, CA | 2 |
| Yang, T | 2 |
| Dong, WQ | 2 |
| Levy, MN | 2 |
| Kuryshev, YA | 2 |
| Brown, AM | 2 |
| Koliakos, G | 1 |
| Papachristou, F | 1 |
| Koussi, A | 1 |
| Perifanis, V | 3 |
| Tsatra, I | 2 |
| Souliou, E | 1 |
| Athanasiou, M | 1 |
| Marshall, SR | 1 |
| Saunders, PW | 1 |
| Hamilton, PJ | 1 |
| Taylor, PR | 1 |
| Mourad, FH | 1 |
| Sheikh-Taha, M | 2 |
| Koussa, S | 2 |
| Khoriaty, AI | 1 |
| Westwood, M | 1 |
| Gaglioti, C | 1 |
| Fogliacco, E | 1 |
| Nisbet-Brown, E | 1 |
| Séchaud, R | 3 |
| Krebs-Brown, AJ | 1 |
| Anderson, JR | 1 |
| Alberti, D | 3 |
| Sizer, KC | 1 |
| Nathan, DG | 1 |
| Chow, KC | 1 |
| Chen, JH | 1 |
| Chiang, YP | 1 |
| Lin, TY | 1 |
| Tsai, CH | 5 |
| De, BK | 1 |
| Roberts, WL | 1 |
| Neocleous, K | 1 |
| Chaston, TB | 1 |
| Heimpel, H | 1 |
| Anselstetter, V | 1 |
| Chrobak, L | 1 |
| Denecke, J | 1 |
| Einsiedler, B | 1 |
| Gallmeier, K | 1 |
| Griesshammer, A | 1 |
| Marquardt, T | 1 |
| Janka-Schaub, G | 1 |
| Kron, M | 1 |
| Kohne, E | 1 |
| Weinberg, ED | 2 |
| NORMAN, CS | 1 |
| HWANG, YF | 1 |
| BROWN, EB | 1 |
| SMITH, RS | 1 |
| PAWELSKI, S | 1 |
| TOPOLSKA, P | 1 |
| ROSZKOWSKI, S | 1 |
| RADECKA, K | 1 |
| Ceci, A | 1 |
| Felisi, M | 1 |
| De Mattia, D | 1 |
| Kubota, N | 1 |
| Miyazawa, K | 1 |
| Shoji, N | 1 |
| Sumi, M | 1 |
| Nakajima, A | 1 |
| Kimura, Y | 1 |
| Oshiro, H | 1 |
| Ebihara, Y | 1 |
| Ohyashiki, K | 1 |
| Chang, JS | 1 |
| Kassou, C | 1 |
| Berdousi, H | 2 |
| Papassotiriou, I | 2 |
| Franchini, M | 6 |
| Gandini, G | 5 |
| Veneri, D | 1 |
| Aprili, G | 5 |
| Chan, KN | 1 |
| Chan, KL | 1 |
| Lam, W | 1 |
| Ng, I | 1 |
| Simonart, T | 1 |
| Cunningham, MJ | 1 |
| Macklin, EA | 1 |
| Riva, A | 1 |
| Bovo, G | 1 |
| Salvioni, A | 1 |
| Vergani, A | 1 |
| Athanassiou-Metaxa, M | 2 |
| Kousi, A | 1 |
| Hatzipantelis, ES | 1 |
| Ikonomou, M | 1 |
| Tsantali, H | 2 |
| Grisoli, M | 1 |
| Trombini, P | 1 |
| Kotyzová, D | 2 |
| Eybl, V | 2 |
| Koutenský, J | 2 |
| Brtko, J | 1 |
| Glattre, E | 1 |
| Tognoni, G | 1 |
| Masera, G | 1 |
| Arora, A | 1 |
| Wren, S | 1 |
| Gregory Evans, K | 1 |
| Davis, B | 1 |
| Prescott, E | 2 |
| Treadwell, MJ | 1 |
| Law, AW | 1 |
| Sung, J | 1 |
| Hackney-Stephens, E | 1 |
| Quirolo, K | 1 |
| Murray, E | 1 |
| Glendenning, GA | 1 |
| Kadkhodaee, M | 1 |
| Gol, A | 1 |
| Hershko, CM | 1 |
| Link, GM | 1 |
| Konijn, AM | 7 |
| Cabantchik, ZI | 5 |
| Cardoso, LM | 1 |
| Pedrosa, ML | 1 |
| Silva, ME | 1 |
| Moraes, MF | 1 |
| Colombari, E | 1 |
| Chianca, DA | 1 |
| González, FA | 1 |
| Alonso, D | 1 |
| Castro, M | 2 |
| Remacha, A | 1 |
| del Arco, A | 1 |
| Martín Núñez, G | 1 |
| Ishizaka, N | 1 |
| Saito, K | 1 |
| Mori, I | 1 |
| Matsuzaki, G | 1 |
| Ohno, M | 1 |
| Nagai, R | 1 |
| Loukopoulos, D | 1 |
| Crobu, G | 1 |
| Muroni, PP | 1 |
| Rees, D | 1 |
| Howard, J | 2 |
| Hyde, C | 1 |
| Alderson, P | 1 |
| Brunskill, S | 1 |
| Link, G | 5 |
| Roggero, S | 1 |
| Vinciguerra, T | 1 |
| Sacchetti, L | 1 |
| Gallo, V | 1 |
| Fischer, R | 3 |
| Nielsen, P | 2 |
| Sheth, S | 2 |
| Tang, H | 1 |
| Jensen, JH | 1 |
| Altmann, K | 1 |
| Prakash, A | 1 |
| Printz, BF | 1 |
| Hordof, AJ | 1 |
| Tosti, CL | 1 |
| Azabagic, A | 1 |
| Swaminathan, S | 1 |
| Brown, TR | 1 |
| Martin, MB | 2 |
| Greenberg, PL | 1 |
| Estornell, J | 1 |
| Orero, M | 1 |
| Pérez, JL | 1 |
| Ridocci, F | 1 |
| Martínez, V | 1 |
| Pathare, AV | 1 |
| Cracolici, E | 1 |
| Malizia, R | 1 |
| De Marchi, D | 1 |
| Karamifar, H | 1 |
| Amirhakimi, G | 1 |
| Sharbatialaei, M | 1 |
| Platis, O | 1 |
| Anagnostopoulos, G | 2 |
| Posantzis, M | 1 |
| Gotsis, E | 2 |
| Tolis, G | 2 |
| Meo, A | 1 |
| Ruggeri, A | 1 |
| La Rosa, MA | 1 |
| Zanghì, L | 1 |
| Morabito, N | 1 |
| Nelson, SC | 1 |
| Hennessy, JM | 1 |
| McDonough, EA | 1 |
| Guck, KL | 1 |
| Rahav, G | 1 |
| Volach, V | 1 |
| Shapiro, M | 1 |
| Rund, D | 1 |
| Rachmilewitz, EA | 1 |
| Goldfarb, A | 1 |
| Nair, SV | 2 |
| Roos, M | 1 |
| Gasser, T | 1 |
| Fortini, M | 1 |
| Raiola, G | 1 |
| Galati, MC | 1 |
| Yilmaz, S | 1 |
| Duman, N | 1 |
| Ozer, E | 2 |
| Kavas, N | 1 |
| Oren, H | 1 |
| Demircioğlu, F | 1 |
| Kumral, A | 1 |
| Ozkan, H | 1 |
| Irken, G | 1 |
| Wu, SF | 2 |
| Chang, JG | 1 |
| Ho, YJ | 1 |
| Wang, CH | 1 |
| Tsai, FJ | 1 |
| Chik, KW | 2 |
| Ling, SC | 1 |
| Lee, AC | 1 |
| Luk, CW | 1 |
| Lam, CW | 1 |
| Ng, IO | 1 |
| Mudiyanse, RM | 1 |
| Kuo, HT | 2 |
| Tsai, MY | 2 |
| Jiang, H | 1 |
| Luan, Z | 1 |
| Xie, J | 1 |
| Zappu, A | 1 |
| Donato, G | 1 |
| Bordone, E | 1 |
| Lavagetto, A | 1 |
| Hewson, N | 1 |
| Ford, JM | 1 |
| Opitz, H | 2 |
| Angelopoulos, N | 1 |
| Rombopoulos, G | 1 |
| Defrère, S | 1 |
| Van Langendonckt, A | 1 |
| Vaesen, S | 1 |
| Jouret, M | 1 |
| González Ramos, R | 1 |
| Gonzalez, D | 1 |
| Donnez, J | 1 |
| El Kelany, RS | 1 |
| Moustafa, KA | 1 |
| Voi, V | 1 |
| Lund, U | 1 |
| Jones, P | 1 |
| Onyekwere, O | 1 |
| Swerdlow, P | 1 |
| Eckman, J | 1 |
| Lane, P | 1 |
| Hassell, K | 1 |
| Kelly, P | 1 |
| Wilson, F | 1 |
| Bernaudin, F | 1 |
| Okpala, I | 1 |
| Ressayre-Djaffer, C | 2 |
| Holland, J | 1 |
| Marks, P | 1 |
| Fung, E | 1 |
| Mueller, BU | 1 |
| Shashaty, G | 1 |
| Frankewich, R | 1 |
| Chakraborti, T | 1 |
| Choudary, J | 1 |
| Al-Fayoumi, S | 1 |
| Kacuba, A | 1 |
| Castillo, S | 1 |
| Robie-Suh, K | 1 |
| Rieves, D | 1 |
| Weiss, K | 1 |
| Pazdur, R | 1 |
| Ambrus, CM | 1 |
| Stadler, I | 1 |
| Toumbis, CA | 1 |
| Stadler, A | 1 |
| Anthone, S | 1 |
| Anthone, R | 1 |
| DeAlarcon, P | 1 |
| Deshpande, G | 1 |
| Conway, J | 1 |
| Vladutiu, AO | 1 |
| Ambrus, JL | 1 |
| Barton, JC | 1 |
| Stumpf, JL | 1 |
| Pearson, HA | 1 |
| Assomull, R | 1 |
| Giagu, N | 1 |
| Maccioni, L | 1 |
| Faa, G | 1 |
| Nemeth, E | 1 |
| Reddy, S | 1 |
| Slakter, J | 1 |
| Aaberg, TM | 1 |
| Singh, RP | 1 |
| Kaiser, PK | 1 |
| Hyde, CJ | 1 |
| Bejaoui, M | 1 |
| Agaoglu, L | 1 |
| Jeng, M | 1 |
| Mangiagli, A | 1 |
| Strauss, G | 1 |
| Girot, R | 2 |
| Watman, N | 1 |
| Ferster, A | 1 |
| Loggetto, S | 1 |
| Abish, S | 1 |
| Cario, H | 1 |
| Zoumbos, N | 1 |
| Roulez, F | 1 |
| Choudhry, VP | 1 |
| Naithani, R | 1 |
| Kefala-Agoropoulou, K | 1 |
| Roilides, E | 1 |
| Lazaridou, A | 1 |
| Karatza, E | 1 |
| Farmaki, E | 1 |
| Augoustides-Savvopoulou, P | 1 |
| Tsiouris, J | 1 |
| Caro, JJ | 2 |
| Delea, TE | 2 |
| Edelsberg, J | 1 |
| Sofrygin, O | 1 |
| Thomas, SK | 2 |
| Phatak, PD | 2 |
| Hagiwara, M | 1 |
| Glimm, E | 1 |
| Fasano, A | 1 |
| Colosimo, C | 1 |
| Miyajima, H | 1 |
| Tonali, PA | 1 |
| Re, TJ | 1 |
| Bentivoglio, AR | 1 |
| Kontos, C | 1 |
| Kyriacou, K | 1 |
| Tsironi, M | 1 |
| Assimakopoulos, G | 1 |
| Polonofi, K | 1 |
| Rigaki, K | 1 |
| Tourkantoni, N | 1 |
| Zafiriou, D | 1 |
| Tzimouli, V | 1 |
| Economou, M | 1 |
| Taparkou, A | 1 |
| Kanakoudi-Tsakalidou, F | 1 |
| Bring, P | 1 |
| Partovi, N | 1 |
| Ford, JA | 1 |
| Yoshida, EM | 1 |
| Manz, C | 1 |
| Naja, M | 1 |
| Eltagui, M | 1 |
| Tarabishi, C | 1 |
| Youssry, I | 1 |
| Sobh, H | 1 |
| Sharaf, I | 1 |
| Mostafa, A | 1 |
| Shaker, O | 1 |
| Angelucci, E | 2 |
| Barosi, G | 1 |
| Camaschella, C | 1 |
| Cazzola, M | 2 |
| Marchetti, M | 1 |
| Tura, S | 1 |
| Besse, EK | 1 |
| Ha, D | 1 |
| Kovtunovych, G | 1 |
| Rouault, TA | 1 |
| Oyee, J | 1 |
| Jewitt, K | 1 |
| Ossa, D | 1 |
| Akehurst, R | 1 |
| Albo, C | 1 |
| Cabrera, J | 1 |
| Dios, A | 1 |
| Ares, C | 1 |
| Constenla, I | 1 |
| López, D | 1 |
| Stål, P | 1 |
| Johansson, I | 1 |
| Ingelman-Sundberg, M | 1 |
| Hagen, K | 1 |
| Hultcrantz, R | 1 |
| McLean, TW | 1 |
| Kurth, S | 1 |
| Sive, AA | 1 |
| Dempster, WS | 1 |
| Rosseau, S | 1 |
| Kelly, M | 1 |
| Malan, H | 1 |
| Heese, HD | 1 |
| Borgna-Pignatti, C | 3 |
| Locatelli, F | 1 |
| Ponchio, L | 1 |
| Beguin, Y | 1 |
| De Stefano, P | 1 |
| Spanos, T | 1 |
| Palamidou, F | 1 |
| Banagi, A | 1 |
| Premetis, E | 1 |
| Mencacci, A | 1 |
| Cenci, E | 1 |
| Boelaert, JR | 2 |
| Bucci, P | 1 |
| Mosci, P | 1 |
| Fè d'Ostiani, C | 1 |
| Bistoni, F | 1 |
| Romani, L | 1 |
| Muretto, P | 1 |
| Lucarelli, G | 1 |
| Ripalti, M | 1 |
| Baronciani, D | 1 |
| Erer, B | 1 |
| Galimberti, M | 1 |
| Giardini, C | 1 |
| Gaziev, D | 1 |
| Polchi, P | 1 |
| Jensen, CE | 1 |
| Tuck, SM | 1 |
| Old, J | 1 |
| Morris, RW | 1 |
| Yardumian, A | 1 |
| Olsen, N | 1 |
| Bagger, JP | 1 |
| Ruzal-Shapiro, C | 1 |
| Hurlet-Jensen, A | 1 |
| Piomelli, S | 1 |
| Berdon, WE | 1 |
| Tilbrook, GS | 1 |
| Bergeron, RJ | 3 |
| Wiegand, J | 3 |
| Di Gregorio, F | 1 |
| Leonardi, C | 1 |
| Sciuto, C | 1 |
| Cannella, A | 1 |
| Pizzarelli, G | 1 |
| Ponka, P | 1 |
| McLaren, CE | 1 |
| Cameron, RG | 1 |
| McClelland, RA | 1 |
| Burt, AD | 1 |
| Fleming, KA | 1 |
| Vassanelli, A | 2 |
| De Gironcoli, M | 3 |
| Galacteros, F | 1 |
| Wright, C | 1 |
| de Montalembert, M | 1 |
| Anghileri, LJ | 1 |
| Thouvenot, P | 1 |
| Stella, M | 1 |
| Pinzello, G | 1 |
| Sher, GD | 1 |
| Bartfay, WJ | 1 |
| Liu, PP | 1 |
| Lehotay, DC | 1 |
| Maertens, J | 1 |
| Demuynck, H | 1 |
| Verbeken, EK | 1 |
| Zachée, P | 1 |
| Verhoef, GE | 1 |
| Vandenberghe, P | 1 |
| Boogaerts, MA | 1 |
| Piatti, G | 1 |
| Allegra, L | 1 |
| Ambrosetti, U | 1 |
| Turati, F | 1 |
| Fiorelli, G | 1 |
| Lee, CT | 1 |
| Liao, SC | 1 |
| Hsu, KT | 1 |
| Lam, KK | 1 |
| Chen, JB | 1 |
| Taramelli, D | 1 |
| Brambilla, S | 1 |
| Sala, G | 1 |
| Bruccoleri, A | 1 |
| Tognazioli, C | 1 |
| Riviera-Uzielli, L | 1 |
| Parkes, JG | 1 |
| Sirna, JB | 1 |
| Miyata, Y | 1 |
| Kajiguchi, T | 1 |
| Saito, M | 1 |
| Takeyama, H | 1 |
| Li, CK | 1 |
| Lai, DH | 1 |
| Shing, MM | 1 |
| Lee, V | 1 |
| Yuen, PM | 1 |
| Hiwase, D | 1 |
| Nursat, N | 1 |
| Cunningham-Rundles, S | 1 |
| Califano, C | 1 |
| McKenzie, P | 1 |
| De Sousa, M | 1 |
| Wayne, AS | 1 |
| Schoenike, SE | 1 |
| Pegelow, CH | 1 |
| Pippard, MJ | 1 |
| Weatherall, DJ | 1 |
| Pattichi, K | 1 |
| Hadjigavriel, M | 1 |
| Prati, D | 1 |
| Breuer, W | 3 |
| Ermers, MJ | 1 |
| Pootrakul, P | 1 |
| Abramov, A | 1 |
| Nick, HP | 1 |
| Powars, DR | 1 |
| Wong, WY | 1 |
| Vachon, LA | 1 |
| Pallister, C | 1 |
| Rotstein, OD | 1 |
| Pinna, A | 1 |
| Corda, L | 1 |
| Carta, F | 1 |
| Rouan, MC | 1 |
| Marfil, F | 1 |
| Mangoni, P | 1 |
| Humbert, H | 1 |
| Maurer, G | 1 |
| Emerit, J | 1 |
| Beaumont, C | 1 |
| Trivin, F | 1 |
| Girelli, D | 1 |
| Lippi, G | 1 |
| Neeman, R | 1 |
| Mourad, F | 1 |
| Hansen, MG | 1 |
| Pearl, G | 1 |
| Levy, M | 1 |
| Cambier, N | 1 |
| Mahieu, M | 1 |
| Ernst, O | 1 |
| Dinopoulos, A | 1 |
| Huang, X | 1 |
| Dai, J | 1 |
| Fournier, J | 1 |
| Ali, AM | 1 |
| Frenkel, K | 1 |
| Hirsh, M | 1 |
| Iancu, TC | 1 |
| Sullivan, JL | 1 |
| Hagège, I | 1 |
| Becker, A | 1 |
| Kerdaffrec, T | 1 |
| Kanfer, A | 1 |
| Kolek, M | 1 |
| Huerta, M | 1 |
| Rosenmann, E | 1 |
| Reinus, C | 1 |
| Ward, A | 1 |
| Green, TC | 1 |
| Huybrechts, K | 1 |
| Arana, A | 1 |
| Wait, S | 1 |
| Eleftheriou, A | 1 |
| Loréal, O | 1 |
| Turlin, B | 1 |
| Pigeon, C | 1 |
| Moisan, A | 1 |
| Ropert, M | 1 |
| Morice, P | 1 |
| Gandon, Y | 1 |
| Jouanolle, AM | 1 |
| Vérin, M | 1 |
| Yoshida, K | 1 |
| Brissot, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias[NCT02041299] | Phase 4 | 230 participants (Actual) | Interventional | 2014-04-17 | Terminated (stopped due to Difficulties with additional recruitment as pool of potential patients was exhausted, and sufficient information for determination of study outcome measure was already obtained) | ||
| Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox[NCT03358498] | 75 participants (Anticipated) | Observational | 2017-12-01 | Not yet recruiting | |||
| A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)[NCT02125877] | Phase 2 | 173 participants (Actual) | Interventional | 2014-07-08 | Completed | ||
| A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions[NCT00600938] | Phase 2 | 197 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Phase 2 Study of Deferasirox-calcium-vitamin D3 to Treat Postmenopausal Osteoporosis (PMOP)[NCT02854722] | Phase 2 | 10 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | ||
| A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload[NCT01511848] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2012-02-29 | Not yet recruiting | ||
| Phase II, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Patients With Severe Cardiac Iron Overload Due to Chronic Blood Transfusion (HYP[NCT01254227] | Phase 2 | 60 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| [NCT00000592] | Phase 3 | 0 participants | Interventional | 1994-07-31 | Completed | ||
| [NCT00006182] | Phase 3 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.[NCT01892644] | Phase 2 | 50 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to Failure to recruit patients with hemochromatosis to the Deferasirox arm) | ||
| Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients[NCT00350662] | Phase 3 | 95 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndromes or Acute Leukemia and Iron Overload[NCT00658411] | 5 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Closed due to slow patient accrual) | |||
| Platelet Changes in Cases of Chronic Iron Over Load[NCT04329286] | 50 participants (Anticipated) | Observational | 2020-04-01 | Not yet recruiting | |||
| Platelet Changes in Cases of Iron Overload(IO)[NCT04329377] | 50 participants (Anticipated) | Observational | 2020-04-01 | Not yet recruiting | |||
| Prospective Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut University Children Hospital (AUCH)[NCT05303506] | 50 participants (Anticipated) | Observational | 2022-07-02 | Not yet recruiting | |||
| Safety of Deferasirox (ICL670) and Deferoxamine (Desferal or DFO) Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload[NCT00901199] | Phase 2 | 22 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Thalassemia Clinical Research Network (TCRN)[NCT00000623] | 1,000 participants (Anticipated) | Observational | 2000-07-31 | Completed | |||
| Acute Effect of a Single Dose of Oral Iron on Pancreatic Beta Cell Function in Healthy Individuals: a Quasi-experimental Single Arm Before-and-after (Pre-post) Study[NCT05238987] | 15 participants (Actual) | Interventional | 2020-10-10 | Completed | |||
| A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis[NCT00067080] | Phase 2 | 195 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Clinical Importance of Treating Iron Overload in Sickle Cell Disease[NCT00981370] | Phase 3 | 1 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to 1 consented patient never started on study drug, lost to follow up) | ||
| A Trial of Oral Nifedipine for the Treatment of Iron Overload[NCT00712738] | Phase 1 | 6 participants (Actual) | Interventional | 2008-06-20 | Completed | ||
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| Hepcidin Levels in Sickle Cell Disease (SCD)[NCT02258997] | 42 participants (Actual) | Observational | 2014-03-31 | Completed | |||
| A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis[NCT00061750] | Phase 3 | 595 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.[NCT00469560] | Phase 3 | 158 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia[NCT00061568] | Phase 1/Phase 2 | 150 participants (Anticipated) | Interventional | 2004-07-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiac iron is measured by MRI in milliseconds (ms). A score of less than 20 ms is indicative of cardiac iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | milliseconds (Least Squares Mean) |
|---|---|
| Deferiprone | -0.022068 |
| Deferoxamine | -0.021773 |
LIC was measured by MRI. A score >7 mg/g dw is indicative of iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | mg of iron per gram of liver dry weight (Least Squares Mean) |
|---|---|
| Deferiprone | -4.13 |
| Deferoxamine | -4.38 |
Serum ferritin provides a measure of iron level in the blood. Normal levels of serum ferritin are under 300 µg/L for females and 400 µg/L for males. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | micrograms per liter (Least Squares Mean) |
|---|---|
| Deferiprone | -385.83 |
| Deferoxamine | -760.89 |
Adult patients completed the SF-36 questionnaire and minors completed the CHQ-PF50. These questionnaires yield a profile of functional health and well-being, based on 8 scales of physical and mental health measures: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and Mental Health (MH), and summary scores are produced for physical well-being and mental well-being. The summaries are scored from 0-100, with higher scores reflecting better outcomes. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| SF-36 Physical Summary | SF-36 Mental Summary | CHQ-PF50 Physical Summary | CHQ-PF50 Psychosocial Summary | |
| Deferiprone | 43.1 | 44.7 | 29.3 | 42.5 |
| Deferoxamine | 43.0 | 40.9 | 30.5 | 41.3 |
Blood samples were collected to assess AUClast. (NCT02125877)
Timeframe: week 1, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose; week 3, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose
| Intervention | umol/L*h (Mean) | |
|---|---|---|
| week1 (n=14,15) | week 3 (n=13,15) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 1110 | 1590 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 1040 | 2110 |
Blood samples were collected to assess deferasirox concentration. Dose-adjusted calculations are presented: (concentration/actual dose)*20 for participants on DFX-DT and (concentration/actual dose)*14 for participants on DFX-FCT. (NCT02125877)
Timeframe: Week 3, day 1, pre-dose (0 hour (h)) and 2 h post-dose; week 13, day 1, pre-dose (0 hour (h)) and 2 h post-dose; and week 21, day 1, pre-dose (0 hour (h)) and 2 h post-dose
| Intervention | umol/L (Mean) | |||||
|---|---|---|---|---|---|---|
| week 3, pre-dose (n=63,70) | week 3, 2 hours post-dose (n=67,76) | week 13, pre-dose (n=69.56) | week 13, 2 hours post-dose (n=74,59) | week 21, pre-dose (n=54,59) | week 21, 2 hours post-dose (n=59,64) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 39.6 | 80.8 | 37.1 | 78.7 | 46.6 | 89.8 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 27.3 | 95.5 | 31.3 | 92.5 | 43.1 | 105 |
The percentage of participants with any GI adverse event, diarrhea, constipation, nausea, vomiting, abdominal pain was assessed. (NCT02125877)
Timeframe: 28 weeks
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any GI adverse event | Abdominal pain | Constipation | Diarrhea | Nausea | Vomiting | |
| Deferasirox Dispersible Tablet (DFX-DT) | 61.6 | 26.7 | 15.1 | 34.9 | 26.7 | 22.1 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 58.6 | 26.4 | 8.0 | 33.3 | 27.6 | 17.2 |
The modified SICT consisted of 13 items that represent 3 domains: adherence, satisfaction and concerns. The adherence domain consisted of 7 items, 6 which were measured using a 5-point response scale and was calculated by summing the 6 items. The score range from 6 to 30 and higher scores indicated worse adherence. The satisfaction domain consisted of 3 items, 2 which were measured using a 5-point response scale and was calculated by summing the 2 items. The score range from 2 to 10 and higher scores indicated worse satisfaction. The concerns domain consisted of 3 items to address any concerns or worries with his/her medication. All 3 items were measured on a 5-point response scale and were calculated by summing the 3 items. The score range from 3 to 15 and higher scores indicated fewer concerns. For all three domains, the meaningful difference between two treatment arms was determined to be 1 point. (NCT02125877)
Timeframe: weeks 2, 3, 13 and 24 (end of treatment or within 7 days of last dose)
| Intervention | score on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| week 2, adherence (n=70,70) | week 2, satisfaction/preference (n=70,70) | week 2, concerns (n=70,70) | week 3, adherence (n=58,51) | week 3, satisfaction/preference (n=58,51) | week 3, concerns (n=58,51) | week 13, adherence (n=59,64) | week 13, satisfaction/preference (n=59,64) | week 13, concerns (n=59,64) | week 24, adherence (n=63,60) | week 24, satisfaction/preference (n=63,60) | week 24, concerns (n=63,60) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 10.3 | 5.2 | 12.9 | 10.9 | 5.4 | 12.4 | 11.2 | 5.4 | 12.7 | 12.5 | 5.8 | 11.8 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 7.6 | 2.8 | 13.8 | 7.7 | 2.6 | 14.0 | 7.8 | 2.9 | 13.6 | 7.5 | 2.9 | 13.7 |
A compliance questionnaire assessed whether the medication was taken. Weekly average compliance was calculated when there were at least four non-missing daily responses. (NCT02125877)
Timeframe: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
| Intervention | Participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| week 1 | week 2 | week 3 | week 4 | week 5 | week 6 | week 7 | week 8 | week 9 | week 10 | week 11 | week 12 | week 13 | week 14 | week 15 | week 16 | week 17 | week 18 | week 19 | week 20 | week 21 | week 22 | week 23 | week 24 | |
| Deferasirox Dispersible Tablet (DFX-DT) | 56 | 64 | 62 | 58 | 56 | 62 | 55 | 56 | 53 | 52 | 50 | 50 | 49 | 51 | 48 | 48 | 43 | 43 | 40 | 40 | 39 | 38 | 36 | 30 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 53 | 64 | 56 | 58 | 58 | 51 | 48 | 46 | 45 | 46 | 42 | 41 | 47 | 42 | 42 | 40 | 39 | 38 | 37 | 36 | 36 | 34 | 33 | 24 |
Blood samples were collected to assess Cmax. (NCT02125877)
Timeframe: week 1, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose; week 3, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose
| Intervention | umol/L (Mean) | |
|---|---|---|
| week 1 (n=14,15) | week 3 (n=14,15) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 74.6 | 118 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 79.3 | 139 |
The percentage of participants with post-baseline laboratory values meeting specified criteria for notable/extended range was assessed. The following laboratory parameters were measured: platelet count, absolute neutrophils, serum creatinine , creatinine clearance, urinary protein/urinary creatinine ratio, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Note that within data categories, creat = creatinine, cons = consecutive, ULN = upper limit of normal and urin = urinary. (NCT02125877)
Timeframe: baseline (BL), 30 weeks
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| platelet count, notable range: <100 x 10^9/L | platelet count, extended range: <50 x 10^9/L | absolute neutrophils, notable range: <1.5 x 10^9/L | absolute neut., extended range: <0.5 x 10^9/L | serum creat, 2 cons >33% incr. from BL and >ULN | creat clearance, notable range: 2 cons <60mL/min | creat clearance, extended range: 2 cons <40mL/min | urin protein/urin creat ratio, 2 cons >1.0 mg/mg | ALT, notable range: >5 x ULN and >2 x BL | ALT, extended range: >10 x ULN and >2 x BL | AST, notable range: >5 x ULN and >2 x BL | AST, extended range: >10 x ULN and >2 x BL | |
| Deferasirox Dispersible Tablet (DFX-DT) | 9.3 | 3.5 | 8.1 | 4.7 | 4.7 | 7.0 | 2.3 | 2.3 | 1.2 | 1.2 | 0 | 1.2 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 8.0 | 5.7 | 13.8 | 0 | 3.4 | 2.3 | 2.3 | 0 | 1.1 | 0 | 1.1 | 0 |
The percentage of participants with adverse events, serious adverse events and deaths was assessed. (NCT02125877)
Timeframe: 28 weeks
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Adverse events | SAEs | Deaths | |
| Deferasirox Dispersible Tablet (DFX-DT) | 89.5 | 15.1 | 0 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 89.7 | 18.4 | 1.1 |
"The palatability questionnaire consisted of 4 items. The first item measured the taste and aftertaste of the medication and were scored a on a 5-point response scale. The second item offered an additional response option of no aftertaste. The last 2 items referred to whether the medication was taken, i.e. swallowed or vomited, and how the participant perceived the amount of medication to be taken. The palatability summary score was calculated using a scoring matrix from items 1, 3 and 4 scores and the score ranges from 0 - 11. Higher scores indicated the best palatability. A meaningful difference between two treatment arms was determined to be 1 point." (NCT02125877)
Timeframe: weeks 2, 3, 13 and 24 (end of treatment or within 7 days of last dose)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| week 2 (n=69,70) | week 3 (n=57,51) | week 13 (n=59,62) | week 24 (n=63,60) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 9.0 | 8.8 | 9.3 | 8.8 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 10.8 | 10.8 | 10.8 | 10.9 |
Blood samples were collected to assess Tmax. (NCT02125877)
Timeframe: week 1, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose; week 3, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose
| Intervention | hour (Median) | |
|---|---|---|
| week 1 (n=14,15) | week 3 (n=14,15) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 3.57 | 2.85 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 2.00 | 2.02 |
The GI symptom diary consisted of 6 items, five which were scored using a 0 - 10 rating scale with item appropriate anchors to rate the symptom, for example, Pain in your belly: 0 = no pain and 10 = worst pain. The GI diary summary score was created using the 10 point response scale for the 5 items. The GI symptom daily diary had a minimum score of 0 and a maximum score of 50. The weekly average score for the 7 days was calculated for each individual item and the GI summary score was created from these weekly averages. Higher scores indicated worse symptoms. A meaningful difference between two treatment arms was determined to be 0.3 point. (NCT02125877)
Timeframe: weeks -1, 4, 8, 12, 16, 20, 24
| Intervention | score on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| week -1 (n=69,65) | week 4 (n=60,64) | week 8 (n=59,51) | week 12 (n=51,45) | week 16 (n=48,41) | week 20 (n40,39) | week 24 (n32,26) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 1.4 | 1.8 | 1.4 | 1.7 | 1.9 | 1.5 | 1.5 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 1.9 | 1.1 | 1.1 | 1.0 | 0.9 | 0.9 | 1.2 |
The dose violation is defined as a dose either missed completely or not taken in accordance with the timing instruction (no later than 12:00 pm. The rate was calculated as [number of dose violations/drug exposure (days)] x 100. (NCT02125877)
Timeframe: weeks 1, 4, 8, 12, 16, 20, 24
| Intervention | percent dose violation (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| week 1 (n=56,53) | week 4 (n=58,58) | week 8 (n=56,46) | week 12 (n=50,41) | week 16 (n=48,40) | week 20 (n=40,36) | week 24 (n=30,24) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 17.7 | 15.8 | 18.0 | 15.7 | 13.5 | 22.6 | 17.1 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 15.8 | 6.7 | 8.4 | 10.7 | 10.0 | 11.3 | 10.1 |
An absolute change from baseline in LVEF after 12 months treatment with deferasirox and compared to.DFO was tested using an analysis of covariance model including baseline left ventricular ejection fraction (LVEF) as a covariate. (NCT00600938)
Timeframe: 12 Month
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL | -0.5 |
| Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO | -0.0 |
An absolute change from baseline in LVEF after 6 months treatment with deferasirox and DFO was summarized (NCT00600938)
Timeframe: 6 Month
| Intervention | Percent (Mean) |
|---|---|
| Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL | -0.95 |
| Deferoxamine (DFO). For Extension Labeled as DFO to DFO | -0.37 |
The number of patients withdrawn from the study due to LVEF <50%, T2* <6 ms or significant decreases in T2* ≥ 33% from baseline was provided per treatment group. (NCT00600938)
Timeframe: 12 Month
| Intervention | Participants (Number) |
|---|---|
| Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL | 3 |
| Core; Deferoxamine (DFO). For Extension Labeled as DFO to DFO | 2 |
Non- inferiority in efficacy of deferasirox compared to deferoxamine (DFO) in treating cardiac iron overload as measured by T2*. A non-inferiority margin of 0.9 (90%) was applied. Due to limitations in performing heart biopsies, T2* (T2 star), a Magnetic Resonance (MR) relaxation parameter expressed in milliseconds, as is an important tool to noninvasively quantify cardiac iron concentration. Studies have shown that myocardial T2* evaluations may predict cardiac events, e.g., impaired (<56%) left ventricular ejection fraction (LVEF) is prevalent among patients with low T2*: found in 62% of patients with T2*<8 ms; 20% with T2* of 8-12 ms; and in 5% with T2* >12 ms (Tanner 2006) (NCT00600938)
Timeframe: 12 Month
| Intervention | Millisecond (Geometric Mean) |
|---|---|
| Core: Deferasirox (ICL) | 1.12 |
| Core: Deferoxamine (DFO) | 1.07 |
Summary statistics of T2* ratio Month 6/baseline (NCT00600938)
Timeframe: 6 Month
| Intervention | Ratio (Geometric Mean) |
|---|---|
| Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL | 1.04 |
| Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO | 1.04 |
The plasma level of deferasirox (ICL670) obtained in this study was summarized descriptively. Plasma concentration was plotted by patient and by visit. Descriptive statistics included the mean, median, SD, and CV, min and max. deferasirox pharmacokinetics (PK) trough levels over the 12 months of treatment and obtained PK profiles for the 40 mg/kg/day deferasirox dose, area under the plasma concentration-time curve for a dosing interval (AUCtau) (NCT00600938)
Timeframe: 12 Month
| Intervention | (h.ng/mL) (Mean) |
|---|---|
| Deferasirox (ICL). For Extension Labeled as ICL to ICL | 2129.70 |
The plasma level of deferasirox (ICL670) obtained in this study was summarized descriptively. Plasma concentration was plotted by patient and by visit. Descriptive statistics included the mean, median, SD, and CV, min and max. deferasirox pharmacokinetics (PK) trough levels over the 12 months of treatment and obtained PK profiles for the 40 mg/kg/day deferasirox dose, maximum plasma concentration (Cmax) (NCT00600938)
Timeframe: 12 Month
| Intervention | umol/L (Mean) |
|---|---|
| Deferasirox (ICL). For Extension Labeled as ICL to ICL | 150.09 |
The plasma level of deferasirox (ICL670) obtained in this study was summarized descriptively. Plasma concentration was plotted by patient and by visit. Descriptive statistics included the mean, median, SD, and CV, min and max. deferasirox pharmacokinetics (PK) trough levels over the 12 months of treatment and obtained PK profiles for the 40 mg/kg/day deferasirox dose, time to reach maximum plasma concentration (Tmax) (NCT00600938)
Timeframe: 12 Month
| Intervention | (h) (Median) |
|---|---|
| Deferasirox (ICL). For Extension Labeled as ICL to ICL | 4.00 |
An absolute change from baseline in LVMI after 6, and 12 months treatment with deferasirox and DFO was summarized (NCT00600938)
Timeframe: 6 Month, 12 Month
| Intervention | gram/m^2 (Mean) | |
|---|---|---|
| Change from Baseline at 6 Month (n= 85, 73) | Change from Baseline at 12 Month/EOS (n= 91, 81) | |
| Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL | 1.01 | 4.13 |
| Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO | 3.32 | 5.25 |
An absolute change from baseline in LVESVI after 6 and 12 months treatment with deferasirox and DFO was summarized. Changes in cardiovascular magnetic resonance (CMR) measured left ventricular end systolic after 6 and 12 months treatment. Left ventricular (LV) end-systolic volume indexed to body surface area (ESVI) is a simple yet powerful echocardiographic marker of LV remodeling that can be measured easily. Left ventricular (LV) end-systolic volume (ESV) has been shown to be an important determinant of survival after myocardial infarction (MI) (NCT00600938)
Timeframe: 6 Month, 12 Month
| Intervention | Milliliter (Mean) | |
|---|---|---|
| Change from baseline at 6 Month (n= 85, 73) | Change from Baseline at 12 Month/EOS (n= 91, 81) | |
| Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL | 1.8 | 1.57 |
| Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO | 0.88 | 0.10 |
An absolute change from baseline in LVEDVI after 6, and 12 months treatment with deferasirox and DFO was summarized (NCT00600938)
Timeframe: 6 Month, 12 Month
| Intervention | Percent (Mean) | |
|---|---|---|
| Change from Baseline at 6 Month (n= 85, 73) | Change from Baseline at 12 Month/EOS (n= 91, 81) | |
| Core; Deferasirox (ICL). For Extension Labeled as ICL to ICL | 1.81 | 1.79 |
| Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO | 1.48 | 1.10 |
Number of patients with adverse events, serious adverse events and death (NCT00600938)
Timeframe: 12 Month
| Intervention | Participants (Number) | ||
|---|---|---|---|
| At least one AE | Serious Adverse Events | Death. None were considered related to study drug. | |
| Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL | 65 | 10 | 1 |
| Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO | 69 | 10 | 1 |
The plasma level of deferasirox (ICL670) obtained in this study was summarized descriptively. Plasma concentration was plotted by patient and by visit. For trough concentration assessments, a 2-mL blood sample was to be taken on arrival at the study site, i.e. prior to the patient receiving the daily deferasirox dose (pre-dose blood sample). A second 2-mL blood sample was to be taken 2 hours later (post-dose sample). At all other visits (Visits 3 - 14), a pre-dose sample was to be taken. For PK profile assessments, 3 blood samples were taken after 1, 2, and 4 hours post-dose in addition to the 2-mL pre-dose (NCT00600938)
Timeframe: Month 1 and month 2 (pre-dose, 1,2 and 4 hours post-dose)
| Intervention | (umol/L) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Month 1, 0 hour (predose) | Month 1, 1 hour (post dos) | Month 1, 2 hour (post dose) | Month 1, 4 hour (post dose) | Month 2, 0 hour (predose) | Month 2, 1 hour (post dose) | Month 2, 2 hour (post dose) | Month 2, 4 hour (post dose) | |
| Deferasirox (ICL). For Extension Labeled as ICL to ICL | 32.25 | 96.32 | 136.47 | 133.33 | 38.66 | 119.48 | 177.19 | 180.76 |
Cardiac function endpoints (LVEF) obtained by CMR at baseline, Months 6, 12, 18 and 24 were summarized by means of descriptive statistics. These analyses were conducted for the measured values as well as for the absolute changes from baseline (NCT00600938)
Timeframe: Months 6, 12, 18 and 24
| Intervention | Percent (Mean) | |||
|---|---|---|---|---|
| Month 6 (n=71,26,40,1) | Month 12 (n= 66,29,42,1) | Month 18 (n=68,26,39,1 ) | Month 24 (n= 63,25,33,1) | |
| Extension: DFO to DFO | -1.8 | 0.3 | -0.8 | -0.6 |
| Extension: DFO to ICL | 0.1 | 0.0 | -1.3 | 0.2 |
| Extension: ICL to DFO | -1.0 | 0 | -10.0 | -18.0 |
| Extension: ICL to ICL | -1.1 | -0.5 | -0.1 | 0.6 |
Cardiac function endpoint (LVEDVI ) obtained by CMR at baseline, Months 6, 12, 18 and 24 were summarized by means of descriptive statistics. These analyses were conducted for the measured values as well as for the absolute changes from baseline (NCT00600938)
Timeframe: Months 6, 12, 18 and 24
| Intervention | mL/m^2 (Mean) | |||
|---|---|---|---|---|
| Month 6 (n=69,26,40,1) | Month 12 (n=64,28,40,1) | Month 18 (n=67,24,35,1) | Month 24 (n=60,23,33,0) | |
| Extension: DFO to DFO | 3.5 | -0.6 | 4.2 | 9.5 |
| Extension: DFO to ICL | 0.5 | 3.0 | 8.3 | 5.4 |
| Extension: ICL to DFO | 1.0 | 4.0 | 36.0 | NA |
| Extension: ICL to ICL | 2.0 | 2.0 | 6.5 | 3.4 |
Cardiac function endpoints (LVESVI) obtained by CMR at baseline, Months 6, 12, 18 and 24 were summarized by means of descriptive statistics. These analyses were conducted for the measured values as well as for the absolute changes from baseline (NCT00600938)
Timeframe: Months 6, 12, 18 and 24
| Intervention | mL/m^2 (Mean) | |||
|---|---|---|---|---|
| Month 6 (n=69,26,40,1) | Month 12 (n=64,28,40,1 ) | Month 18 (n=67,24,35,1 ) | Month 24 (n=60,23,33,0 ) | |
| Extension: DFO to DFO | 3.4 | -0.8 | 2.8 | 4.3 |
| Extension: DFO to ICL | 0 | 0.6 | 4.1 | 1.7 |
| Extension: ICL to DFO | 1 | 2 | 28.0 | NA |
| Extension: ICL to ICL | 1.7 | 1.5 | 2.4 | 1.6 |
Cardiac function endpoints (LVMI) obtained by CMR at baseline, Months 6, 12, 18 and 24 were summarized by means of descriptive statistics. These analyses were conducted for the measured values as well as for the absolute changes (NCT00600938)
Timeframe: Months 6, 12, 18 and 24
| Intervention | gram/m^2 (Mean) | |||
|---|---|---|---|---|
| Month 6 (n=69,26,40,1) | Month 12 (n=64,28,40,1) | Month 18 (n=67,24,35,1) | Month 24 (n=60,23,33,0) | |
| Extension: DFO to DFO | 1.8 | 9.1 | -0.1 | 6.7 |
| Extension: DFO to ICL | 3.2 | 3.4 | 4.0 | 10.3 |
| Extension: ICL to DFO | -6.0 | 1 | 37.0 | NA |
| Extension: ICL to ICL | 1.4 | 4.2 | 4.8 | 5.6 |
The measured T2* values, the ratio (post-baseline / baseline T2*) at Month 6, 12, 18 and 24 was summarized for FAS population along with two-sided 95% CIs. The geometric means of the ratio was presented for all treatment groups (NCT00600938)
Timeframe: Months 6, 12, 18 and 24
| Intervention | Ratio (Geometric Mean) | |||
|---|---|---|---|---|
| Month 6 (n=71,26,40,1) | Month 12(n=66, 29, 41, 1) | Month 18 (n=68, 26, 39, 1) | Month 24 (n=63, 25, 33, 1) | |
| Extension : ICL to ICL | 1.06 | 1.17 | 1.24 | 1.38 |
| Extension; DFO to ICL | 1.03 | 1.07 | 1.13 | 1.21 |
| Extension: DFO to DFO | 1.05 | 1.06 | 1.18 | 1.33 |
| Extension: ICL to DFO | 1.00 | 1.17 | 1.05 | 1.11 |
Results of liver iron content (LIC) measurements by MRI was summarized by descriptive statistics. The absolute value and the absolute change from baseline in LIC at Months 6, 12, 18 and 24 were provided by treatment group. (NCT00600938)
Timeframe: Months 6, 12, 18 and 24
| Intervention | mg Fe/g dw (Mean) | |||
|---|---|---|---|---|
| Month 6 (n=71,26,38,1) | Month 12 (n=69,29,40,1) | Month 18 (n=70,23,38,1) | Month 24 (n=60,24,33,1) | |
| Extension: DFO to DFO | -12.66 | -19.44 | -26.09 | -26.02 |
| Extension: DFO to ICL | -6.30 | -7.98 | -10.87 | -10.96 |
| Extension: ICL to DFO | -3.80 | -3.90 | -2.90 | -3.20 |
| Extension: ICL to ICL | -4.56 | -10.22 | -12.26 | -15.74 |
Serum ferritin values was summarized by descriptive statistics. Absolute value and the absolute change from baseline in serum ferritin by month was provided by treatment group. (NCT00600938)
Timeframe: Months 6, 12, 18 and 24
| Intervention | ug/L (Mean) | |||
|---|---|---|---|---|
| Month 6 (n=72,28,38,0) | Month 12 (n=70,29,40,1) | Month 18 (n=66,24,39,1) | Month 24 (n=59,24,30,0) | |
| Extension: DFO to DFO | -1307.14 | -1877.00 | -2426.92 | -2724.00 |
| Extension: DFO to ICL | -1054.87 | -1223.73 | -1494.82 | -1513.23 |
| Extension: ICL to DFO | NA | -498.00 | -1067.00 | NA |
| Extension: ICL to ICL | -626.10 | -988.46 | -1962.14 | -2239.03 |
Cardiac iron concentration (derived from T2* values) at baseline, Months 6, 12, 18 and 24 were summarized by descriptive statistics. The absolute change from baseline at Months 6, 12, 18 and 24 were also summarized by treatment group. Lliver iron concentration is expressed in units (mg of iron / g of liver tissue dry weight (dw) (NCT00600938)
Timeframe: Months 6, 12, 18 and 24
| Intervention | mg Fe/g dw (Mean) | |||
|---|---|---|---|---|
| Month 6 (n=71,26,40,1) | Month 12 (n=66,29,41,1) | Month 18 (n=68,26,39,1) | Month 24 (n=63,25,33,1) | |
| Extension: DFO to DFO | -0.12 | -0.12 | -0.45 | -0.69 |
| Extension: DFO to ICL | -0.08 | -0.14 | -0.20 | -0.34 |
| Extension: ICL to DFO | 0 | -0.77 | -0.24 | -0.52 |
| Extension: ICL to ICL | -0.12 | -0.38 | -0.47 | -0.70 |
Cardiac T2* is the most sensitive and reproducible test in detecting myocardial iron load. A cardiac T2* value of <10 ms is defined as severe cardiac iron overload. Participants who do not have baseline T2* or do not have any post-baseline T2* are excluded from the analysis. (NCT01254227)
Timeframe: From Baseline to Month 12
| Intervention | ratio (Geometric Mean) |
|---|---|
| All Participants | 1.09 |
Time from date of start of study treatment to date when first achieving T2* ≥ 10 ms (but at least 10% relative increase from baseline) was summarized using the reverse Kaplan-Meier estimates (1 - Kaplan-Meier estimates) for the FAS. (NCT01254227)
Timeframe: At 24 months
| Intervention | milliseconds/ms (Median) |
|---|---|
| All Participants | 722.0 |
Cardiac iron concentration (mg Fe/g dw) was quantified using the formula (cardiac iron concentration (mg Fe/g dw) = 45 * T2* (ms) ^ (-1.22) and analyzed over time. (NCT01254227)
Timeframe: From the Baseline, Month 6, 12, 18 and Month 24
| Intervention | mg Fe/g dw (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 6 | Month 12 | Month 18 | Month 24 | |
| All Participants | 4.18 | 4.31 | 3.93 | 3.51 | 3.14 |
The change in cardiac iron content was calculated as ratio of Cardiac T2* at different time points; the efficacy endpoint analyses were performed on the Full Analysis Set (FAS). (NCT01254227)
Timeframe: From Baseline to Months 6, 18 and 24
| Intervention | ratio (Geometric Mean) | ||
|---|---|---|---|
| Month 6 | Month 18 | Month 24 | |
| All Participants | 1.02 | 1.17 | 1.30 |
Magnetic resonance imaging (MRI)-measured cardiac T2* and cardiac function reflected by left and right ventricle ejection fraction. A standardized MRI protocol for T2* acquisition technique will be used in the centers. Images will be reviewed centrally by an expert MRI reader. (NCT01254227)
Timeframe: From the Months 6, 12, 18 and 24
| Intervention | Percent Ejection Fraction (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 6 | Month 12 | Month 18 | Month 24 | |
| All Participants | 66.5 | 0.1 | -0.2 | 0.6 | 0.9 |
Magnetic resonance imaging (MRI)-measured cardiac T2* and cardiac function reflected by left and right ventricle ejection fraction. A standardized MRI protocol for T2* acquisition technique will be used in the centers. Images will be reviewed centrally by an expert MRI reader. (NCT01254227)
Timeframe: From the Months 6, 12, 18 and 24
| Intervention | Percent Ejection Fraction (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 6 | Month 12 | Month 18 | Month 24 | |
| All Participants | 67.1 | -1.2 | -1.6 | -2.1 | -1.4 |
The number of evaluable participants at each visit were used as the denominator for the calculation of proportion at each visit. (NCT01254227)
Timeframe: From the Months 6, 12, 18 and 24
| Intervention | percentage of participants (Geometric Mean) | |||
|---|---|---|---|---|
| Month 6 | Month12 | Month 18 | Month 24 | |
| All Participants | 12.50 | 19.23 | 33.33 | 47.22 |
Survival information for the 5 patients who were treated with deferoxamine was collected. This information was used to determine transplant-related mortality, relapse, disease-free and overall survival. (NCT00658411)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Transplant-Related Mortality (Deferoxamine) | 0 |
| Relapse (Deferoxamine) | 0 |
| Disease-Free Survival (Deferoxamine) | 5 |
| Overall Survival (Deferoxamine) | 0 |
"All patients meeting the criteria for Severe iron overload as defined by BOTH:~ferritin ≥ 1000 ng/ml and liver iron content(LIC) ≥ 5 mg/gdw were enrolled and received chelation therapy with Deferoxamine. All patients who received chelation therapy were monitored for grade 3 or above toxicity Attributable to Deferoxamine(grades defined by the CTCAE Version 3). The number of participants with grade 3 or higher toxicities were measured and used to determine the safety of chelation therapy." (NCT00658411)
Timeframe: Baseline , 6 month, 1 year
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Baseline | 6 month | 1 year | |
| Deferoxamine | 5 | 0 | 0 |
Comparison of average serum creatinine over 12 months of combined chelation therapy compared with baseline serum creatinine. (NCT00901199)
Timeframe: 12 months
| Intervention | mg/dl (Mean) |
|---|---|
| Deferasirox (Exjade) and Desferal (DFO) | 0.09 |
Change in liver iron concentration from baseline to 12 months with the use of combined chelation therapy. The change was calculated as the liver iron concentration at 12 months minus the value at baseline. (NCT00901199)
Timeframe: 12 months
| Intervention | mg/g (Median) |
|---|---|
| Deferasirox (Exjade) and Desferal (DFO) | -6.2 |
102 reviews available for deferoxamine and Iron Overload
| Article | Year |
|---|---|
The many faces of the adamantyl group in drug design.
Topics: Adamantane; Animals; Antimalarials; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Age | 2011 |
Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities.
Topics: Animals; Humans; Iron Chelating Agents; Iron Overload; Pyridones | 2020 |
Protective Effects of Curcumin against Iron-induced Toxicity.
Topics: Curcumin; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones | 2022 |
Emerging Roles of the Iron Chelators in Inflammation.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Inflammation; Iron; Iron Chelating Agent | 2022 |
Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron | 2022 |
Iron chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating A | 2023 |
Clinical Challenges with Iron Chelation in Beta Thalassemia.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyr | 2023 |
Combination chelation therapy.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hum | 2023 |
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Chelation Therapy; Deferoxamine; Drug | 2020 |
Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator.
Topics: Animals; Antineoplastic Agents; Chelating Agents; Chemistry, Pharmaceutical; COVID-19 Drug Treatment | 2021 |
Iron overload and iron chelating agent exposure in anemia-associated outer retinal degeneration: a case report and review of the literature.
Topics: beta-Thalassemia; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Retinal Degeneration; | 2021 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2017 |
Iron overload in myelodysplastic syndromes (MDS).
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Erythropoiesis; Hepcidins; Humans; Intestin | 2018 |
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; H | 2018 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Defer | 2018 |
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans; | 2018 |
The Role of Deferiprone in Iron Chelation.
Topics: Anemia, Sickle Cell; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Erythr | 2018 |
Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
Topics: Databases, Factual; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Humans; Iron; Iron | 2019 |
The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: where do we stand?
Topics: Animals; Antimicrobial Cationic Peptides; Deferoxamine; Hematologic Neoplasms; Hematology; Hematopoi | 2013 |
Management of the thalassemias.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron | 2013 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; | 2013 |
Oral deferiprone for iron chelation in people with thalassaemia.
Topics: Administration, Oral; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; I | 2013 |
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Def | 2014 |
A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.
Topics: beta-Thalassemia; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agent | 2014 |
Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.
Topics: Animals; Cardiomyopathies; Deferoxamine; Disease Models, Animal; Humans; Iron; Iron Overload; Iron-R | 2015 |
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Mana | 2016 |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; | 2016 |
Clinical Management of Patients With Thalassemia Syndromes.
Topics: Benzoates; Chelation Therapy; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Ma | 2016 |
Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea.
Topics: Anemia, Aplastic; Deferoxamine; Endocrine System; Female; Humans; Iron; Iron Overload; Korea; Liver; | 2008 |
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
Topics: Administration, Oral; Benzoates; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron C | 2008 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agen | 2009 |
[Pathogenesis of transfusional iron overload and iron chelation therapy].
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Drug Design; Erythroc | 2009 |
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Topics: Aged; Anemia; Benzoates; Blood Component Transfusion; Chelation Therapy; Combined Modality Therapy; | 2009 |
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Interactions; Drug Therap | 2010 |
Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusio | 2010 |
An update on disordered iron metabolism and iron overload.
Topics: Animals; Blood Transfusion; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron | 2010 |
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron | 2010 |
Iron-chelating therapy for transfusional iron overload.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyt | 2011 |
Iron overload and allogeneic hematopoietic stem-cell transplantation.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; | 2011 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Def | 2012 |
[Iron overload and iron chelation therapy].
Topics: Benzoates; Deferasirox; Deferoxamine; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelatin | 2012 |
Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Topics: Benzoates; Cardiomyopathy, Dilated; Chelation Therapy; Cross-Sectional Studies; Deferasirox; Deferip | 2012 |
Iron mobilization using chelation and phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overloa | 2012 |
Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating A | 2012 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Ir | 2013 |
Growth and puberty and its management in thalassaemia.
Topics: Adolescent; Adult; Amenorrhea; beta-Thalassemia; Body Height; Calcification, Physiologic; Child; Def | 2002 |
Genetic regulation of cell function in response to iron overload or chelation.
Topics: Animals; Cation Transport Proteins; Cell Cycle; Deferoxamine; DNA-Binding Proteins; Energy Metabolis | 2003 |
Results of long term iron chelation treatment with deferoxamine.
Topics: Deferoxamine; Ear, Inner; Endocrine System Diseases; Eye; Heart Diseases; History, 20th Century; Hum | 2002 |
Long term deferiprone chelation therapy.
Topics: Animals; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iro | 2002 |
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
Topics: Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Risk; Thalassem | 2003 |
Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Topics: Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Deficiencies; Iron Overload | 2003 |
Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation.
Topics: Adolescent; Adult; Aged; Anemia, Dyserythropoietic, Congenital; Child; Child, Preschool; Cholelithia | 2003 |
Iron chelation in chemotherapy.
Topics: Animals; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Lactoferrin; Pyrid | 2003 |
Pharmacotherapy of iron overload in thalassaemic patients.
Topics: Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; I | 2003 |
Purging iron from the heart.
Topics: Cardiomyopathies; Cardiotonic Agents; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron | 2004 |
Iron-chelating therapy with the new oral agent ICL670 (Exjade).
Topics: Administration, Oral; Animals; Benzoates; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; | 2005 |
Monitoring and treatment of iron overload: state of the art and new approaches.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Hemosiderin; Humans; Iron; Iron Chelat | 2005 |
Overcoming the challenge of patient compliance with iron chelation therapy.
Topics: Deferoxamine; Humans; Infusions, Parenteral; Iron Chelating Agents; Iron Overload; Patient Complianc | 2005 |
Treating iron overload: the state of the art.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overloa | 2005 |
Recent acquisitions in the management of iron overload.
Topics: Deferoxamine; Humans; Infusion Pumps; Iron Chelating Agents; Iron Overload; Transfusion Reaction | 2005 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridone | 2005 |
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemo | 2005 |
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overloa | 2005 |
Objectives and mechanism of iron chelation therapy.
Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; | 2005 |
Combined therapy with deferoxamine and deferiprone.
Topics: Agranulocytosis; Biological Transport; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic | 2005 |
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; | 2005 |
T2* magnetic resonance and myocardial iron in thalassemia.
Topics: Adult; Calibration; Cardiomyopathies; Chelation Therapy; Child; Cohort Studies; Combined Modality Th | 2005 |
Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Topics: Administration, Oral; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Erythroc | 2006 |
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis | 2006 |
Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
Topics: Animals; Bacterial Infections; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iro | 2006 |
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; | 2006 |
The impact of iron overload and its treatment on quality of life: results from a literature review.
Topics: Chelation Therapy; Deferoxamine; Episode of Care; Humans; Iron Overload; Quality of Life; Sickness I | 2006 |
New advances in iron chelation therapy.
Topics: Administration, Oral; Deferoxamine; Heart Diseases; Hematologic Diseases; Humans; Iron Chelating Age | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferipron | 2007 |
Deferasirox.
Topics: Adult; Benzoates; Child; Deferasirox; Deferoxamine; Hematologic Diseases; Hemosiderosis; Humans; Iro | 2007 |
Oral deferiprone for iron chelation in people with thalassaemia.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridone | 2007 |
Light and shadows in the iron chelation treatment of haematological diseases.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; | 2007 |
[Retinal pigment epithelium--desferal].
Topics: Animals; Deferoxamine; Humans; Injections, Intravenous; Iron Overload; Optic Nerve Diseases; Risk Fa | 2007 |
Current status of iron overload and chelation with deferasirox.
Topics: Benzoates; beta-Thalassemia; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron Chela | 2007 |
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cost of Illness; Deferiprone; Deferoxamine; Humans | 2007 |
Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Topics: Benzoates; Chemistry, Pharmaceutical; Crystallography, X-Ray; Deferasirox; Deferiprone; Deferoxamine | 2007 |
Pediatric iron overload.
Topics: Chelating Agents; Child; Deferoxamine; Humans; Iron; Iron Overload; Neoplasms | 2007 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, C | 2008 |
Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelat | 2008 |
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Diet; Drug Therapy, Combination; Humans; Iron Che | 2008 |
[Iron overload and iron chelation therapy in transfusion-dependent patients].
Topics: Benzoates; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron O | 2008 |
Oral iron chelators.
Topics: Administration, Oral; Benzoates; Chelating Agents; Child; Deferasirox; Deferiprone; Deferoxamine; Er | 2008 |
A risk-benefit assessment of iron-chelation therapy.
Topics: Administration, Oral; Clinical Trials as Topic; Deferiprone; Deferoxamine; Guidelines as Topic; Huma | 1997 |
Iron chelators for clinical use.
Topics: Biological Transport; Deferoxamine; Drug Delivery Systems; Edetic Acid; Ferric Compounds; Free Radic | 1998 |
Iron chelators for thalassaemia.
Topics: Administration, Oral; Aza Compounds; Chelating Agents; Deferiprone; Deferoxamine; Edetic Acid; Human | 1998 |
Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism.
Topics: Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Reticulocytes | 1998 |
[Secondary iron overload].
Topics: Adult; Anemia, Dyserythropoietic, Congenital; Anemia, Hemolytic; Bone Marrow Examination; Chelating | 1998 |
[Iron chelation in 1998].
Topics: Administration, Oral; Deferiprone; Deferoxamine; Ferritins; Humans; Injections, Intramuscular; Injec | 1998 |
[Development of arterial thrombus of Mucorales hyphae during deferoxamine therapy in a patient with aplastic anemia in transformation to myelodysplastic syndrome].
Topics: Anemia, Aplastic; Chelating Agents; Deferoxamine; Fatal Outcome; Female; Humans; Iron Overload; Midd | 2000 |
Oral iron chelation therapy for thalassaemia: an uncertain scene.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron | 2000 |
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Topics: Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reac | 2000 |
Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major.
Topics: Anemia, Hemolytic; beta-Thalassemia; Blood Group Incompatibility; Blood Transfusion; Cardiovascular | 2000 |
Iron metabolism, free radicals, and oxidative injury.
Topics: Antioxidants; Deferoxamine; Drug Therapy, Combination; Free Radicals; Homeostasis; Humans; Hydrogen | 2001 |
Chelation therapy in beta-thalassemia: an optimistic update.
Topics: beta-Thalassemia; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overl | 2001 |
Practical management of iron overload.
Topics: Bone Marrow Transplantation; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Patie | 2001 |
[Iron overload and myelodysplastic syndromes].
Topics: Administration, Oral; Aged; Biopsy; Chelation Therapy; Deferiprone; Deferoxamine; Erythrocyte Transf | 2001 |
53 trials available for deferoxamine and Iron Overload
| Article | Year |
|---|---|
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron | 2022 |
Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254.
Topics: Anemia; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload | 2023 |
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Humans; Iron; Iron C | 2024 |
Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage.
Topics: Animals; Apoproteins; Brain Ischemia; Deferoxamine; Female; Humans; Iron; Iron Overload; Lipid Perox | 2018 |
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
Topics: Adult; Blood Transfusion; Chelation Therapy; Deferoxamine; Female; Humans; Iron Chelating Agents; Ir | 2018 |
Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Topics: Administration, Oral; Adult; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Deferasirox; De | 2019 |
A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Deferasirox; Deferoxamine; Double-Blind M | 2019 |
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therap | 2013 |
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferoxamine; Female; Ferritins; | 2014 |
Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Child; Deferiprone; Deferoxamine; Female; | 2014 |
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; | 2015 |
Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Child; Deferoxamine; Female; Humans; Iron; Iron | 2015 |
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxa | 2015 |
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2015 |
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Female; Heart; Humans; Iron Chelatin | 2015 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Pre | 2015 |
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxa | 2009 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Cardiomyopathies; Child; Deferiprone; Deferoxami | 2010 |
Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results.
Topics: Adult; Aged; Aged, 80 and over; Blood Transfusion; Chelation Therapy; Child; Cross-Sectional Studies | 2009 |
Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Administrati | 2010 |
Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Topics: Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron C | 2010 |
Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
Topics: Adolescent; beta-Thalassemia; Blood Proteins; Blood Transfusion; Chelation Therapy; Child; Deferipro | 2012 |
Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT.
Topics: Adult; Chelation Therapy; Deferoxamine; Drug Monitoring; Early Termination of Clinical Trials; Feasi | 2013 |
Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Drug Synergism; F | 2013 |
A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
Topics: Adolescent; Adult; Antimicrobial Cationic Peptides; beta-Thalassemia; Deferoxamine; Double-Blind Met | 2013 |
Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias.
Topics: Adult; Aged; Anemia; Chelation Therapy; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; I | 2003 |
Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Chelating Agents; Child; Deferiprone; Defero | 2003 |
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.
Topics: Adolescent; Adult; Area Under Curve; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Dose-Re | 2003 |
Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; Deferoxamine; Female; Fe | 2003 |
Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Combined Modality Therapy; Deferiprone; Defe | 2003 |
Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Com | 2004 |
Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deferiprone; Deferoxamine; Erythrocyte | 2006 |
Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Humans; Iron Overload; Magnetic Resonanc | 2006 |
Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Thera | 2004 |
Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
Topics: Adolescent; Adult; beta-Thalassemia; Body Height; Child; Child, Preschool; Deferoxamine; Female; Glu | 2006 |
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modali | 2006 |
A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Topics: Adolescent; Adult; Arthralgia; beta-Thalassemia; Biopsy, Needle; Chelation Therapy; Child; Combined | 2006 |
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chel | 2006 |
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.
Topics: Adolescent; Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Overlo | 2006 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood | 2007 |
Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasi | 2006 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2007 |
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
Topics: Adolescent; Adult; Antidotes; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Def | 2007 |
Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major.
Topics: Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferoxamine; Erythrocyte Transfusion; F | 2008 |
Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Deferiprone; Deferoxamine; Drug Admin | 2008 |
The impact of neocyte transfusion in the management of thalassaemia.
Topics: Adolescent; beta-Thalassemia; Cell Separation; Centrifugation, Density Gradient; Chelation Therapy; | 1996 |
Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients.
Topics: Adolescent; Bone Marrow Transplantation; Chelation Therapy; Child; Combined Modality Therapy; Defero | 1997 |
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Biopsy; Child; Deferiprone; Deferoxamine; Disease Progression; | 1998 |
Combined therapy with deferiprone and desferrioxamine.
Topics: Adolescent; Adult; Aged; beta-Thalassemia; Deferiprone; Deferoxamine; Dose-Response Relationship, Dr | 1998 |
Early iron reduction programme for thalassaemia patients after bone marrow transplantation.
Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Bone Marrow Transplantation; Chelating Ag | 2000 |
Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload.
Topics: Adult; Aged; Chelating Agents; Deferoxamine; Female; Ferritins; Follow-Up Studies; Humans; Infusions | 2000 |
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; De | 2001 |
293 other studies available for deferoxamine and Iron Overload
| Article | Year |
|---|---|
Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
Topics: Antineoplastic Agents; Ascorbic Acid; Benzoates; Cell Line, Tumor; Cell Proliferation; Crystallograp | 2008 |
Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
Topics: Adamantane; Administration, Oral; Animals; Binding Sites; Carboxylic Acids; Cell Proliferation; Cell | 2010 |
Intracellular Iron Binding and Antioxidant Activity of Phytochelators.
Topics: Antioxidants; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Mimosine; Pyridones; | 2022 |
Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; Ferritins; | 2022 |
Iron overload-induced ferroptosis of osteoblasts inhibits osteogenesis and promotes osteoporosis: An in vitro and in vivo study.
Topics: Animals; Deferoxamine; Dextrans; Ferroptosis; Glutathione; Iron; Iron Overload; Malondialdehyde; Mic | 2022 |
Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.
Topics: Animals; Catecholamines; Deferasirox; Deferiprone; Deferoxamine; Dopamine; Iron; Iron Chelating Agen | 2022 |
Iron-overloaded follicular fluid increases the risk of endometriosis-related infertility by triggering granulosa cell ferroptosis and oocyte dysmaturity.
Topics: Animals; Deferoxamine; Endometriosis; Female; Ferroptosis; Follicular Fluid; Granulosa Cells; Humans | 2022 |
Fluorene methoxycarbonyl-PEG-deferoxamine conjugates "hitchhike" with albumin in situ for iron overload therapy.
Topics: Albumins; Deferoxamine; Fluorenes; Humans; Iron; Iron Chelating Agents; Iron Overload; Polyethylene | 2022 |
New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis.
Topics: Amines; Animals; Deferiprone; Deferoxamine; Dextrans; Ferroptosis; Hemochromatosis; Humans; Iron; Ir | 2022 |
Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
Topics: Animals; Chelating Agents; Deferoxamine; Iron Overload; Rats; Rats, Sprague-Dawley | 2023 |
Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
Topics: Animals; Chelating Agents; Deferoxamine; Iron Overload; Rats; Rats, Sprague-Dawley | 2023 |
Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
Topics: Animals; Chelating Agents; Deferoxamine; Iron Overload; Rats; Rats, Sprague-Dawley | 2023 |
Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
Topics: Animals; Chelating Agents; Deferoxamine; Iron Overload; Rats; Rats, Sprague-Dawley | 2023 |
Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
Topics: Animals; Chelating Agents; Deferoxamine; Iron Overload; Rats; Rats, Sprague-Dawley | 2023 |
Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
Topics: Animals; Chelating Agents; Deferoxamine; Iron Overload; Rats; Rats, Sprague-Dawley | 2023 |
Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
Topics: Animals; Chelating Agents; Deferoxamine; Iron Overload; Rats; Rats, Sprague-Dawley | 2023 |
Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
Topics: Animals; Chelating Agents; Deferoxamine; Iron Overload; Rats; Rats, Sprague-Dawley | 2023 |
Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
Topics: Animals; Chelating Agents; Deferoxamine; Iron Overload; Rats; Rats, Sprague-Dawley | 2023 |
Amelioration effects of the soybean lecithin-gallic acid complex on iron-overload-induced oxidative stress and liver damage in C57BL/6J mice.
Topics: Animals; Antioxidants; Deferoxamine; Gallic Acid; Glycine max; Iron; Iron Overload; Lecithins; Lipid | 2023 |
Oral Non-absorbable Polymer-Deferoxamine Conjugates for Reducing Dietary Iron Absorption.
Topics: Animals; Caco-2 Cells; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Iron, Dieta | 2023 |
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overloa | 2023 |
Natural polyphenol-based nanoparticles for the treatment of iron-overload disease.
Topics: Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Nanoparticles; Polyphenols | 2023 |
Nephrolithiasis in two patients on iron chelation therapy: A case report.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Human | 2023 |
Ferroptosis inhibitor improves cardiac function more effectively than inhibitors of apoptosis and necroptosis through cardiac mitochondrial protection in rats with iron-overloaded cardiomyopathy.
Topics: Animals; Apoptosis; Cardiomyopathies; Deferoxamine; Ferroptosis; Humans; Iron; Iron Overload; Male; | 2023 |
Vanillin serves as a potential substitute for chemical chelator desferal in iron-overloaded mice.
Topics: Animals; Antioxidants; Catalase; Deferoxamine; Iron; Iron Chelating Agents; Iron Overload; Male; Mic | 2023 |
PM2.5 induces ferroptosis in human endothelial cells through iron overload and redox imbalance.
Topics: Antigens, CD; Apoferritins; Apoptosis; Cyclohexylamines; Deferoxamine; Endothelial Cells; Ferritins; | 2019 |
Impact of iron chelators on growth and expression of iron-related genes of Cryptococcus species.
Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus; Cryptococcus neoformans; Deferasiro | 2020 |
Renal clearable nanochelators for iron overload therapy.
Topics: Animals; Deferoxamine; Iron Chelating Agents; Iron Overload; Kidney; Male; Mice; Nanoparticles; Tiss | 2019 |
Iron overload inhibits self-renewal of human pluripotent stem cells via DNA damage and generation of reactive oxygen species.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Deferoxamine; DNA Damage; Ferric Compounds; Humans; Induc | 2020 |
Prospective CMR Survey in Children With Thalassemia Major: Insights From a National Network.
Topics: Adolescent; Age Factors; beta-Thalassemia; Cardiomyopathies; Child; Deferiprone; Deferoxamine; Femal | 2020 |
Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Neutralizing; Antiviral Agents; B-Lymphocytes; Betaco | 2020 |
Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Female; Ferritin | 2020 |
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluati | 2020 |
Superparamagnetic iron oxide nanoparticles promote ferroptosis of ischemic cardiomyocytes.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Autophagy; Deferoxamine; Endopla | 2020 |
Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload | 2021 |
Reactive Oxygen Species-Triggered Dissociation of a Polyrotaxane-Based Nanochelator for Enhanced Clearance of Systemic and Hepatic Iron.
Topics: Animals; Deferoxamine; Dissociative Disorders; Humans; Iron; Iron Chelating Agents; Iron Overload; L | 2021 |
Efficient Iron and ROS Nanoscavengers for Brain Protection after Intracerebral Hemorrhage.
Topics: Animals; Antioxidants; Brain; Catechols; Cerebral Hemorrhage; Collagenases; Deferoxamine; Iron; Iron | 2021 |
Benefits of Iron Chelators in the Treatment of Parkinson's Disease.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Deferoxamine; Dopaminergic Neurons; Ferric Comp | 2021 |
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; | 2021 |
Iron overload inhibits BMP/SMAD and IL-6/STAT3 signaling to hepcidin in cultured hepatocytes.
Topics: Animals; Bone Morphogenetic Protein 6; Cell Line, Tumor; Deferoxamine; Hepatocytes; Hepcidins; Human | 2021 |
Iron chelation suppresses secondary bleeding after intracerebral hemorrhage in angiotensin II-infused mice.
Topics: Angiotensin II; Animals; Cerebral Hemorrhage; Deferoxamine; Drug Combinations; Hemoglobins; Hyperten | 2021 |
Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; He | 2017 |
Evaluation of iron chelating and antioxidant potential of Epilobium hirsutum for the management of iron overload disease.
Topics: Animals; Antioxidants; Deferoxamine; Epilobium; Iron; Iron Chelating Agents; Iron Overload; Male; Ra | 2017 |
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; | 2017 |
The aim of iron chelation therapy in thalassaemia.
Topics: beta-Thalassemia; Chelation Therapy; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overloa | 2017 |
Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hum | 2018 |
Detection and inhibition of lipid-derived radicals in low-density lipoprotein.
Topics: 4-Chloro-7-nitrobenzofurazan; Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferas | 2017 |
Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine | 2018 |
Activation of the molecular and functional effects of Nrf2 against chronic iron oxide nanorod overload-induced cardiotoxicity.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Cardiotoxicity; Deferiprone; Deferoxamine; Deoxyguanosine; Glu | 2018 |
Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major.
Topics: Adolescent; beta-Thalassemia; Blood Glucose; Chelation Therapy; Child; Child, Preschool; Deferiprone | 2018 |
Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Blood Transfusion; Chelation Therapy; Combined Moda | 2018 |
Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
Topics: Animals; Deferoxamine; Disease Models, Animal; Female; Ferritins; Human Umbilical Vein Endothelial C | 2018 |
Zebrafish larvae as a model to demonstrate secondary iron overload.
Topics: Animals; beta-Thalassemia; Chelation Therapy; Deferoxamine; Disease Models, Animal; Immunohistochemi | 2018 |
Improvement of chronic hepatitis B by iron chelation therapy in a patient with iron overload: A case report.
Topics: Adult; Chelation Therapy; Deferoxamine; Ferritins; Hepatitis B Surface Antigens; Hepatitis B, Chroni | 2017 |
The kinetics of dimethylhydroxypyridinone interactions with iron(iii) and the catalysis of iron(iii) ligand exchange reactions: implications for bacterial iron transport and combination chelation therapies.
Topics: Bacteria; Catalysis; Chelation Therapy; Deferiprone; Deferoxamine; Edetic Acid; Ferric Compounds; Hu | 2018 |
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Topics: Anemia, Aplastic; Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therap | 2018 |
Deferoxamine-induced electronegative ERG responses.
Topics: Atrophy; Deferoxamine; Electroretinography; Fluorescein Angiography; Humans; Iron Overload; Male; Mi | 2018 |
ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.
Topics: Animals; Cell Line; Cell Survival; Chelation Therapy; Deferoxamine; Female; Gels; Iron; Iron Chelati | 2018 |
The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network.
Topics: Adolescent; Adult; Aged; Chelation Therapy; Child; Deferoxamine; Female; Follow-Up Studies; Heart; H | 2018 |
Iron overload by transferrin receptor protein 1 regulation plays an important role in palmitate-induced insulin resistance in human skeletal muscle cells.
Topics: Adult; Animals; Antigens, CD; Case-Control Studies; Cells, Cultured; Deferoxamine; Diabetes Mellitus | 2019 |
MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Substitution | 2018 |
Chelation therapy for secondary neonatal iron over load: Lessons learned from rhesus hemolytic disease.
Topics: Blood Transfusion; Chelation Therapy; Cholestasis; Deferoxamine; Erythroblastosis, Fetal; Female; Fe | 2018 |
Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?
Topics: Animals; beta-Thalassemia; Chelating Agents; Deferiprone; Deferoxamine; Humans; Hydroxyurea; Iron Ov | 2018 |
Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis.
Topics: Adult; Animals; Chemokine CCL2; Deferoxamine; Diet, Fat-Restricted; Female; Femur; Ferric Compounds; | 2019 |
Deferoxamine Alleviates Iron Overload and Brain Injury in a Rat Model of Brainstem Hemorrhage.
Topics: Animals; Brain Stem Hemorrhage, Traumatic; Chelating Agents; Collagenases; Deferoxamine; Heme Oxygen | 2019 |
Compliance with Deferoxamine Therapy and Thyroid Dysfunction of Patients with β-Thalassemia Major in Syria.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Case-Control Studies; Child; Cross-Sectional Studie | 2019 |
Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoates; Cell Line, Tumor; Chlorides; Crosses, Genetic; | 2013 |
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
Topics: Benzoates; Child, Preschool; Deferasirox; Deferoxamine; Health Care Costs; Humans; Iron Chelating Ag | 2013 |
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; | 2013 |
Usefulness of pulsed wave tissue doppler imaging in assessment of left ventricular functions in children with beta-thalassemia major.
Topics: beta-Thalassemia; Chelating Agents; Child; Deferoxamine; Echocardiography, Doppler; Female; Humans; | 2013 |
Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.
Topics: Adult; beta-Thalassemia; Deferiprone; Deferoxamine; Female; Heart Diseases; Humans; Iron Chelating A | 2013 |
Nitric oxide-mediated regulation of ferroportin-1 controls macrophage iron homeostasis and immune function in Salmonella infection.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cation Transport Proteins; Deferoxa | 2013 |
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Mar | 2013 |
Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients.
Topics: Adult; Aged; Apoptosis; Bone Marrow Cells; Cell Cycle; Cell Proliferation; Colony-Forming Units Assa | 2013 |
Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters.
Topics: Adult; Aging; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Disease Sus | 2014 |
Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron O | 2014 |
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Defer | 2013 |
Sickle cell anemia: the impact of discovery, politics, and business.
Topics: Anemia, Sickle Cell; Animals; Cost Savings; Deferoxamine; Disease Models, Animal; Drug Delivery Syst | 2013 |
Design of long circulating nontoxic dendritic polymers for the removal of iron in vivo.
Topics: Animals; Biocompatible Materials; Cell Survival; Chelating Agents; Complement Activation; Deferoxami | 2013 |
Therapeutic effect of deferoxamine on iron overload-induced inhibition of osteogenesis in a zebrafish model.
Topics: Animals; Bone and Bones; Cell Differentiation; Deferoxamine; Disease Models, Animal; Iron Overload; | 2014 |
Iron overload in a teenager with xerocytosis: the importance of nuclear magnetic resonance imaging.
Topics: Adolescent; Anemia, Hemolytic, Congenital; Chelation Therapy; Deferoxamine; Female; Humans; Hydrops | 2013 |
MR quantitative susceptibility imaging for the evaluation of iron loading in the brains of patients with β-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Brain; Chelating Agents; Deferoxamine; Female; Humans; Iron; Ir | 2014 |
Bad liver and a broken heart.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron | 2014 |
Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Drug Therapy, Comb | 2014 |
Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload.
Topics: Adult; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Carotid Intima-Media Thic | 2014 |
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; | 2014 |
Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease.
Topics: Adult; Aged; Benzoates; Biomarkers; Cytokines; Deferasirox; Deferoxamine; Female; Ferritins; Follow- | 2014 |
Desferrioxamine-caffeine (DFCAF) as a cell permeant moderator of the oxidative stress caused by iron overload.
Topics: Antioxidants; Caffeine; Cell Membrane Permeability; Deferoxamine; Drug Evaluation, Preclinical; Ferr | 2014 |
Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine.
Topics: Adolescent; Anaphylaxis; beta-Thalassemia; Blood Transfusion; Deferoxamine; Desensitization, Immunol | 2014 |
Continuing treatment with Salvia miltiorrhiza injection attenuates myocardial fibrosis in chronic iron-overloaded mice.
Topics: Animals; Collagen Type I; Collagen Type III; Deferoxamine; Drugs, Chinese Herbal; Endomyocardial Fib | 2015 |
Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
Topics: Adult; Ceruloplasmin; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Diseases; Humans; | 2015 |
Diagnosis: Melanoderma after Hematopoietic Stem Cell Transplantation.
Topics: Antilymphocyte Serum; Busulfan; Deferoxamine; Diagnosis, Differential; Ecchymosis; Humans; Infant; I | 2015 |
Comment on "deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial".
Topics: beta-Thalassemia; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridone | 2015 |
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; D | 2015 |
Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice.
Topics: Animals; Antidotes; beta-Globins; beta-Thalassemia; Deferiprone; Deferoxamine; Dextrans; Female; Fib | 2015 |
Severe bacterial infections in patients with non-transfusion-dependent thalassemia: prevalence and clinical risk factors.
Topics: Adolescent; Adult; Bacterial Infections; Child; Deferoxamine; Female; Ferritins; Humans; Iron Overlo | 2015 |
Model-Based Optimisation of Deferoxamine Chelation Therapy.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Computer Simulation; Deferoxamine; Do | 2016 |
Does aceruloplasminemia modulate iron phenotype in thalassemia intermedia?
Topics: alpha-Globins; Base Sequence; beta-Globins; beta-Thalassemia; Ceruloplasmin; Deferoxamine; Exons; Ge | 2016 |
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Ca | 2016 |
TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.
Topics: Animals; Caco-2 Cells; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male | 2016 |
Decorporation of Iron Metal Using Dialdehyde Cellulose-Deferoxamine Microcarrier.
Topics: Animals; Cellulose; Chemistry, Pharmaceutical; Deferoxamine; Drug Carriers; Iron; Iron Overload; Kin | 2017 |
Effects of iron overload condition on liver toxicity and hepcidin/ferroportin expression in thalassemic mice.
Topics: Animals; bcl-2-Associated X Protein; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Cha | 2016 |
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe | 2016 |
Combination of Oral Iron Chelators for Thalassemia.
Topics: beta-Thalassemia; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Thalassemia | 2016 |
Calcium channel blockers ameliorate iron overload-associated hepatic fibrosis by altering iron transport and stellate cell apoptosis.
Topics: Animals; Apoptosis; Calcium Channel Blockers; Cell Line; Collagen; Deferoxamine; Diltiazem; Hepatic | 2016 |
Deferoxamine inhibits microglial activation, attenuates blood-brain barrier disruption, rescues dendritic damage, and improves spatial memory in a mouse model of microhemorrhages.
Topics: Animals; Blood-Brain Barrier; Cerebral Hemorrhage; Deferoxamine; Dendrites; Disease Models, Animal; | 2016 |
In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Topics: Animals; Deferoxamine; Female; Glycerol; Human Umbilical Vein Endothelial Cells; Humans; Iron Chelat | 2016 |
A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
Topics: Acetylcysteine; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Benzoates; Brain; Deferasir | 2016 |
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone; | 2016 |
Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine.
Topics: Central Serous Chorioretinopathy; Deferoxamine; Fluorescein Angiography; Fundus Oculi; Hemoglobinuri | 2016 |
Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.
Topics: Animals; Chelation Therapy; Deferoxamine; Iron; Iron Chelating Agents; Iron Overload; Mice; Rotaxane | 2016 |
The regulation of iron metabolism by hepcidin contributes to unloading-induced bone loss.
Topics: Absorption, Physiological; Animals; Bone and Bones; Bone Resorption; Deferoxamine; Down-Regulation; | 2017 |
Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Topics: Cardiomyopathies; Deferiprone; Deferoxamine; Ferritins; Heart Failure; Hemochromatosis; Hemochromato | 2016 |
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.
Topics: Deferasirox; Deferoxamine; Hepatitis C; Humans; Hypertension, Portal; Iron Overload; Liver Cirrhosis | 2018 |
Liver transplantation from a deceased donor with β-thalassemia intermedia is not contraindicated: A case report.
Topics: beta-Thalassemia; Chelating Agents; Chelation Therapy; Child; Contraindications; Deferoxamine; Femal | 2017 |
Effects of deferoxamine on blood-brain barrier disruption after subarachnoid hemorrhage.
Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Brain Edema; Brain Injuries; Cognition; Deferoxamine | 2017 |
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
Topics: Adolescent; Adult; Chelation Therapy; Child; Costs and Cost Analysis; Deferiprone; Deferoxamine; Fem | 2008 |
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
Topics: Adolescent; Adult; Chelation Therapy; Child; Costs and Cost Analysis; Deferiprone; Deferoxamine; Fem | 2008 |
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
Topics: Adolescent; Adult; Chelation Therapy; Child; Costs and Cost Analysis; Deferiprone; Deferoxamine; Fem | 2008 |
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
Topics: Adolescent; Adult; Chelation Therapy; Child; Costs and Cost Analysis; Deferiprone; Deferoxamine; Fem | 2008 |
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
Topics: Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Dr | 2008 |
Brain edema after intracerebral hemorrhage in rats: the role of iron overload and aquaporin 4.
Topics: Animals; Aquaporin 4; Brain Chemistry; Brain Edema; Cerebral Hemorrhage; Deferoxamine; Female; Histo | 2009 |
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
Topics: Acute Kidney Injury; Benzoates; Chelation Therapy; Cost-Benefit Analysis; Deferasirox; Deferiprone; | 2008 |
Left ventricular non-compaction in identical twins with thalassaemia and cardiac iron overload.
Topics: beta-Thalassemia; Deferoxamine; Diseases in Twins; Echocardiography; Female; Ferritins; Genetic Pred | 2009 |
Effect of iron-chelator deferiprone on the in vitro growth of staphylococci.
Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Microbial Sensitivity | 2009 |
Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Overload; Pyridones; Siderophores; T | 2009 |
Association between porphyria cutanea tarda and beta-thalassemia major.
Topics: Adult; Anemia; beta-Thalassemia; Chloroquine; Deferoxamine; Female; Hepatitis C; Humans; Iron Overlo | 2009 |
Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte | 2010 |
Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment.
Topics: Adolescent; Adult; Blood Transfusion; Child; Cross-Sectional Studies; Deferoxamine; Female; Follow-U | 2009 |
Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
Topics: Anemia; Blood Transfusion; Deferoxamine; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Nu | 2009 |
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
Topics: Chelation Therapy; Chronic Disease; Cyprus; Deferiprone; Deferoxamine; Female; Ferritins; Genetic Te | 2009 |
Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxa
Topics: Adolescent; Adult; Chelation Therapy; Child; Deferiprone; Deferoxamine; Diagnosis, Differential; Dru | 2009 |
A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Topics: Blood Transfusion; Chelation Therapy; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, C | 2009 |
A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Clinical Protocols; | 2009 |
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.
Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Neg | 2009 |
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine; | 2009 |
Early cardiac iron overload in children with transfusion-dependent anemias.
Topics: Adolescent; Anemia; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Deferiprone; Defe | 2009 |
Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Erythrocytes; Erythroid Cells; | 2010 |
A case of iron overload cardiomyopathy: beneficial effects of iron chelating agent and calcium channel blocker on left ventricular dysfunction.
Topics: Aged, 80 and over; Calcium Channel Blockers; Cardiomyopathies; Deferoxamine; Ferritins; Humans; Iron | 2009 |
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.
Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Ove | 2009 |
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Topics: Aged; Aged, 80 and over; Chelation Therapy; Comorbidity; Deferoxamine; Disease Progression; Female; | 2010 |
Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat.
Topics: Administration, Oral; Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical and Drug | 2010 |
Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.
Topics: Adenosine Triphosphate; Animals; Benzoates; Biological Transport; Cell Line; Cell Polarity; Deferasi | 2010 |
Iron chelation therapy in myelodysplastic syndromes.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Education, Continuing; Hum | 2010 |
Iron chelation therapy in MDS: does it improve survival?
Topics: Chelation Therapy; Deferoxamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fol | 2010 |
Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2010 |
Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; F | 2010 |
New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Fe | 2010 |
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Defer | 2010 |
The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Topics: Anti-Infective Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Infections; Iron; | 2010 |
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; | 2010 |
Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.
Topics: Binding Sites; Chromatography, Gel; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; | 2010 |
More pieces to the iron chelation puzzle.
Topics: Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Over | 2010 |
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Topics: Adult; Chromatography, High Pressure Liquid; Deferiprone; Deferoxamine; Female; Ferric Compounds; Hu | 2010 |
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therap | 2010 |
Pathogenesis and management of iron toxicity in thalassemia.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; | 2010 |
Combined iron chelation therapy.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Combinations; Ferritins; Humans | 2010 |
Treatment options for thalassemia patients with osteoporosis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Calcitonin; Clinical Trials as Topic; Defer | 2010 |
Iron chelation therapy for patients with sickle cell disease and iron overload.
Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferip | 2010 |
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
Topics: Benzoates; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Insura | 2010 |
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Drug | 2011 |
Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
Topics: Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Aspartate Aminotransferases; Chelation | 2010 |
Iron toxicity in mice with collagenase-induced intracerebral hemorrhage.
Topics: Animals; Body Weight; Cell Death; Cerebral Hemorrhage; Collagenases; Deferoxamine; Fluorescent Antib | 2011 |
Unrelated hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia and iron overload.
Topics: Anemia, Dyserythropoietic, Congenital; Benzoates; Bone Marrow Transplantation; Child, Preschool; Def | 2012 |
Chelators to the rescue: different horses for different courses!
Topics: Aldehydes; Animals; Deferoxamine; Humans; Hydrazones; Iron Chelating Agents; Iron Overload; Isoniazi | 2011 |
Increased oxidative stress and iron overload in Jordanian β-thalassemic children.
Topics: beta-Thalassemia; Case-Control Studies; Catalase; Child; Child, Preschool; Deferoxamine; Enzyme Assa | 2011 |
Evaluation of myocardial and hepatic iron loading by MRI T2* in multi-transfused patients with repeated blood loss as compared to thalassaemia major patients and controls.
Topics: Blood Transfusion; Child, Preschool; Deferoxamine; Female; Gastrointestinal Hemorrhage; Humans; Infa | 2011 |
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
Topics: Adult; Analysis of Variance; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female; | 2011 |
Desferrioxamine treatment of iron overload secondary to RH isoimmunization and intrauterine transfusion in a newborn infant.
Topics: Blood Transfusion, Intrauterine; Deferoxamine; Humans; Infant, Newborn; Infant, Premature; Iron Over | 2011 |
Challenges of adherence and persistence with iron chelation therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasir | 2011 |
The effect of iron overload and chelation on erythroid differentiation.
Topics: Animals; Antigens, CD34; Apoptosis; Cell Differentiation; Cells, Cultured; Deferoxamine; Erythroblas | 2012 |
Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Child; Cross-Sectional Studies; Deferoxamine | 2012 |
Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.
Topics: Child, Preschool; Deferoxamine; Female; Humans; Iron Overload; Male; Transfusion Reaction | 2012 |
Thalassemia: cardiac iron and chelators.
Topics: Benzoates; Deferasirox; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; | 2012 |
The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies.
Topics: Chelating Agents; Chelation Therapy; Deferiprone; Deferoxamine; Edetic Acid; Humans; Iron Overload; | 2013 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
How I treat transfusional iron overload.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Hematologic Diseases; Humans; Iron Chelating Agen | 2012 |
Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Topics: Adolescent; Adult; beta-Thalassemia; Body Burden; Child; Deferiprone; Deferoxamine; Drug Therapy, Co | 2013 |
A woman in her seventies with reduced general condition, dyspnoea and generalised pain.
Topics: Aged; Anemia, Refractory; Anemia, Sideroblastic; Chelation Therapy; Deferoxamine; Diagnosis, Differe | 2012 |
Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Blood Transfusion; Cohort Studies; Cost-Benefit A | 2012 |
Ferric iron uptake into cardiomyocytes of β-thalassemic mice is not through calcium channels.
Topics: Animals; Azoles; beta-Thalassemia; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-T | 2013 |
A comparison of the biological activities of human osteoblast hFOB1.19 between iron excess and iron deficiency.
Topics: Alkaline Phosphatase; Anemia, Iron-Deficiency; Apoptosis; Calcification, Physiologic; Cell Line; Cel | 2012 |
Mechanism of protective effects of Danshen against iron overload-induced injury in mice.
Topics: Alanine Transaminase; Animals; Animals, Outbred Strains; Anti-Inflammatory Agents, Non-Steroidal; Ap | 2013 |
Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Cost-Benefit Analysis; Cross-Sectional Stu | 2013 |
Pulmonary iron overload in thalassemia major presenting as small airway disease.
Topics: Adult; Airway Obstruction; beta-Thalassemia; Biopsy; Chelation Therapy; Combined Modality Therapy; D | 2002 |
Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferoxamine; Femal | 2002 |
Congenital erythropoietic porphyria: dilemmas in present day management.
Topics: Adult; Anemia, Hemolytic; Blood Transfusion; Bone Diseases; Deferoxamine; Female; Hematopoietic Stem | 2002 |
A sensitive test for early myocardial iron loading.
Topics: beta-Thalassemia; Cardiomyopathies; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magn | 2003 |
Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Chelating Agents; Deferoxamine; Echocardiogra | 2003 |
Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool.
Topics: Adult; Aged; Anemia; Case-Control Studies; Chelation Therapy; Deferoxamine; Ferritins; Follow-Up Stu | 2003 |
Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy.
Topics: Animals; Cardiomyopathies; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2003 |
Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia.
Topics: Acetylglucosaminidase; Adolescent; Adult; Aged; Albuminuria; beta 2-Microglobulin; beta-Thalassemia; | 2003 |
The dangers of iron overload in pyruvate kinase deficiency.
Topics: Aged; Chelating Agents; Deferoxamine; Humans; Iron Overload; Liver; Magnetic Resonance Imaging; Male | 2003 |
Treatment of cardiac iron overload in thalassemia major.
Topics: beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart Dise | 2003 |
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Deferoxamine; Disease-Free Survival; Female | 2003 |
Performance characteristics of the Dimension RxL iron and total iron-binding capacity methods.
Topics: Anemia, Iron-Deficiency; Deferoxamine; Drug Overdose; Hemoglobins; Humans; Iron; Iron Chelating Agen | 2003 |
Do we need more iron-chelating drugs?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyr | 2003 |
THE TREATMENT OF IRON OVERLOAD WITH DESFERRIOXAMINE B.
Topics: Anemia; Anemia, Aplastic; Blood Transfusion; Deferoxamine; Humans; Hydroxamic Acids; Iron Chelating | 1964 |
EVALUATION OF DEFEROXAMINE IN IRON OVERLOAD.
Topics: Anemia; Deferoxamine; Humans; Iron; Iron Overload; Pentetic Acid; Pharmacology; Toxicology; Urine | 1964 |
CHELATING AGENTS IN THE DIAGNOSIS AND TREATMENT OF IRON OVERLOAD IN THALASSEMIA.
Topics: Adolescent; Blood Transfusion; Chelating Agents; Child; Deferoxamine; Diagnosis; Drug Therapy; Human | 1964 |
THE VALUE OF DESFERRIOXAMINE AS A DIAGNOSTIC TEST IN IRON OVERLOAD.
Topics: Body Fluids; Deferoxamine; Diagnosis; Diagnostic Tests, Routine; Humans; Iron; Iron Overload; Urine | 1965 |
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy.
Topics: Aged; Anemia, Refractory; Deferoxamine; Echocardiography; Fatal Outcome; Heart Diseases; Heart Ventr | 2003 |
Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Deferoxamine; Female; Gerbillinae; Heart Failure; Iron; Iro | 2003 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D | 2004 |
Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update.
Topics: Aged; Anemia; Deferoxamine; Female; Humans; Injections, Subcutaneous; Iron Chelating Agents; Iron Ov | 2004 |
Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients.
Topics: Adolescent; Adult; beta-Thalassemia; Case-Control Studies; Deferoxamine; Female; Ferritins; Humans; | 2004 |
Iron: a target for the management of Kaposi's sarcoma?
Topics: Africa; Deferiprone; Deferoxamine; Female; Herpesvirus 8, Human; Humans; Iron Chelating Agents; Iron | 2004 |
Complications of beta-thalassemia major in North America.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; | 2004 |
Type 3 hemochromatosis and beta-thalassemia trait.
Topics: Adult; Amino Acid Substitution; beta-Thalassemia; Biopsy; Cardiomyopathy, Dilated; Chelation Therapy | 2004 |
Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.
Topics: Adult; Ceruloplasmin; Chelation Therapy; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating A | 2004 |
Effects of kojic acid on oxidative damage and on iron and trace element level in iron-overloaded mice and rats.
Topics: Administration, Oral; Animals; Deferoxamine; Iron Chelating Agents; Iron Overload; Lipid Peroxidatio | 2004 |
Desferrioxamine related maculopathy: a case report.
Topics: Aged; Aged, 80 and over; Atrophy; Deferoxamine; Diagnosis, Differential; Female; Glaucoma, Open-Angl | 2004 |
Adherence to deferoxamine therapy: heeding Hippocrates and Osler.
Topics: Adult; Child; Cross-Over Studies; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Needle | 2004 |
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.
Topics: Adult; Cardiomyopathies; Case-Control Studies; Deferoxamine; Female; Humans; Infusions, Intravenous; | 2004 |
Barriers to adherence of deferoxamine usage in sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Caregivers; Chelation Therapy; Child; Child, Preschool; Cognition D | 2005 |
The role of nitric oxide in iron-induced rat renal injury.
Topics: Animals; Arginine; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitor | 2004 |
Iron chelation therapy.
Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Live | 2005 |
Baroreflex function in conscious rats submitted to iron overload.
Topics: Animals; Baroreflex; Blood Pressure; Consciousness; Deferoxamine; Heart Rate; Iron Chelating Agents; | 2005 |
[Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes].
Topics: Aged; Anemia, Refractory; Anemia, Sideroblastic; Blood Transfusion; Deferoxamine; Female; Ferritins; | 2005 |
Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats.
Topics: Aldehydes; Angiotensin II; Animals; Aorta; Aortic Diseases; Apoferritins; Chemokine CCL2; Deferoxami | 2005 |
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agent | 2005 |
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Topics: Adolescent; Adult; Agranulocytosis; beta-Thalassemia; Cardiovascular Diseases; Child; Deferiprone; D | 2005 |
Methods for noninvasive measurement of tissue iron in Cooley's anemia.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Combined Modality Therapy; Deferoxamine; Female; Ferriti | 2005 |
Management of the "difficult" iron-overloaded patient.
Topics: Adolescent; Chelation Therapy; Child; Deferoxamine; Humans; Infusion Pumps; Infusions, Parenteral; I | 2005 |
Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine.
Topics: beta-Thalassemia; Cardiomyopathies; Child; Deferoxamine; Ferritins; Heart; Humans; Iron; Iron Overlo | 2006 |
[Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Heart Failure; Humans; Iron C | 2006 |
Reduced insulin growth factor I concentrations in iron-overloaded beta thalassaemic patients with normal growth hormone secretion and liver function.
Topics: Adolescent; Alanine Transaminase; beta-Thalassemia; Body Height; Child; Child, Preschool; Deferoxami | 2004 |
New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Topics: beta-Thalassemia; Carboxylic Acids; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Design | 2006 |
Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation.
Topics: Adolescent; Anemia, Sideroblastic; Biomarkers; Bone Marrow Transplantation; Chelation Therapy; Combi | 2006 |
Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload.
Topics: Adolescent; Child; Child, Preschool; Deferoxamine; Drug Administration Schedule; Female; Humans; Iro | 2006 |
Severe infections in thalassaemic patients: prevalence and predisposing factors.
Topics: Adolescent; Adult; Bacterial Infections; beta-Thalassemia; Child; Deferoxamine; Female; Ferritins; H | 2006 |
Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.
Topics: beta-Thalassemia; Cardiomyopathies; Chi-Square Distribution; Deferoxamine; Female; Ferritins; Humans | 2006 |
A case of rhesus hemolytic disease with hemophagocytosis and severe iron overload due to multiple transfusions.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Cholestasis, Intrahepatic; Deferoxamine; Female; Humans; Infan | 2006 |
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Topics: Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; | 2006 |
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Ch | 2006 |
Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Child; Combined Modality T | 2006 |
Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.
Topics: Abortion, Eugenic; Adolescent; Adult; Blood Transfusion; Chelation Therapy; Combined Modality Therap | 2006 |
Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
Topics: Activities of Daily Living; Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Atti | 2006 |
Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
Topics: Adaptation, Psychological; Administration, Oral; Adolescent; Adult; Attitude to Health; beta-Thalass | 2006 |
Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload.
Topics: Animals; Chromatography, High Pressure Liquid; Deferoxamine; Dopamine; Electric Stimulation; Electro | 2006 |
Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
Topics: Adolescent; Adult; Analysis of Variance; beta-Thalassemia; Blood Glucose; Chelation Therapy; Child; | 2006 |
Iron overload enhances epithelial cell proliferation in endometriotic lesions induced in a murine model.
Topics: Animals; Cell Division; Deferoxamine; Disease Models, Animal; Disease Progression; Endometriosis; Ep | 2006 |
Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Ascorbic Acid; Deferiprone; Deferoxamine; Deoxyg | 2006 |
Oral iron chelators: new opportunities and new dilemmas.
Topics: Administration, Oral; Animals; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Siderosis | 2006 |
Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
Topics: Anemia; Blood Transfusion; Chemical Fractionation; Child; Chromatography, Gel; Deferoxamine; Hemochr | 1999 |
Iron studies in infants born to an iron overloaded mother with beta-thalassemia major: possible effects of maternal desferrioxamine therapy.
Topics: Adult; beta-Thalassemia; Deferoxamine; Female; Fetal Blood; Humans; Infant, Newborn; Injections, Sub | 2007 |
Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Topics: Adolescent; Adult; Antimicrobial Cationic Peptides; beta-Thalassemia; Blood Transfusion; Chelation T | 2007 |
Diagnostic and therapeutic challenges.
Topics: Abdominal Pain; Aged; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Glomerulon | 2007 |
Pearson syndrome in an infant heterozygous for C282Y allele of HFE gene.
Topics: Anemia, Sideroblastic; Deferoxamine; Fatal Outcome; Female; Hemochromatosis; Hemochromatosis Protein | 2007 |
Clinical and economic burden of infused iron chelation therapy in the United States.
Topics: Adolescent; Adult; Blood Transfusion; Child; Cohort Studies; Deferoxamine; Female; Ferritins; Humans | 2007 |
Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Cardiomyopathies; Chelation Therapy; Child; Child, Preschool | 2008 |
Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability.
Topics: Brain; Ceruloplasmin; Deferoxamine; Diabetes Mellitus; Disease Progression; Family; Female; Heredode | 2008 |
Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron; Iro | 2008 |
Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Topics: Adult; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Fe | 2008 |
Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.
Topics: Adolescent; Adult; Autoantibodies; B-Lymphocytes; beta-Thalassemia; Chelation Therapy; Child; Deferi | 2008 |
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Topics: Adult; Chelation Therapy; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, Combination; | 2008 |
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Decision Support Techniques; Deferasirox; Def | 2008 |
Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia.
Topics: Cell Line; Cytosol; Deferoxamine; Fibroblasts; Frataxin; Friedreich Ataxia; Gene Expression Regulati | 2008 |
Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
Topics: Adult; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Bene | 2008 |
[Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Combined Modality Therapy | 1995 |
Hepatotoxicity induced by iron overload and alcohol. Studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation.
Topics: Alanine Transaminase; Animals; Antidotes; Blotting, Western; Cytochrome P-450 CYP2E1; Deferoxamine; | 1996 |
Pelvic osteomyelitis in a sickle-cell patient receiving deferoxamine.
Topics: Adolescent; Anemia, Sickle Cell; Chelation Therapy; Deferoxamine; Humans; Ilium; Injections, Subcuta | 1996 |
Bone marrow and chelatable iron in patients with protein energy malnutrition.
Topics: Bone Marrow; Child; Child, Preschool; Deferoxamine; Free Radicals; Humans; Infant; Iron; Iron Overlo | 1996 |
A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Child; Deferoxamine; Erythropoiesis; Growth; Hemogl | 1997 |
Iron overload alters innate and T helper cell responses to Candida albicans in mice.
Topics: Animals; Candida albicans; Candidiasis; Cytokines; Deferoxamine; Disease Susceptibility; Ferric Comp | 1997 |
Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferoxamine; Endocrine System Diseases; Female; Genotyp | 1997 |
Cardiac function during iron chelation therapy in adult non-thalassaemic patients with transfusional iron overload.
Topics: Adolescent; Adult; Aged; Aging; Antidotes; Ascorbic Acid; beta-Thalassemia; Chelating Agents; Corona | 1997 |
Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy.
Topics: Adolescent; Anemia, Sickle Cell; Catheterization, Central Venous; Chelation Therapy; Deferoxamine; F | 1997 |
HBED: A potential alternative to deferoxamine for iron-chelating therapy.
Topics: Animals; Antidotes; Chelating Agents; Deferoxamine; Edetic Acid; Haplorhini; Iron Overload; Male; Ra | 1998 |
[Intensive intravenous chelation in thalassemic patients with iron overload].
Topics: Adolescent; Adult; Chelation Therapy; Deferoxamine; Echocardiography; Humans; Infusions, Intravenous | 1998 |
Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
Topics: Adult; Aged; Chelating Agents; Chelation Therapy; Deferoxamine; Female; Hematologic Diseases; Hemato | 1998 |
ATP in iron overload-induced intracellular calcium changes.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Channels; Carcinoma, Ehrlich Tumor; Deferoxamine; | 1998 |
HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
Topics: Administration, Oral; Animals; Cebus; Deferoxamine; Edetic Acid; Injections, Intravenous; Injections | 1999 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron Chelating Agents; Iron | 1998 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyr | 1998 |
Effect of transfusion on lipid peroxidation products in the plasma of thalassemic patients.
Topics: Aldehydes; beta-Thalassemia; Biomarkers; Chelation Therapy; Deferiprone; Deferoxamine; Erythrocyte T | 1999 |
Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis.
Topics: Adult; Bone Marrow Transplantation; Deferoxamine; Female; Humans; Iron Overload; Male; Middle Aged; | 1999 |
Beta-thalassemia and pulmonary function.
Topics: Adolescent; Adult; beta-Thalassemia; Breath Tests; Carbon Dioxide; Carbon Monoxide; Chelation Therap | 1999 |
Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
Topics: Anemia; Chelating Agents; Deferoxamine; Erythropoiesis; Erythropoietin; Female; Ferritins; Humans; I | 1999 |
Effects of iron on extracellular and intracellular growth of Penicillium marneffei.
Topics: Animals; Deferoxamine; Humans; Interferon-gamma; Iron; Iron Overload; Lipopolysaccharides; Mice; Nit | 2000 |
Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts.
Topics: Animals; Animals, Newborn; Cells, Cultured; Chelation Therapy; Collagen; Culture Media, Conditioned; | 2000 |
Primary pseudomonas meningitis in an adult, splenectomized, multitransfused thalassaemia major patient.
Topics: Adolescent; Adult; Aged; beta-Thalassemia; Blood Transfusion; Chelating Agents; Chelation Therapy; C | 2000 |
Effect of transfusional iron overload on immune response.
Topics: Adolescent; Adult; beta-Thalassemia; CD8-Positive T-Lymphocytes; Chelating Agents; Child; Child, Pre | 2000 |
Financial analysis of chronic transfusion for stroke prevention in sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Child; Cost-Benefit Analysis; Deferoxamine; Erythrocyte Transfusion | 2000 |
Advances in iron chelating therapy.
Topics: Deferoxamine; Drug Administration Routes; Drug Therapy; Humans; Iron Chelating Agents; Iron Overload | 2000 |
Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
Topics: Adolescent; Adult; Apoproteins; Calibration; Chelation Therapy; Child; Deferiprone; Deferoxamine; Dr | 2001 |
ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Topics: Animals; Benzoates; Bile; Cells, Cultured; Deferasirox; Deferoxamine; Drug Evaluation, Preclinical; | 2001 |
Progression of iron overload in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Biopsy, Needle; Child; Child, Preschool; Cohort Studies; Def | 2001 |
Incomplete cerebral infarctions are not silent.
Topics: Adolescent; Anemia, Sickle Cell; Blood Flow Velocity; Bone Marrow Transplantation; Brain Damage, Chr | 2001 |
Yersinia enterocolitica as a cause of intra-abdominal abscess: the role of iron.
Topics: Abdominal Abscess; Abdominal Pain; Adult; Anti-Bacterial Agents; beta-Thalassemia; Chelating Agents; | 2001 |
Rapid recovery with oral zinc sulphate in deferoxamine-induced presumed optic neuropathy and hearing loss.
Topics: Administration, Oral; Adult; Astringents; Chelating Agents; Deferoxamine; Female; Hearing Loss, Sens | 2001 |
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.
Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine | 2001 |
Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Topics: Animals; Blood Transfusion; Cells, Cultured; Deferiprone; Deferoxamine; Dose-Response Relationship, | 2001 |
Association of phlebotomy and subcutaneous bolus injection of deferoxamine for the treatment of anemic patients with iron overload.
Topics: Anemia; beta-Thalassemia; Combined Modality Therapy; Deferoxamine; Female; Humans; Injections, Subcu | 2001 |
Intussusception due to Yersinia enterocolitica enterocolitis in a patient with beta-thalassemia.
Topics: beta-Thalassemia; Child, Preschool; Deferoxamine; Enterocolitis; Humans; Hypertrophy; Ileum; Intussu | 2001 |
Variations of ferritin levels over a period of 15 years as a compliance chelation index in thalassemic patients.
Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Deferoxamine; Drug Monitoring; Ferrit | 2001 |
Ferrous ion autoxidation and its chelation in iron-loaded human liver HepG2 cells.
Topics: 2,2'-Dipyridyl; Carcinoma, Hepatocellular; Culture Media; Deferoxamine; Drug Combinations; Ferric Co | 2002 |
Acquisition, storage and release of iron by cultured human hepatoma cells.
Topics: Apoproteins; Carcinoma, Hepatocellular; Culture Media; Deferoxamine; Ferric Compounds; Ferritins; Hu | 2002 |
Stored iron and myocardial perfusion deficits.
Topics: Animals; Coronary Artery Disease; Deferoxamine; Ferritins; Humans; Hypercholesterolemia; Iron; Iron | 2002 |
Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients.
Topics: Adult; Chelating Agents; Chelation Therapy; Deferoxamine; Female; Ferritins; Humans; Infusion Pumps; | 2001 |
The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice.
Topics: Animals; Catalase; Deferiprone; Deferoxamine; Glutathione; Glutathione Peroxidase; Iron Chelating Ag | 2002 |
The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.
Topics: Animals; Deferiprone; Deferoxamine; Disease Models, Animal; Female; Gerbillinae; Iron Chelating Agen | 2002 |
HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
Topics: Acute Disease; Animals; Blood Pressure; Cebus; Chronic Disease; Deferoxamine; Disease Models, Animal | 2002 |
Impact of thalassemia major on patients and their families.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Cost of Illness; Deferoxamine; Diabetes Complications; E | 2002 |
Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights.
Topics: Ceruloplasmin; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Magnetic R | 2002 |